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Abstract 
	 2	
My laboratory is interested in studying Sox (Sry-related HMG box) proteins, a family of 
transcription factors (TFs) present throughout the animal kingdom and important for the 
regulation of several fundamental processes during development (Pevny and Lovell-Badge, 
1997; Wegner, 1999; Bowles et al., 2000). In particular,  we focused on SOX18 that, together 
with SOX7 and SOX17, belongs to the SoxF subgroup (Bowles et al. 2000). In humans, 
mutations in SOX18 are associated with the Hypotrichosis-Lymphedema-Telangiectasia 
(HLT) syndrome, combining defects in hair, blood vessels and lymphatic development 
(Irrthum et al., 2003). In zebrafish, Sox18 and Sox7 have a redundant role in regulating 
arterio-venous differentiation (Cermenati et al. 2008; Herpers et al. 2008; Pendeville et al. 
2008; Hermkens et al. 2015), while only Sox18 is involved in lymphatic development 
(Cermenati et al., 2013). However, a recent article questioned the relevance of Sox18 role in 
zebrafish lymphatic vessel development, because a sox18 mutant did not show a lymphatic 
phenotype (van Impel et al. 2014). To clarify Sox18 role in zebrafish lymphangiogenesis, we 
made use of a new, independent mutant allele: sox18sa12315. In vivo analyses show that sox18 
mutant behaves as a null, indeed sox18 mutation, associated with sox7 perturbation, causes 
the absence of trunk tail circulation, the same phenotype observed in sox7/sox18 double 
partial morphants and in sox7/sox18 double mutants (Cermenati et al., 2008; Hermkens et al. 
2015). Our data also point out that Sox18 has a conserved role in zebrafish 
lymphangiogenesis, with an interplay with VegfC in the formation of the thoracic duct (TD). 
The analyses of sox18sa12315 mutation in two transgenic backgrounds reveal that, even if the 
mutation does not cause strong alterations of lymphatic system development, TD defects are 
statistically significant in homozygotes. Perturbation of Vegfc signaling exacerbates TD 
defects in a genotype-dependent manner; TD defects are highly enhanced in homozygotes, 
but even heterozygotes show statistically significant alterations when vegfc is slightly 
perturbed. The ectopic expression of sox7 in the posterior cardinal vein (PCV), from which 
lymphatic precursors originate, can explain the only subtle lymphatic defects observed in 
sox18 mutants transgenic line used for TD analyses. However, sox7 ectopic expression is not 
seen in all the fish lines we have analyzed, suggesting that also in zebrafish, as in mouse, the 
fine regulation of soxF genes depends on the genetic background.  
On the other hand, we are interested in studying the complex interplay between Sox and 
Notch signaling.  This year we published a collaborative article showing, with knockdown 
and knockout approaches, that SoxF transcription factors positively regulate notch1b and 
Notch1 vascular expression in zebrafish and mouse, respectively (Chiang et al., 2017). This 
work identifies SoxF responsive enhancers in Notch1 and notch1b loci in mouse and in 
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zebrafish, respectively. SoxF binding to the zebrafish notch1b enhancer is functionally 
relevant: arterial ISV defects are indeed found in enhancer mutants under experimental 
conditions, which slightly perturb Notch signaling. 
My laboratory is also interested in studying the role of sox13 (subgroup D), a gene vaguely 
linked to angiogenesis in different models (Roose et al., 1998; McGary et al. 2010). We have 
the evidence that Sox13 is implicated in zebrafish angiogenesis and that SoxF positively 
regulate sox13 (subgroup D) endothelial expression. In particular, sox13 morphants show 
ISV defects and an upregulation of some genes implicating in the Notch pathway. In vivo 
SPIM time lapse was used to characterize in a dynamic way, through long-term time lapse 
analysis, the ISV defects observed in sox13 morphants. With a combination of knockdown 
approaches in zebrafish and overexpression studies in vitro on ECs, we gathered evidence of 
an involvement of Sox13 in promoting endothelial cell migration.  
Finally, we confirmed that SoxF positively regulate sox13 by performing ISH analyses both 
in morphants and mutants. 
Since SoxF positively regulate the Notch signaling and positively regulate the expression of 
sox13, a negative regulator of the Notch pathway, we can speculate the existence of a 
complex regulatory network between SoxF and Sox13 in fine-tuning vascular development. 
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Each organism develops through a series of events that lead to the formation of a complex 
multicellular system starting from a zygote. These processes require delivery of nutrients, 
oxygen, cellular and humoral factors to the developing organs and structures; all these 
functions are conducted by a functional cardiovascular system that is fundamental for a 
correct embryogenesis. For these reasons the establishment of a functional cardiovascular 
system is one of the earliest events that occur during organogenesis. 
An accurate knowledge of the players, the signaling pathways and the mechanisms that 
regulate the correct patterning of the cardiovascular system is really relevant, especially 
because the molecular mechanisms involved in pathological processes could be sometimes 
similar or identical to those used during embryogenesis (Folkman, 1995). 
In the past centuries, different animal models were used to examine the anatomy, the 
physiology and the development of the heart and the vascular vessels. The first description 
of the vascular network was performed in 1661 by Marcello Malpighi using a chicken 
embryo, while in 1905 M. Hoyer illustrated the lymphatic system in early tadpoles 
(Carmeliet, 2005). In the last two decades, the zebrafish has emerged as an innovative model 
system to go deeper into the mechanisms of cardiovascular development and the players that 
regulate this process in vertebrates since it provides a series of advantages (Lawson and 
Weinstein 2002b). The external development and the optical clarity of the embryos make it 
possible to perform in vivo imaging of the vascular system using a variety of labelling 
techniques such as endothelial specific expression of fluorescent proteins and 
microangiography (Lawson and Weinstein 2002b).  
Morpholino and mRNA injection in the embryo at very early developmental stages are 
powerful techniques for manipulating gene expression. 
Moreover, in 2006, the existence of a lymphatic system has been demonstrated also in 
zebrafish through the characterization of the thoracic duct (TD) and other lymphatic vessels 
in developing and adult zebrafish (Kuchler et al., 2006; Yaniv et al., 2006). This system 
shares important features with the lymphatic vessels of higher vertebrates including 
conserved anatomy, characteristic morphology, expression and function of genes important 
for mammalian lymphatic development and functional features, such as lack of connection 
to the blood vasculature and ability to clear fluid and macromolecules from surrounding 
tissues (Yaniv et al., 2006). 
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1.1 KNOCKDOWN AND KNOCKOUT APPROACHES IN ZEBRAFISH 
One of the great advantages of using zebrafish as a model system is the possibility to 
manipulate gene expression by using morpholinos (MOs). MO oligomers differ from 
standard nucleic acids because of the presence of a six-ring heterocycle backbone and non-
ionic phosphorodiamidate linkages that makes MOs more stable when injected in vivo. 
Morpholinos have a high affinity for RNA and minimal off-target. They are injected into 1-
2 cell stage zebrafish embryos and they can act by blocking translation or by interfering with 
splicing; some MOs can also block microRNA maturation (Kok et al., 2015).   
Given their ease use in zebrafish, MOs have enabled widespread analysis of gene function. 
However, MOs can induce p53-dependent apoptosis and off-target cell-type-specific changes 
in gene expression that confound phenotypic analysis (Robu et al., 2007). 
The recent development of new genome engineering techniques, such as TAL 
effector nucleases (TALENs) and, especially, clustered regularly interspaced short 
palindromic repeats (CRISPR/Cas9), has allowed the facile generation of a lot of mutants 
(Kok et al., 2015). In CRISPR/Cas9 knockout technique, an RNA is injected into one-cell 
stage embryos, where it binds to its target DNA and induces a double strand break. Non-
homologous end joining imprecise repair of this break introduces small insertions or 
deletions that can lead to mutations when targeting coding sequence. Lesions that occur 
within the germline are inherited by the progeny (Kok et al., 2015). 
The availability of so many mutants has opened a debate in the zebrafish community about 
morpholino validity and reliability. This happens because not all the zebrafish mutants show 
the same phenotype of the corresponding morphants (Kok et al., 2015). It is the case of sox18 
mutants that do not show lymphatic defects; this questions sox18 role in zebrafish 
lymphangiogenesis (van Impel et al. 2014). Another example is provided by the zebrafish 
mutant in the endothelial extracellular- matrix (ECM) gene egfl7 that does not show the same 
vascular defects of the corresponding morphants (Rossi et al., 2015).  
Initially it was stated that the phenotypic difference between morphants and the 
corresponding mutants was the prove of MO unreliability and off-target effects (Kok et al. 
2015). However, recent studies have proposed gene expression compensation in mutant, but 
not knockdown animals, as the reason for the observed differences (Mohamed and Stainier 
2017).  
The before mentioned article about the zebrafish egfl7 mutant (Rossi et al., 2015) was the 
first work demonstrating the activation of a compensatory network to buffer against 
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deleterious mutations which was not observed after translational or transcriptional 
knockdown. The authors demonstrated that their TALENs mutant does not show the vascular 
phenotype of the corresponding morphant because of the upregulation of other ECM proteins, 
specifically Emilins. This upregulation occurs in the mutant but not in morphant embryos. 
Moreover, minor or no vascular defects were observed upon egfl7MO injections into egfl7 
mutants, indicating that the phenotypic differences are not due to MO toxicity. 
Similarly, vegfaa mutants do not show the same phenotype of their corresponding morphants 
because of vegfab upregulation, that occurs only in mutants (Rossi et al., 2015). 
Discrepant phenotypes between mutants and their corresponding knocked-down animals 
have been reported not only in zebrafish but also in many other model systems. For example, 
germline mutants for Pkm2 are viable and fertile; however, conditional deletion of Pkm2 in 
MEFs limits nucleotide synthesis, leading to cell-cycle arrest. Similarly, Sirt1 mutant mice 
have no obvious liver defects, while hepatocyte-specific Sirt1 mutant mice develop fatty 
liver. In all the cases the hypothesis is that a compensatory network becomes established 
during germline maturation or embryonic development, allowing the organism to adapt to 
the mutation (Mohamed and Stainier 2017).  
Two possible triggers of the transcriptional adaptation response have been proposed 
(Mohamed A. et al., 2017): the DNA lesion and the mutant mRNA.  
In the first case, in response to a lesion, global chromatin reorganization may positively affect 
chromatin accessibility around the compensating gene, thereby leading to increased 
expression levels. Part of such a model is consistent with the process of dosage compensation 
in Drosophila where the male-specific lethal (MSL) proteins, together with other proteins, 
form a complex on the male X chromosome leading to H4K16 acetylation and subsequent 
induction of an open chromatin configuration, which is more accessible for transcription 
(Mohamed A. et al., 2017).  
Many studies have reported that small non-coding RNAs generate from regions spanning a 
double-stranded break (DSB). These DSB-induced RNAs may act as guides for specific 
transcription factors or chromatin remodelers. The transmission of the transcriptional 
adaptation response to the next generation could occur through genomic imprinting via 
histone modification (Mohamed A. et al., 2017). 
In addition, induction of GADD45A expression following DNA damage has been reported to 
induce global DNA demethylation in HEK293T cells, leading to increased activation of 
methylation-silenced promoters (Mohamed A. et al., 2017).  
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Another explanation to the transcriptional adaptation could be the presence of aberrant RNA 
forming as consequence of the mutation. If RNA fragments are long enough, they act 
similarly to long non-coding RNAs and, for example, guide specific transcription factors or 
chromatin remodelers to the regulatory regions of compensating genes through homology-
mediated base pairing. 
In conclusion, today it is believed that some mutants do not show the same phenotype 
of the corresponding knocked-down models because of genetic compensation that occurs 
when a DNA lesion was generated but not after gene knockdown. So, morpholinos reliability 
is still recognized, but there are some recommendations to take into account when using 
MOs. One of these is to design MOs targeting exons encoding domains that are necessary 
for protein function (Kok et al., 2015); moreover, the use of two or more independent MOs 
is recommended. It is also important to use MO doses that do not induce p53 expression and, 
if necessary, alleviate off-target phenotypes by simultaneously reducing p53 levels. One 
should use the dose of MO that does not cause additional phenotypes in a null mutant 
background (Rossi	et	al.,	2015). It is also proposed to perform rescue assay with both a wild-
type and a mutated form of the RNA of interest; the mutated form should not to give a rescue. 
The comparison of chromatin accessibility and epigenetic changes at the upregulated genes’ 
regulatory regions in wild-type, mutant, and knockdown samples will thus be interesting. 
Eventually, whenever possible, the best way to be sure that a MO does not have off target 
effects is to compare the phenotype of the morphant with that of the corresponding mutant, 
if available, taking in consideration that in the mutant genetic compensation could occur. 
 
1.2 VASCULAR DEVELOPMENT: VASCULOGENESIS AND ANGIOGENESIS	
The external development, the optical clarity and the capacity to easily visualize the vascular 
tree and the blood circulation using a variety of labelling techniques make the zebrafish a 
useful model to study vascular morphogenesis in vivo. Furthermore, the small size of the 
zebrafish embryo ensures a sufficient supply of oxygen by passive diffusion for them to 
survive and develop for several days in condition of absence of blood circulation. This makes 
possible the in vivo study of conditions that alter considerably the cardiovascular system 
(Weinstein 2002).  
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Zebrafish has a closed circulatory system which shares many characteristics with 
those of humans and other higher vertebrates. In particular, the anatomical processes and the 
molecular mechanisms that regulate the assembly of a primary vascular network and its 
successive remodelling are highly conserved (Isogai et al., 2001; Isogai et al., 2003). 
Two fundamental phases characterize vascular development in vertebrates: vasculogenesis 
and angiogenesis.  
The primitive vascular network in vertebrate embryos forms by vasculogenesis. This process 
consists of de novo blood vessel formation by angioblasts aggregation and cavitation (Risau 
and Flamme, 1995). Angiogenesis is the process in which the primary vascular plexus 
remodels into an arborized network of large and small vessels by sprouting and branching 
(Risau, 1997). Lymphatic capillaries are mainly derived from veins (Sabin, 1902; Alitalo, 
2011) (Fig. 1.1). 
 
Fig. 1.1 Development of the vascular system in vertebrates. During vasculogenesis, endothelial progenitors 
give rise to a primitive vascular network, that will be remodeled and expanded during angiogenesis. Lymph 
vessels develop via trans-differentiation from veins. (Modified from Carmeliet, 2005).   
1.2.1 Vasculogenesis in zebrafish 
In zebrafish, as in other vertebrates, it has been hypothesized that endothelial and 
hematopoietic cells derive from a common progenitor, the hemangioblast, which originates 
from the lateral plate mesoderm (LPM) (Davidson and Zon, 2004).  
The first evidence of the existence of these cells was provided from the cloche mutant, in 
which there is a great reduction of both endothelial and hematopoietic progenitors (Stainier 
et al., 1995). In addition, genes such as stem cell leukemia -scl- and fetal liver kinase-
1/vascular endothelial growth factor receptor 2 –flk1/vegfr2 are required for the formation 
of both lineages in both zebrafish and mouse (Kallianpur et al., 1994; Kabrun et al., 1997; 
Liao et al., 1998).  
State of the art 
	 10	
Endothelial specification occurs during early somitogenesis when angioblasts, 
endothelial cell precursors, begin to express genes specific of endothelial identity (Fouquet 
et al., 1997). Among these genes, a set of E26 transformation-specific (ETS) transcription 
factors are fundamental (Lelievre et al., 2001; Sumanas and Lin, 2006; Pham et al., 2007). 
Indeed, the simultaneous knockdown of four ETS genes (fli1a, fli1b, ets1 and ets-variant-2) 
caused severe defects in vascular development (Pham et al. 2007). 
Recently, it has been demonstrated that in zebrafish etv2/etsrp marks two different 
populations of angioblasts within the posterior LPM: medial angioblast and lateral 
angioblasts. These populations originate at different time points and are located at different 
distances from the dorsal midline. The former population corresponds to arterial progenitors 
of the dorsal aorta (DA), while lateral angioblasts give rise to the venous endothelial cells of 
the posterior cardinal vein (PCV) (Kohli et al., 2013). 
Both vascular endothelial growth factor (Vegf) and sonic hodgehog (Shh) 
concentrations are important for the proper migration and contribution of both pools of 
angioblasts to the DA and the PCV (Lawson and Weinstein, 2002).  
At around the 10 somite stage, shh, expressed by the notochord, induces the expression of 
vegf  by the surrounding somites (Lawson and Weinstein, 2002) (Fig. 1.2). Vegf is important 
for medial angioblasts migration intersomitically to the midline over the endoderm in the 
anterior to posterior direction to form the DA. After the 15 somites stage, lateral precursors 
migration starts to give rise to the PCV with a migrational behavior similar to that of the 
medial angioblasts, (Kohli et al., 2013) (Fig. 1.2). 
 
 
Fig. 1.2 Molecular control of vasculogenesis. During early somitigenesis shh expression by the notochord 
induces vegf expression in the somites (10 som). After the 10-somite stage, medial angioblasts migrate to the 
midline directly to the dorsal position where they differentiate as arterial cells. Shortly after the 15-somite stage, 
the lateral angioblasts migrate to the ventral position at the midline where they differentiate as venous 
endothelial cells. (Neural tube in purple, notochord expressing shh in brown, vegf expressed in the ventral 
somites, medial angioblasts in red and lateral angioblasts in blue) (Kohli et al., 2013). 
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In an alternative proposed model, the DA forms by classical vasculogenesis, whereas 
formation of the PCV involves a selective sprouting of venous-fated angioblasts from the 
DA; cell-cell segregation allows distinct arterial and venous vessels to form (Herbert et al., 
2009). 
At around 24 hours post fertilization (hpf), blood circulation starts and the main axial vessels 
are formed and luminized (Isogai et al., 2001). Initially, blood flows through a simple single 
circulatory loop which goes caudally from the heart through the DA and returns rostrally via 
the PCV (Lawson and Weinstein, 2002) (Fig.1.3). 
 
 
 
Fig. 1.3 Primary circulation in zebrafish embryo at 30 hpf. Blood leaves the heart (H) and enters the lateral 
dorsal aortae (LDA), which converge into the dorsal aorta (DA). The circulation flows into the caudal artery 
(CA), then into the caudal vein (CV) and returns rostrally through the posterior cardinal vein (PCV). Finally, it 
leaches through the Duct of Cuvier (DC), before returning to the heart (Lawson and Weinstein, 2002). 
 
 
In the past, it was thought that arteries and veins acquired structurally and functionally 
distinct features in response to a different blood flow rates and pressure. Now we know that 
arteries and veins are specified by a complex genetic program before the onset of circulation 
(Lawson and Weinstein, 2002).  
In mice, arterial-venous differentiation is driven by EphrinB2/Ephrin-ReceptorB4 signaling 
(Wang et al., 1998). In zebrafish, the Notch pathway activates an arterial while repressing a 
venous cell fate program within the presumptive DA. Embryos lacking Notch activity fail to 
induce arterial specific efnb2a expression, and exhibit ectopic expression of venous markers 
(Lawson et al., 2001).  
Eventually COUP-TFII, a member of the orphan nuclear receptor superfamily, is specifically 
expressed in venous but not arterial endothelium. Ablation of COUP-TFII in endothelial cells 
enables veins to acquire arterial characteristics, including the expression of Notch signaling 
molecules. Thus, COUP-TFII has a critical role in repressing Notch signaling to maintain 
vein identity, which suggests that vein identity is under genetic control and is not derived by 
a default pathway (You et al. 2005; Aranguren et al. 2013; Swift et al. 2009). 
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1.2.2 Angiogenesis in zebrafish 
The primary vascular plexus, formed by vasculogenesis, remodels in a mature and more 
complex network of vessels during angiogenesis.  
If we focus our attention on the trunk/tail region of the zebrafish embryo, the main vessels 
which are formed through this process are: the intersomitic vessels (ISVs), the dorsal 
longitudinal anastomotic vessels (DLAVs), the sub-intestinal vein (SIV) basket, and the 
caudal vein plexus (CVP; Fig.1.4). Each structure is regulated by a specific interplay of 
different molecular pathways (Isogai et al., 2001). 
 
 
 
Fig.1.4 Microangiography of zebrafish embryos at 2 and 3 days post fertilization (dpf). (A and A’). Vessels 
of the trunk-tail region: dorsal longitudinal anastomotic vessel (DLAV), dorsal aorta (DA), intersomitic vessels 
(Se or ISV), caudal artery (CA), caudal vein (CV), posterior cardinal vein (PCV), sub-intestinal artery (SIA) 
and vein (SIV)(Isogai et al., 2001). 
 
 
In zebrafish, as in other vertebrates, ISVs are among the first angiogenic vessels to 
form. Their formation requires two waves of endothelial cell migration that occur at different 
developmental stages, first from the DA and then from the PCV (Isogai et al., 2003). 
At 22 hpf, a set of primary sprouts emerges from the DA and migrates towards the dorsal 
region of the embryo, following each vertical somites boundary (Fig.1.5A). These sprouts 
reach the dorsal portion of the embryo and branch rostrally and caudally to connect with their 
neighbors to form the DLAVs (Fig.1.5B-D) (Ellertsdottir et al., 2010). 
At 32-34 hpf, secondary sprouts begin to emerge from the PCV, growing dorsally alongside 
the primary ISVs (Fig.1.5 C and D). About half of these secondary sprouts connects with the 
adjacent primary ISVs which loose the connection with the DA and become venous ISVs 
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(vISV; Fig1.5 D and E). The primary ISVs which are not attached by the secondary sprouts 
maintain an arterial identity and constitute the arterial ISVs (aISVs) (Isogai et al., 2003).  
 
 
 
Fig.1.5 ISV and DLAV formation in the zebrafish trunk. Primary sprouts start from the DA and migrate 
dorsally to form aISV (or SA) and DLAV (A-C). Secondary sprouts originate from the PCV and a half of these 
connect to primary ISV, forming vISV (or SV; C-E) (Ellertsdottir et al., 2010). 
The other half of the secondary sprouts stop at the horizontal myoseptum and give rise to a 
pool of lymphatic precursors, the parachordal lymphangioblasts (PLs) (Bussmann et al., 
2010).  
Both in mouse and in zebrafish, a single ISV sprout is formed by two different types 
of cells: the tip and the stalk cells. The tip cell is located in the apical portion of the sprout 
and it is characterized by long dynamic filopodial extensions, essential for the correct growth 
and migration of the vessel (Gerhardt et al., 2003; Siekmann and Lawson, 2007b). The stalk 
cells are behind the tip cells and are important to make up the base of the sprout and maintain 
the connection with the vessel of origin (Siekmann and Lawson, 2007a).  
Regulation of the correct identity of each of these cells is essential for the proper patterning 
of the vasculature. As new vessels grow, migrating endothelial cells must also proliferate, 
which presents tip cells with a problem, as each daughter cell must acquire a different 
migratory profile dependent on their resultant position. The more distal daughter takes on tip 
cell identity, while the more proximal daughter becomes the trailing stalk cell. A very recent 
work reveals that tip cells use a form of asymmetric cell division to promptly generate 
daughters with distinct tip or stalk cell identity (Fig. 1.6). After tip cell division, the distal 
daughter immediately acquires tip cell- like motility whereas the proximal daughter displays 
motility near identical to a stalk cell (Costa et al., 2017). The motility of each daughter cell 
after division is positively correlated with their size: the larger distal daughter of tip cell 
division inherits a greater proportion of the Vegf signaling machinery and displays higher 
levels of Vegf signaling, establishing it as the leading tip cell (Costa et al., 2017).  
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Fig. 1.6 Asymmetric endothelial cell division. Highly motile endothelial tip cells sprout from parental vessels 
(1) and lead stalk cells (2). Upon tip cell division, the mitotic spindle (3) is displaced to the proximal pole of 
the cell (4) before anaphase. This introduces cell size asymmetry and generates daughter cells with distinct Vegf 
signaling levels and behaviors (5). (Costa et al., 2017)  
Vegfa signaling, which induces an endothelial cell to acquire a motile and invasive 
behavior, is required for tip cell differentiation (Gerhardt et al., 2003). 
In the tip cell, Vegfr2 is active and stimulates the up-regulation of the Notch ligand Delta-
like4 (Dll4) that up-regulates the Notch signaling in the neighboring cells, making them to 
acquire a stalk cell identity through a lateral inhibition mechanism (Fig. 1.7) (Leslie et al., 
2007; Siekmann and Lawson, 2007b; Jakobsson et al., 2010).  Notch activation in the stalk 
cells suppresses angiogenetic activity of Vegfr-3/Flt4 signaling (Siekmann and Lawson, 
2007b; Tammela et al., 2008).   Notch signaling inhibition, by DAPT (a g-secretase inhibitor) 
or by genetic manipulation, causes hyper-sprouting both in zebrafish and in mouse 
(Siekmann and Lawson 2007; Hellstrom et al. 2007). The lateral inhibition mechanism has 
been recently questioned by Shane Herbert (DVB Meeting) because it takes too long to occur; 
the acquisition of stalk cell identity must be driven by a process faster than lateral inhibition. 
The Wnt pathway is also important during angiogenesis. While in mice its role is well 
defined, indeed loss-of-function and gain-of-funcion mutants shows anomalous sprouting 
(Corada et al. 2010), there are only two articles describing its role in zebrafish (Cirone et al. 
2008; Gore et al. 2011). However also in zebrafish, Wnt pathway alteration leads to defects 
in ISVs formation.  
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Fig. 1.7 Molecular mechanism of tip and stalk identity acquisition well reviewed in (Herbert and Stainier, 
2011). 
The caudal vein plexus is formed by a dorsal and a ventral vein interconnected by a 
series of sprouts which give rise to an honeycomb-like structure (Isogai et al., 2001). 
Sprouting from the axial vein is mainly regulated by bone morphogenetic protein (BMP) 
signaling (Wiley et al., 2011). However, also Vegfa, which is considered the typical regulator 
of arterial sprouting, seems to be involved in CVP remodeling (Rissone et al., 2012).  
The SIVs run cranial ward along the yolk or the ventral walls of the intestine on both 
right and left sides (Isogai et al., 2001). These vessels originate from the duct of Cuvier at 2 
dpf, however a partial contribution from the PCV has been recently proposed (Hen et al., 
2015). During the next 24 hours, these vessels evolve in vascular plexus across most of the 
dorsal–lateral aspect of the yolk ball and will provide, together with the supra-intestinal 
artery, blood supply to absorb the yolk (Nicoli and Presta, 2007). The molecular mechanisms 
that regulate the SIV basket formation are not well characterized as in other districts, however 
an involvement of BMP signaling has been demonstrated , electing BMP as a main regulator 
of venous angiogenesis (Wiley et al., 2011). A recent work (Hen et al., 2015) show that other 
molecular pathways are important for the SIV formation. While the BMP signaling is 
essential for the ventral migration and expansion of the plexus (Wiley et al., 2011), the dorsal 
migration phase is driven by the kdrl/plcg1 axis. The Notch signaling is dispensable for 
earlier phases of SIV formation, but it is essential for the late step, indeed Notch pathway 
participates in the remodeling of the subintestinal plexus involving retraction of venuos 
leading buds (Hen et al., 2015). 
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1.2.3 Lymphangiogenesis  
The lymphatic system has a lot of important functions such as control of tissue fluid 
homeostasis, fat absorption and a role in the immune response; for this reason it is a very 
crucial part of the vascular system (Tammela and Alitalo, 2010). 
In mammals, the lymphatic system has a venous origin, indeed, lymphatic precursors 
arise from the cardinal vein and give rise to the early lymph-sacs (Sabin, 1902; Oliver and 
Srinivasan, 2010). The remodeling of these structures, the ballooning from the cardinal vein 
and the migration as single cells allow the formation of the mature lymphatic vasculature 
(Francois et al., 2012; Hagerling et al., 2013).  
The existence of a zebrafish lymphatic system has been demonstrated only in the last 
decade; lymphatic vessels derive mainly from veins also in zebrafish as in mammals (Kuchler 
et al., 2006; Yaniv et al., 2006). 
As I mentioned above, lymphangiogenesis starts at 1.5 days post fertilization (dpf) when 
lymphatic precursors (PLs) originate from secondary sprouting, arising from the PCV, 
migrate along aISVs and transiently reside at the horizontal myoseptum at around 2-2.5 dpf. 
Then, some precursors migrate dorsally forming lymphatic intersomitic vessels (ISLVs) and 
the dorsal longitudinal lymphatic vessels (DLLVs), while other PLs migrate ventrally and 
give rise to the thoracic duct (TD; Fig. 1.8), the main trunk lymphatic vessel (Bussmann et 
al., 2010). The TD, located between the DA and the PCV, starts forming at 3.5 dpf and it is 
completely formed at 5 dpf.  
Recently, it has been demonstrated that PLs derive from a specific subset of cells positioned 
in the ventral wall of the PCV and that express genes characteristics of both arterial and 
venous lineages such as notch1b, nr2f2 and fzd7a (Nicenboim J. et al 2015).  
In the last few years, new zebrafish transgenic lines allowed to uncover previously 
uncharacterised lymphatic vascular beds, such as the facial lymphatics (FLs), the lateral 
lymphatics (LL), the intestinal lymphatics (IL) (Koltowska et al., 2013) and the lymphatic 
vessels of the brain (Jung et al., 2017).  
The molecular pathways driving zebrafish lymphangiogenesis are shared with 
mammals and the most important of them is the signaling driven by vascular endothelial 
growth factor VEGFC and its receptor VEGFR3/Flt4. 
 
State of the art 
	 17	
 
Fig. 1.8 An overview of lymphatic system development. Schematic model of early lymphatic development 
in zebrafish (A) and mouse (B). Arteries and veins are shown in red and blue, respectively. In both zebrafish 
and mouse, the cardinal vein (CV, blue) acts as a source of cells that become specified towards a lymphatic fate 
(green), giving rise to parachordal cells (PACs), which are the building blocks of the fish lymphatic system, or 
lymph sacs in the case of mouse. In mouse, lymphatic endothelial cells (LECs) also bud off from intersomitic 
veins (B, middle panel). In zebrafish, lymphatic progenitors are derived from a subpopulation of specialized 
angioblasts (yellow) within the posterior cardinal vein (PCV) through asymmetric cell division (Jung et al., 
2017).  
Mammalian VegfC is a potent inducer of lymphatic sprouting (Jeltsch et al., 1997; Saaristo 
et al., 2002) and Vegfc knockout mice die during embryogenesis due to lymphatic system 
alterations (Karkkainen et al. 2004). Analogously, in zebrafish, the vegfc knockdown affects 
TD formation, zebrafish vegfc mutants fail to establish a proper lymphatic system, 
developing lymphatic hypoplasia and lymphedema and zebrafish flt4 mutant (expando) lacks 
lymphatics vessels and venous sprouting (Kuchler et al., 2006; Yaniv et al., 2006; Hogan et 
al., 2009).  
Another gene important for zebrafish lymphatic development is ccbe1 (collagen and calcium 
binding EGF domain 1). The story of this gene shows the importance of zebrafish as a model 
to study lymphangiogenesis, since ccbe1 has been discovered for the first time in zebrafish 
in the full-of-fluid mutants lacking lymphatic vasculature (Hogan et al. 2009b). Then the 
murine counterpart has been studied and now we know that, in human, mutations in this gene 
cause the Hennekam syndrome, characterized by lymphedema and mental disabilities 
(Alders et al. 2009; Connell et al. 2010). ccbe1 is expressed in non-endothelial cells and acts 
non-autonomously during embryonic lymphangiogenesis driving lymphangioblasts 
migration from the PVC during secondary sprouting (Hogan et al. 2009b). Moreover, ccbe1 
is involved in VEGF-C activation, indeed, together with	ADAMTS3 metalloproteinase, it is 
essential for the cleavage of VEGF-C into its active form both in vivo and in vitro 
(Vaahtomeri et al., 2017). Importantly, CCBE1-inactivating mutations have been found in 
patients with Hennekam syndrome, which involves severe lymphedema (Alders et al. 2009, 
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2013; Connell et al. 2010). Furthermore, homozygous Ccbe1 mutations prevent the formation 
of all primitive lymphatic structures both in mouse and zebrafish (Hogan et al. 2009b; Bos et 
al. 2011). 
SoxF transcription factors are important for lymphangiogenesis. In mammals, Sox18, with 
Prox1 and Coup-TFII, is at the top of the molecular hierarchy of TFs that drive lymphatic 
development. In venous cells, Sox18 cooperates with the nuclear receptor Coup-TFII to 
activate the expression of the lymphatic master gene Prox1 (Fig. 1.9) (Watabe 2012). 
 
 
Fig. 1.9 Lymphatic transcriptional specification network. The hypothetical interaction between Sox18 and 
Coup-TFII (dotted line) activates Prox1transcription in a subset of venous endothelial cells that are committed 
in a lymphatic lineage. Prox1 is able to maintain its own expression in lymphatic cells (modified by Watabe 
2012). 
Venous cells expressing Prox1 are committed in a lymphatic lineage and start to migrate 
following Vegfc gradient to give rise to the early lymph-sacs (Oliver and Srinivasan 2010).  
However, recent data published on zebrafish mutants have questioned the 
evolutionary conservation of the entire Sox18/Prox1/Coup-TFII regulatory axis because 
prox1ai278, coup-TFIIhu10330 and sox18hu10320 
 
mutants were reported not to share 
lymphatic defects (van Impel et al. 2014).  
Knockdown studies in my laboratory, instead, showed that Sox18 plays a conserved role in 
lymphatic development, indeed sox18 morphants are not able to form a normal thoracic duct. 
Moreover, sox18 genetically interacts with the central lymphatic growth factor vegfc in the 
early phases of lymphatic development since the combined partial knockdown of sox18 and 
vegfc, using subcritical doses of specific morpholinos, causes defects in both venous and 
lymphatic sprouting (Cermenati et al. 2013). These data are in agreement with a recent work 
demonstrating that prox1a has a crucial role also in zebrafish lymphangiogenesis and suggest 
that Sox18/Prox1/Coup-TFII regulatory axis could be conserved also in this animal model 
(Koltowska et al. 2015). 
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1.3 THE SOX FAMILY  
SOX (Sry-related-HMG box) proteins are a family of transcription factors found throughout 
the animal kingdom. They have been implicated in cell fate decisions in numerous 
developmental processes and they have diverse tissue-specific expression patterns during 
early development (Pevny and Lovell-Badge, 1997; Wegner, 1999; Bowles et al., 2000). 
SOX proteins are characterized by the presence of a DNA-binding high mobility 
group (HMG) box domain (Bowles et al., 2000). The HMG box is 79 aa long and consists of 
three alfa helices which can bind the minor groove of the DNA to ATTGTT or related 
sequences motifs. This binding widens the minor groove and causes DNA to bend towards 
the major groove (fig. 1.10) (Lefebvre et al. 2007; Kamachi and Kondoh, 2013).  
 
 
 
 
 
 
Fig. 1.10 Tridimensional representation of DNA/HMG-box interaction. A) Topological model of the Sox 
HMG (blue) bound to DNA (gray). Helices a1–a3, N-and C-termini and the position of the CATTGT core 
element are marked. B) The DNA bases and the DNA contact amino acids are shown as ball-and-sticks. 
(Modified from Hou et al. 2017). 
 
In 1990, SRY (Sex determining region Y) was the first SOX family gene identified in humans 
and mouse where it is important for male sexual determination (Gubbay et al. 1990).By 
convention, HMG domains of SOX proteins are at least 50% identical to the HMG domain 
of SRY. However, over the years, new SOX genes, which do not confirm this rule, have been 
identified. For these reasons, recent studies classify SOX proteins on the base of the 
conservation of a key motif within the HMG box: the sequence RPMNAFMVW (position 5-
13) that appears to be conserved in all SOX proteins but not in the most closely related 
outgroups (Bowles et al., 2000). In mouse and humans, the SOX family comprises 20 genes 
(Schepers et al., 2002) that have been divided into 8 groups (A-G) according to sequence 
similarity and genomic organization (Bowles et al., 2000) (Fig. 1.11). 
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Fig.1.11 Schematic representation of SOX proteins highlighting conserved region and domain within 
SOX family groups. Proteins are arranged in groups as defined by HMG box domain sequence. Various 
structural features, motifs, and functional regions are shown along with intron positions and sizes where known 
(Bowles et al., 2000). 
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The identity of the HMG-box domain is very high (70-95%) among proteins of the same 
subgroup, while proteins belonging to different subgroups may show only a minor degree of 
identity both in the HMG-box and in other regions (Lefebvre et al. 2007). 
It is not unusual that members of the same groups, when expressed in the same 
developing tissue, share equivalent functions, and so, many redundant roles between SOX 
proteins that co-regulate the same targets have been observed (Kamachi and Kondoh, 2013).  
The transcriptional activity of a SOX protein is strictly related to the necessity to form a 
complex with other partner transcription factors, thus, a Sox binding site in the DNA is 
accompanied by a second binding site for its partner (Kondoh and Kamachi, 2010). During 
the interaction with the partners, the HMG-box domain is important for protein-protein 
interaction, but the other domains of the SOX protein are fundamental both to stabilize and 
to give specificity to the interaction.  
A three-step model has been proposed to explain the specificity of the interaction between 
SOX protein and their targets.  In this model, the SOX proteins and the equivalent partner 
bind to adjacent sites on the DNA and interact through the HMG-box domain. The so formed 
protein complex is then influenced by not HMG-box domains of the SOX protein (Fig. 1.12) 
(Wilson and Koopman 2002). 
 
 
 
 
 
 
 
 
 
Fig.1.12 Model to explain the specificity of SOX protein transcriptional activity. The SOX protein and its 
partner (in pink) bind adjacent sites on the DNA and interact towards the HMG-box domains (in orange). Not 
HMG-box domains influence the complex by stabilizing it. (Wilson and Koopman 2002). 
The correct shuttling nucleus-cytoplasm is very important to regulate SOX protein activity. 
Even in this case a major role is performed by the HMG-box domain. In the C-terminus and 
in the N-terminus of this domain there are nuclear localization signals (NLS/NES) that are 
recognized by importins to mediate the active transport of transcription factors from the 
State of the art 
	 22	
nucleus to the cytoplasm (Poulat et al. 1995). Alteration in this process of import-export 
cause severe defects during organogenesis (Poulat et al. 1995; Smith and Koopman 2004). 
1.3.1 SOXF group 
SOX18, together with SOX7 and SOX17, belongs to the SOXF group (Bowles et al. 2000). 
The structure of the SoxF genes is conserved throughout the animal kingdom and it is 
characterized by the presence of only one intron within the HMG-box coding region (Bowles 
et al. 2000).  
SoxF proteins are characterized by high identity in the HMG-box domain, localized at the N-
terminus. A trans-activation domain (TAD) is in the central part of Sox18 and Sox7, while 
in Sox17, the TAD domain is located at the C-terminus (Hosking et al., 1995). A beta-catenin 
interaction motif is present in the C-terminus of Sox7 and Sox18; in Sox17 this motif 
precedes the TAD domain (fig. 1.13) (Sinner et al., 2004; Sandholzer et al., 2007).  
Fig.1.13 Schematic representation of SOXF structure in mammals. SOXF proteins have an HMG-box 
(blue) at the N-terminus, a transactivation domain (green) and a beta-catenin interaction motif (red) at the C-
terminus (Lilly et al. 2016). 
Like other Sox proteins, also SoxF proteins interact with different partners to regulate 
specific cellular processes. For example, biochemical analyses demonstrated that, during 
endothelial differentiation, SOX18 interacts with MEF2C (Hosking et al. 2001) and RBPJ 
(Fontaine et al., 2017; Overman et al., 2017) through the HMG-box domain. Not HMG-box 
domains are crucial to stabilize the interaction, indeed deletion of these domains disrupts the 
formation of SOX18 and MEF2C complex (Hosking et al. 2001).  
SoxF proteins play key and redundant roles in endothelial cells differentiation during 
embryogenesis both in mammals and zebrafish (Francois et al. 2010). The three SoxF genes 
show overlapping expression patterns and, in mouse, Sox17/Sox18 double mutants show 
more severe defects at the level of the endocardium if compared with single mutants 
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(Sakamoto et al. 2007). In addition, the combined deletion of Sox7, Sox17, and Sox18, but 
not the deletion of individual genes, at the onset of retinal angiogenesis leads to a dense 
capillary plexus with a nearly complete loss of radial arteries and veins (Zhou Y. et al. 2015). 
In mouse, SoxF genes are transiently expressed in endothelial cells during vascular 
development (Francois et al. 2010). Sox18 is also expressed in the mesenchymal component 
of all hair types, where it regulates the normal differentiation of the dermal papillae (Villani 
et al., 2017). Sox17 is initially expressed in the endoderm (Downes and Koopman 2001; Lilly 
et al., 2016); its endothelial expression is established later and is limited to arteries (Corada 
et al. 2014; Lilly et al., 2016). Sox17 has been shown to be critical for hemogenic 
endothelium specification before endothelial-to-hematopoietic transition (EHT) (Bos et al., 
2015; Clarke et al., 2013). The loss of Sox17 promotes hematopoietic fate over endothelial 
fate during EHT. Sox17 negatively regulates hematopoietic fate through repression of Runx1 
and Gata2 (Lizama et al., 2015). 
soxF genes share a similar, though not identical, expression pattern also in zebrafish. 
sox17 is initially expressed in the endoderm (Alexander et al. 1999) and it is important for 
left-right asymmetry establishment (Aamar and Dawid 2010). Later, sox17 is detectable also 
in a subset of cells of the DA possibly corresponding to the putative hemogenic endothelium 
(unpublished observations). As for sox7 and sox18, their expression is largely overlapping in 
endothelial cells of all blood vascular beds during embryogenesis and they play redundant 
roles in arterio-venous differentiation (Cermenati et al. 2008; Herpers et al., 2008; Pendeville 
et al.,2008).  
sox18 is detectable at 6-8 somites stage in bilateral stripes corresponding to the 
posterior lateral plate mesoderm (PLM; Fig. 1.14 D and F) and, at a lower level, in the 
anterior lateral plate mesoderm (ALM; Fig. 1.14 F) (Cermenati et al. 2008), where the 
presumptive common precursors of blood and endothelial cells reside (Gering et al., 1998; 
Brown et al., 2000). Moreover, sox18 is expressed in the innermost PLM fli1-positive cells, 
corresponding to endothelial cell precursors, as revealed by double in situ hybridization 
analysis (ISH) (Fig. 1.14 F). Later in development, sox18 marks the developing axial and 
intersomitic vessels (ISVs), the intermediate cell mass (ICM), where endothelial and blood 
cell precursors reside, and the developing head vasculature (Fig. 1.14 J-K-L-M) (Cermenati 
et al., 2008). At around 24 hpf, a sox18 signal is also detectable in the eye region (Fig. 1.14 
L) (Cermenati et al., 2008).  
The sox7 signal is detectable a little bit earlier than that of sox18 in the LPM during 
somitogenesis (4 somites), but at the following stages, up to 29 hpf, sox7 and sox18 are 
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expressed in the same vascular districts (Cermenati et al., 2008). However, sox7 expression 
in the PCV goes down earlier and at 36 hpf only sox18 is detectable in this venous trunk 
vessel (Cermenati et al., 2013). Sox7 appears to be particularly important for the LDA 
(Lateral Dorsal Aortae) development and sox7 mutants show abnormal shunts between the 
arteries and the veins of the head (Hermkens et al. 2015). 
 
 
Fig. 1.14 sox7 and sox18 expression pattern during zebrafish embryogenesis from 8 somites stage to 36 
hpf by WISH. Double ISH with fl1a endothelial cell precursors marker (modified from Cermenati et al., 2008). 
sox7 and sox18 redundant role in vascular development is demonstrated by the fact 
that the knockdown of either gene, using moderate doses of specific morpholinos, has 
minimal effects on vessels, but sox7/sox18 double partial morphants show multiple fusions 
between the major axial vessels. In these embryos, endothelial cells are specified but fail to 
acquire a full arterio-venous identity (Cermenati et all. 2008). It is important to underline that 
in sox7/sox18 double partial morphants, venous markers are more affected than arterial ones 
and that the most downregulated gene is vsg1 (vessel specific gene 1) (Cermenati et all., 
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2008). This gene has initially a panendothelial expression, but later during development, it is 
restricted to the veins (Covassin et al. 2006; Quian et al. 2005). 
Sox18 is involved in vascular and lymphatic development in different species 
(Irrthum et al., 2003; Francois et al., 2008). In humans, mutations in SOX18 are associated 
with the Hypotrichosis-Lymphedema-Telangiectasia (HLT) syndrome, characterized by 
defects in hair, blood vessels and lymphatic development (Irrthum et al., 2003); a renal failure 
associated with SOX18 mutations has been recently reported (hence HLT has been renamed 
HLT-renal defect syndrome or HLTRS) (Moalem et al., 2014). Initially, it was supposed that 
at the basis of HLTS there were mutations in VEGFC and FOXC2, two genes already 
implicated in many pathologies affecting the lymphatic system. Then it was observed that 
the syndrome had many similarities to the phenotypes caused by spontaneous mutations in 
Sox18 in mice. The murine counterpart of the disease is indeed represented by the ragged 
phenotype, first described in the 1950s, due to mutations in Sox18 (Slee, 1957; Pennisi et al., 
2000).  
Human A104P and W95R mutations affect the HMG-box domain interfering with the 
binding to the DNA; they are inherited recessively (Irrthum et al. 2003). The dominant 
mutation C240X affects the transactivation domain and causes the production of a truncated 
protein (fig. 1.15). Four allelic variants of the ragged phenotype have been identified. The 
most severe mouse allele, ragged-opossum (RaOp), causes embryonic lethality before E11.0 
in homozygous mutant mice (Green and Mann, 1961; Pennisi et al., 2000b; Downes and 
Koopman 2001). This mutation falls within the transactivation domain giving rise to a 
truncated SOX18 protein which acts in a dominant-negative manner and interferes with 
functionally redundant SOX transcription factors (Pennisi et al., 2000a; Downes and 
Koopman,2001). 
 
 
 
431 aa  
 
Fig. 1.15 Scheme of SOX18 mutations. Mutations identified by Irrthum and colleagues are indicated with blue 
pools, while the red pool indicates de novo mutation described in a patient with aortic dilatation. W95R/A104P 
mutations are recessive and fall in the HMG-box domain; C240X falls within the transactivation domain; 
asterisks indicate X (modified from Wuennemann et al. 2016). 
On the other hand, Sox18-null mice were originally described as viable and presented only a 
mild coat defect (Pennisi et al., 2000a). Some years later, in another study, Sox18 null mice 
State of the art 
	 26	
showed gross subcutaneous edema at E13.5 and died after E14.5 (Fig. 1.16) (Francois et al., 
2008).  
 
Fig. 1.16 Sox18-/- (B6) and RaOp/RaOp mutant embryos show edema at E13.5 (white arrows) (Francois et 
al., 2008). 
The difference between the two studies was the background in which experiments were 
carried out: mixed 129-CD1 background in the former study and pure B6 in the latter. In the 
absence of Sox18, in a mixed, but not in a pure background, Sox7 and Sox17 are ectopically 
upregulated during mouse lymphangiogenesis and they act as strain specific modifiers 
compensating lymphatic defects caused by Sox18 dysfunction (Hosking et al., 2009). 
In mice, Sox18 acts as a molecular switch to induce differentiation of lymphatic endothelial 
cells (LECs) (Francois et al., 2008). It has been demonstrated that Sox18 is expressed in a 
subset of cardinal vein cells where it activates the expression of the transcription factor 
prospero-related homeobox 1 (Prox1) by binding to its promoter. Coup-TFII probably 
cooperates with Sox18 in Prox1 activation.  Over-expression of Sox18 in blood vascular 
endothelial cells induces them to express Prox1 and other lymphatic endothelial markers, 
while Sox18-null embryos in the pure B6 background show a complete blockage of 
lymphatic endothelial cell differentiation from the cardinal vein (Francois et al., 2008). Prox1 
positive cells then migrate to form lymphatic vessels, under the control of a VegfC signal 
(Fig. 1.17).  
My laboratory showed that sox18 has a conserved role also in zebrafish lymphangiogenesis, 
indeed sox18 morphants are not able to form a normal thoracic duct. Moreover, sox18 
genetically interacts with the central lymphatic growth factor vegfc in the early phases of 
lymphatic development, since the combined partial knockdown of sox18 and vegfc, using 
subcritical doses of specific morpholinos, causes defects in both venous and lymphatic 
sprouting in zebrafish (Cermenati et al. 2013). 
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Fig. 1.17 Control of LEC specification via Sox18-CoupTFII-Prox1 axis. (Yang et al., 2012). 
However, a recent article questioned Sox18 role in zebrafish lymphatic vessels development, 
showing that sox18 mutants do not show a lymphatic phenotype (van Impel et al. 2014).  
It is of crucial importance to clarify this issue to understand if the molecular pathway 
regulating lymphatic development is conserved in both mammals and zebrafish.  
1.3.2 Sox13 
SOX13 belongs to the SoxD group with its closely related SOX proteins, SOX5 and SOX6.  
Differently from the other SOX proteins, SoxD proteins have their HMG-box domain in the 
C-terminus and do not present a trans-activation nor a trans-repression domain.  
This means that SOXD proteins regulate transcription by interacting with other proteins with 
functional domains (Lefebvre 2010). For example, Sox5 and Sox6 interact with Sox9, a 
member of the SoxE, to drive chondrocytes differentiation (Lefebvre et al. 1998; Han and 
Lefebvre 2008), while they seem to inhibit oligodendrocytes development (Stolt et al. 2006). 
In particular, it seems that SoxD proteins bind DNA as dimers, thereby preferential binding 
to pairs of DNA recognition sites (Lefebvre, 2010). 
Other domains characteristic of SoxD group are a coiled-coil leucine zipper domain, in the 
N-terminus and a neighboring glutamine-rich sequence stretch, which was named Q box 
(Kido et al., 1998; Lefebvre, 2010). The leucine zipper is known to serve as a protein–protein 
interaction domain; the Q-box domain may reinforce the leucine zipper-mediated protein–
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protein interaction or function to specify target proteins during the interaction (Kido et al., 
1998).  
In mice, the Sox13 expression pattern during embryogenesis was firstly analyzed by 
Roose and colleagues by in situ hybridization on histological sections (Roose et al., 1998).  
Sox13 signal was found in many structures such as the saccular and in the utricular 
components of the inner ear, the ampullae of the semicircular canals, the thymus and in 
developing central nervous system where it identifies a sub-population of post-mitotic 
differentiating neuronal cells  (Wang et al., 2005; Wang et al., 2006).  
SOX13 was also expressed in the condensing mesenchyme and cartilage progenitor cells 
during endochondral bone formation, in the limb as well as in the somite sclerotome and its 
derivatives (Wang et al., 2006). Finally, SOX13 was detected in the developing kidney, 
pancreas, and liver as well as in the visceral mesoderm of the extra-embryonic yolk sac and 
in the spongiotrophoblast layer of the placenta (Wang et al., 2006); Sox13 is also involved 
in differentiation of oligodendrocyte (Baroti et al., 2017).  
As for vessels, Sox13 was first detected in the wall of the great arteries at E13.5 (Roose et 
al., 1998; Fig. 1.18 A), while the vein walls did not express Sox13. Just before birth (E18.5), 
staining in the arteries is strongly increased and it appears confined to the media and intima 
layers (Fig. 1.18 C). In addition to the great vessels, Sox13 expression included other smaller 
vessels.  
 
Fig. 1.18 Sox13 expression in arterial walls during embryonic development in mice. In situ hybridization 
on histological sections at E13.5 (A), E16.5 (B), E18.5 (C) and P1 newborns (D). ao: aorta, pa: pulmonary 
artery. Positive signals have been detected also in thymus (th); (modified from Roose et al., 1998).  
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In humans, Northern blot analyses reveal that SOX13 is expressed in multiple tissues, 
including heart, brain, placenta, lung, liver, kidney, and pancreas; this suggests that SOX13 
may be involved in a variety of cellular processes (Kasimiotis et al., 2000). 
One of these processes is T-cell differentiation during which Sox13 promotes gamma-delta 
T cell development (Gray et al. 2013) while opposing alpha-beta T cell differentiation 
(Melichar et al., 2007). One effect of Sox13 deficiency on gamma-delta T cells is to diminish 
progenitor survival (Turchinovich and Hayday, 2011). In addition, Sox13 may enhance IL-7 
responsiveness for the survival of such thymocytes.  
During T cell differentiation SOX13 acts by directly binding and presumably sequestering 
TCF1 and/or modifying its activity (Melichar et al., 2007). TCF1 is one of the member of the 
canonical Wnt signaling pathway; TCF1 associates with the coactivator beta-catenin 
regulating the expression of target genes.  
In T cell differentiation, SOX13 acts as an inhibitor of the Wnt signaling because it binds 
TCF1 preventing it from binding beta-catenin (Melichar et al., 2007). The ability of SOX13 
to modulate Wnt activity has been further demonstrated (Marfil et al., 2010), indeed   the 
binary interactions between Hhex, SOX13, and TCF to regulate Wnt activity has been shown 
both in vitro and in vivo. The addition of Hhex results in the formation of the Hhex-SOX13 
complex that could restore the TCF1-beta catenin interaction and results in 
restoration/elevation of the Wnt levels (Marfil et al., 2010).  
ISH analyses in Xenopus laevis, revealed that sox13 was detectable in some vascular 
districts and that sox13 knockdown, by morpholino injection, altered expression of a vascular 
marker (McGary et al. 2010). Furthermore, SOX13 siRNA-mediated knockdown in HUVEC 
causes defects also in HUVECs, which fail to form vessels-like structures when cultured in 
2D-matrigel (McGary et al. 2010). However, these data are very preliminary and just point 
to a possible angiogenic function: the 2D-matrigel is not the best assay to reproduce 
physiological conditions.  
In zebrafish, RT-PCR analysis reveals that sox13 transcripts are present from early 
developmental stages up to 5 dpf. In adult zebrafish, sox13 is detected in ovary, kidney, gills, 
gut and, at a very low level, also in liver, heart and muscle (Omini, unpublished). 
In particular, sox13 expression is widely detectable in the developing Central Nervous 
System (CNS) (Fig. 1.19), as described in mice (Wang et al., 2005; Wang et al., 2006).  
During somitogenesis, sox13 is weakly expressed by angioblasts and later it is detectable in 
the forming axial vessels. At 22 hpf, as for vascular territories, sox13 is expressed only in the 
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endothelium of the dorsal aorta and in the intermediate cell mass (ICM), where cells of the 
erythroid lineage develop (Fig. 1.18, Omini et al., unpublished).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1.19 Sox13 expression profile during embryonic development in zebrafish. (See the text). Black 
triangles indicate the lateral mesoderm from different points of view. The main axial vessels are indicated with 
white triangles. i: DA, s: somites. (Omini et all., unpublished). 
Since sox13 is transiently expressed in endothelial cells, my laboratory studied its role in 
vascular development. Morpholino-induced knockdown experiments reveal that sox13 is 
involved in angiogenesis, since sox13 morphants show a wide range of ISV defects that lead 
to partially formed or completely absent DLAVs. These defects are specific because they 
could be rescued by sox13 RNA injection.  
ISVs defects of sox13 morphants are similar to those caused by Notch pathway hyper-
activation. So, my laboratory investigated if there was a relationship between Sox13 and the 
Notch pathway. The expression of the Notch-controlled gene efnB2 is slightly upregulated in 
sox13 morphants and the Notch pathway inhibitor DAPT is able to rescue ISVs migration 
and DLAVs formation defects in sox13 morphants.  All these findings suggest an 
involvement of Sox13 in zebrafish angiogenesis as a modulator of the Notch signaling 
pathway (Omini et al., unpublished). 
My laboratory also proposed for the first time an involvement for Sox13 in primitive 
erythropoieisis. Indeed, sox13 is expressed in the ICM, where primitive erythrocyte 
progenitors accumulate before entering circulation. sox13 morphants present defects both in 
T-cell and in erythrocyte differentiation, pointing to a role for Sox13 in these processes 
(Omini et al., unpublished).  
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1.4 AIM OF THE PROJECT 
The interest of my laboratory is to study the role of Sox genes in vascular development, using 
zebrafish as model system. We focus our attention on sox18 and sox13, both expressed in 
endothelial cells and involved in angiogenesis.  
Our data on zebrafish morphants demonstrated that sox7 and sox18 have a redundant 
role in arterio-venous differentiation (Cermenati et al. 2008) and that sox18 has a conserved 
role in zebrafish lymphangiogenesis (Cermenati et al. 2013). However, data published on 
mutants then questioned the evolutionary conservation of the entire Sox18/Prox1/Coup-TFII 
regulatory axis (van Impel et al. 2014).  
We tried to clarify the role of sox18 in zebrafish vascular and lymphatic development by 
characterizing a new, independent mutant allele: sox18sa12315 that should behave as a null 
allele.  
In this context, we tried also to elucidate the relationship existing between the SoxF and the 
Notch pathway. It is known from literature that artero-venous differentiation is driven by 
VEGFA and Notch pathways both in mammals and in zebrafish. VEGF pathway activates 
Notch signaling that is fundamental for arterial commitment (Lawson and Weinstein 2002a); 
in zebrafish, the main molecules involved in this process are the receptors Notch1 and Notch4 
and the ligands Dll4 and Rbpj (Lawson and Weinstein 2002a).  
However, alterations of the Notch pathway do not fully recapitulate the angiogenic defects 
caused by vegfa deletion (Lawson and Weinstein 2002c; Carmeliet et al. 1996), suggesting 
that other molecular pathways may be implicated in arterial differentiation.  
One of the most promising candidates are SoxF transcription factors, indeed RNA sequencing 
unpublished data from my laboratory suggest a link between SoxF and Notch. In sox7/sox18 
double partial morphants notch1b, a Notch1 orthologous gene, is strongly downregulated at 
22hpf, a developmental stage close to the onset of primary angiogenesis. So, I was included 
in a collaborative research project that tried to elucidate the interplay of SoxF with Notch 
pathway. My aim was to investigate notch1b expression in sox7/sox18 double partial 
morphants and in sox18sa12315 mutants by In Situ Hybridization (ISH). This technique has the 
advantages to give spatial information about gene expression allowing me to understand if 
the downregulation seen in RNAseq data occurs only in the vascular district or not. 
My laboratory has evidence that also sox13 is involved in zebrafish vascular 
development, since it is transiently expressed in the DA and sox13 morphants show defects 
in the ISVs (Omini et al., unpublished). 
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Furthermore, sox13 expression in the DA is downregulated in sox7/sox18 double partial 
morphants, suggesting that SoxF may regulate sox13 expression (Boezio et al., unpublished).  
On one hand, I collaborated in setting up the experimental condition of long-term time-lapse 
analyses with SPIM (Bassi et al. 2015) to dynamically characterize the angiogenic 
phenotypes of sox13 morphants in vivo.  
On the other hand, I combined analysis on morphants and mutants to confirm that Sox18 and 
Sox7 positively regulate sox13.  
The interplay between SoxF and Sox13 could be a mechanism in the fine-tuning of Notch 
signaling during vascular development, since the Notch pathway seems to be regulated in a 
positive way by SoxF and in a negative way by Sox13. 
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2.1 ZEBRAFISH AS A MODEL SYSTEM 
2.1.1	Zebrafish: breeding and reproduction	
Zebrafish (Danio rerio) is a small freshwater teleost tropical fish. It belongs to the Cyprinidae. 
Sexual maturity is reached at about 3-4 months: from this moment, during each mating, females 
can lay up to 100-200 eggs, which are externally fertilized. 
The laboratory housing system is composed of stand-alone systems with multiple shelves 
carrying several 1-10 l tanks. Water is continuously recirculated and filtered by a pump-system 
and it is maintained at 28°C. Water parameters such as pH and conductivity are daily monitored: 
their optimal values are respectively 7.2 and 400-600 µS. There are other parameters like nitrite 
and nitrate levels, which are periodically checked. Males and females are housed together in 
common tanks, and they are fed three times a day with brine shrimps and granular food. They 
follow an artificial light cycle of 14 hours of light and 10 hours of dark.  
For breeding, the evening before mating, males and females are put in specific smaller tanks 
where they are separated by a net. In this way, mating is still prevented, but pheromones can be 
exchanged. The following morning, when light turns on, the net is removed: once fish are 
together, eggs can be laid and fertilized. Eggs are collected and eventually injected depending 
on experiments. Then, fertilized eggs are transferred into Petri dishes with Fish Water and grown 
at 28°C in a dedicated incubator. If experiments require the analysis of embryos at 24 or more 
hours post fertilization (hpf), they are kept in PTU1X (1-Phenyl-2-Thiourea; Sigma), in order to 
inhibit pigmentation. To get new adult fish, zebrafish are grown in Petri dishes during their 
embryonic and early larval stages. Starting from 6 days post fertilization (dpf), larvae are grown 
in 3 l tanks until they reach a size sufficient to ascertain their sex. 
 
Fish water 
- 0.1g Instant Ocean Sea Salt   
- 0.1 g NaHCO3  
- 0.19 g CaSO4  
- 500 µl methylene blue (0.4 mg/ml)   
- deionized H2O for a final volume of 1 l  
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System tanks water composition 
- 150 ml di Instant Ocean Sea Salt solution in 30 l 
- 2 g NaHCO3/250 l (added only when the pH is lower than 7.2)  
  
Instant Ocean Sea Salt solution 
- 34 g Instant Ocean Sea Salt   
- deionized H2O to a final volume of 1 l  
  
PTU10X 
- 0.3 g PTU (1-Phenyl-2-Thiourea; Sigma)  
- 1 l Fish water 
 
2.1.2 Zebrafish lines 
We use six different lines for our experiments: 
• AB wild-type line for reverse transcriptase analysis on sox13 morphants. 
• Transgenic line tg(fli1a:EGFP)y1, for sox13 knockdown experiments. This line is 
characterized by the presence of the EGFP (Enhanced Green Fluorescent Protein) coding 
sequence (cds) under the endothelial fli1a promoter region (Lawson and Weinstein, 
2002). The line was obtained from the Didier Stainier laboratory (Max Planck Institute 
for Heart and Lung Research, Bad Nauheim). 
• Transgenic line tg(gata1:dsRed)sd2;(kdrl:EGFP)s843 for in vivo time lapse analysis with the 
SPIM technology. This line is characterized by the presence of EGFP cds under the 
endothelial kdrl promoter region and the dsRed reporter cds under the hematopoietic 
gata1 promoter region. The line was provided by Massimo Santoro lab, Università degli 
studi di Torino, Italy. 
• sox18sa12315 mutant line generated by the zebrafish mutation project (ZMP) (A systematic 
genome-wide analysis of zebrafish protein-coding gene function) at Sanger Insitute 
(http://www.sanger.ac.uk). In this mutant the transition  G>A occurs in the second exon 
of sox18 gene, within the HMG-box domain coding sequence, leading to the formation 
of a premature stop codon (W132X). Identified carries are kept  in heterozygosity and  
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the line is maintained by outcrossing with an AB wild-type line. The sox18sa12315 line is 
used for in vivo analysis and for several in situ hybridization (ISH) experiments. 
• Mutant line sox18sa12315/+; tg(lyve1:dsRed)nz101 for thoracic duct analysis. In this line, 
previously generated in our laboratory, the fluorescent dsRed protein (Discosoma sp Red 
fluorescent Protein) is under the control of the lyve1 venous/lymphatic promoter region 
and combined with the sox18 mutation. 
• Mutant line sox18sa12315/+; tg(fli1a:EGFP)y1 for lymphatic precursors and thoracic duct 
analyses. In this line, previously generated in our laboratory, the fluorescent protein 
EGFP is under the endothelial fli1a promoter region and combined with the sox18 
mutation. 
 
2.2 MORPHOLINOS INJECTION AND MICROINJECTION CONTROLS 
Morpholinos are synthetic molecules, usually 25 bases in length, that bind to complementary 
sequences of RNA or single-stranded DNA by standard nucleic acid base-pairing. In terms of 
structure, the difference between morpholinos and DNA is that, while morpholinos have standard 
nucleic acid bases, those bases are bound to morpholine rings, instead of 2-deoxyribose, linked 
through phosphorodiamidate groups instead of phosphates. Replacement of anionic phosphates 
with the uncharged phosphorodiamidate groups eliminates ionization in the usual 
physiological pH range, so that morpholinos are uncharged molecules in organisms or cells. 
Morpholino can act by blocking translation or by interfering with the splicing process. In the 
first case, the morpholino is designed to target the AUG codon region of the RNA of interest to 
interfere with the translation initiation complex. Splice blocking morpholinos, instead, are 
designed to target splicing sites and interfere with the normal splicing of the transcript of interest. 
In this case intron retention or exon skipping can occur with the formation of an aberrant mRNA 
codifying for a non-functional protein.  
Morpholinos are resuspended in a saline solution with appropriate physiological parameters 
(Danieau Buffer 1X), and additioned with a fluorescent vital tracer, dextran labeled with 
tetramethylrhodamine (hereafter “rhodamine”, Invitrogen), or alternatively, with phenol red 
(Sigma). These dyes allow checking the injection efficacy and the correct distribution of the 
morpholino in the embryos.  Microinjection is performed through a micromanipulator 
(Micromanipulator 5171; Eppendorf), and a microinjector (Femtojet; Eppendorf.) A 
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borosilicate-glass needle containing the morpholino solution is assembled on this injection 
system. Morpholinos are injected at the proper concentration in the yolk of fertilized eggs at the 
stage of 1-2 cells, aligned in a Petri dish, on a cover slip with a thin layer of water. 
To evaluate the specificity of the morpholino-induced phenotypes, some embryos are injected 
with a control morpholino, named standard control morpholino (std-MO). std-MO targets a 
human β-globin intron mutation that causes β-thalassemia and has no RNA targets in zebrafish. 
In this way, it is possible to understand whether the embryo phenotypes are due to the 
morpholino specific action or to the injection procedure.  
Injected embryos are transferred into Petri dishes containing Fish Water and put in a 28°C 
incubator. They are let grow here until they reach the desired developmental stage. Only embryos 
positive to rhodamine or phenol red staining are selected, to be sure to analyze correctly injected 
embryos. In this way, false negatives are avoided.  
 
Microinjection solution 
- 1-1.25 µl morpholino stock or dilutions (MO stock and MO dilutions are in Danieau 
Buffer) 
- 0.5 µl rhodamine-dextran 10 kDa  
- Danieau Buffer 1X for a final volume of 5 µl 
 
Morpholinos are resuspended in Sigma water and stored at -20°C at the concentration of 1mM. 
They are opportunely diluted in Danieau Buffer depending on the required dose for each embryo, 
which is injected with 4 nl of the injection solution.  
 
Rhodamine-dextran (10kDa)  
A 5% rhodamine solution in RNase-free water is prepared starting from the stock powder 
(D1816, Invitrogen). This solution is considered as 100X. Starting from it, 10X aliquots are 
prepared and stored in darkness at -20°C. The solution is injected in embryos at a concentration 
of 1X. 
 
Danieau Buffer 1X  
- 58 mM NaCl  
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- 0.7 mM KClO, 
- 4 mM MgSO4 
- 0.6 mM Ca(NO3)25 mM 
- HEPES pH 7.2 
 
Before injection, morpholinos and the Danieau Buffer are heated at 65°C for 5 minutes. Then, 
rhodamine is added to the solution and the needle is loaded and assembled on the 
micromanipulator. 
 
2.2.1 Sequences of the morpholinos 
Antisense morpholinos are purchased from Gene Tools (LLC, Philomath, OR).  
For in vivo analysis of blood circulation in sox18 mutants, sox7MO1 (Cermenati et al. 2008) is 
used, while for PLs and TD analyses, vegfc-MO2 is used (Yaniv et al., 2006). These two 
morpholinos are used at subcritical doses that is to say the dose of morpholino that does not 
cause a full phenotype but only a marginal or a null phenotype when injected in a non-mutant 
background. 
For sox7MO1, we use the subcritical doses described in Cermenati et al., 2008, while to find the 
subcritical dose of vegfcMO2 we performed a dose response curve.  A high dose of vegfcMO2 
(0.5 pmol) is used as control of vegfcMO effectiveness; 0.045 pmol and 0.03 pmol are the two 
doses chosen for the transgenic background and for the kind of structure and or the 
developmental stage analyzed. 
sox13-MO3 is used for SPIM analysis. This morpholino targets the region between the second 
intron and the third exon of the sox13 gene (i2e3 splice site), interfering with the correct splicing 
of the transcript.  
For ISVs analysis sox13MO4 is used. This morpholino targets the region between the ninth 
intron and the tenth exon (i9e10 splice site) of sox13 gene. 
std-MO            5’-CCTCTTACCTCAGTTACAATTTATA-3’  
sox7- MO1  5’-ACGCACTTATCAGAGCCGCCATGTG-3’  
vegfc-MO2      5’-AGACAGAAAATCCAAATAAGTGCAT-3’ 
sox13-MO3     5’-GAGAACGCTCCTATAAACAGAGATA-3’ 
sox13MO4      5’ – CTCCCAAGAAGCCTGGAGAGTGAAA – 3’ 
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2.3 PLASMID DNA: PREPARATION AND PURIFICATION 
2.3.1 Bacterial Transformation with plasmids 
The transformation reaction is based on a heat shock which causes formation of holes in the 
bacterial cell membrane of chemically competent cells. DNA molecules can enter the cell 
through these pores.  E. coli “DH5α sub-cloning efficiency” (Invitrogen) competent cells are 
used for the transformation with plasmid vectors.  
 
Procedure: 
- Thaw 50 µl of competent cells on wet ice. 
- Add to the cells 1-10 ng of plasmid DNA. 
- Mix gently and keep on ice for 30 minutes. 
- Heat shock at 42°C for 20 seconds. 
- Incubate on ice for 2 minutes. 
- Add to cells 950 μl of liquid LB medium (Luria-Bertani) and incubate at 37°C for 1hour 
in agitation. 
- Plate 20-200 μl from each transformation on solid LB medium containing the specific 
antibiotic depending on the plasmid resistance. 
 
Bacteria are let grow on the plates at 37°C o/n (overnight). Then, single colonies are inoculated 
in 100 ml of liquid LB medium containing the right antibiotic to select transformed bacteria. 
Again, bacteria are let grow in agitation, at 37°C o/n. In this way, it is possible to increase the 
quantity of bacterial cells, and therefore, the quantity of the desired plasmid.  
 
Liquid LB medium 
- NaCl 1%  
- Yeast extract 0.5%  
- Tryptone 1% 
 
Solid LB medium 
- LB medium 
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- Agar 15g/l 
 
2.3.2 Plasmid DNA purification 
To extract and purify plasmid DNA, "Hispeed Plasmid Midi Kit" (Qiagen) and/or "QIAprep 
Spin Plasmid Miniprep kit" (Qiagen) is used, following the procedures suggested by the 
associated protocols. 
To quantify the DNA in each sample, absorbance at 260 nm is measured, considering that 1 O.D. 
at 260nm = 50 µg/ml for DNA. 
Moreover, absorbance at 280 nm is measured. Sample quality and purity is estimated considering 
the O.D.260/O.D.280 ratio, whose optimal values for DNA range between 1.8 and 1.9. 
 
2.4 AGAROSE GEL ELECTROPHORESIS 
The electrophoresis technique allows separating molecules of nucleic acids according to their 
molecular weight. In this way, it is possible to check the dimension and the quality of DNA or 
RNA samples. The agarose gel is prepared starting from agarose powder (UltraPure Agarose; 
Invitrogen) which is dissolved in TAE 1X at high temperatures. Ethidium bromide (25 µl 
ethidium bromide stock 0.5 µg/ml every 100ml of gel; Sigma) is added to the molten agarose 
before it gets solid. It is an intercalating agent, which emits fluorescence when hit by UV light, 
therefore allowing visualization of DNA or RNA molecules. Once solid, the agarose gel is 
submerged in a specific electrophoretic apparatus containing TAE 1X. Samples are mixed with 
a coloured loading dye to facilitate loading on the gel and to visualize the electrophoretic run. A 
molecular weight marker containing DNA or RNA fragments of known molecular weights and 
concentrations is loaded on the gel as well. This allows to estimate the size of each DNA or RNA 
sample and to quantify them. The electrophoretic run is performed at a voltage of 2-3V/cm.  
 
TAE 1X  
- 40 mM Tris acetate pH 8.0  
- 1 mM EDTA pH 8.0  
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2.4.1 DNA electrophoresis 
DNA samples aliquots are diluted in TE 1X and mixed with Loading-Dye Solution 6X.  
It is possible to choose among several molecular weight markers, which differ in the dimension 
of the DNA fragments:  
- GeneRuler 1Kb DNA Ladder (Thermo scientific) 
- GeneRuler 100 bp plus DNA Ladder (Thermo scientific) 
- LMW DNA ladder, NEB 
 
Loading-Dye Solution 6X 
- 60% glycerol in TE 
- 0.3% bromophenol blue  
- 0.3% xylene cyanol 
- 60 mM EDTA  
- 10 mM Tris-HCl pH 7 
 
2.4.2 RNA electrophoresis 
For RNA samples, a specific electrophoretic apparatus with cooling liquid is used. Agarose gel 
and TAE 1X solution must be prepared fresh. Moreover, all the components of the apparatus 
must be cooled at 4°C for at least 1 hour before the electrophoretic run. This limits RNA damages 
caused by the heat generated by electric current. RNA samples are diluted in DEPC water and 
mixed with 2X RNA Loading-Dye (Thermo Scientific). A specific RNA molecular weight marker 
is used: RiboRuler High Range RNA Ladder (Thermo Scientific). Before loading the agarose gel, 
samples and molecular weight markers are kept at 70°C for 10 minutes in order to get them 
completely denatured. 
2X RNA Loading Dye 
- 95% formamide 
- 0.025% SDS  
- 0.025% bromophenol blue  
- 0.025% xylene cyanol 
- 0.025% ethidium bromide 
- 0.5 mM EDTA   
Materials and methods 
	 42	
2.5 REVERSE TRANSCRIPTASE PCR (RT-PCR) 
Reverse transcription polymerase chain reaction (RT-PCR) is a variant of polymerase chain 
reaction (PCR) and it is commonly used to qualitatively detect gene expression through creation 
of complementary DNA (cDNA) transcripts from RNAs and their amplification. 
 
2.5.1 Extraction of total RNA from embryos 
Total RNA are extracted from embryos with Trizol using the protocol described below. 
 
Homogenization 
- Start from 20-30 embryos 
- Add 500 µl of Trizol (Ambion) 
- Incubate RT 5 minutes 
- Centrifuge 12000 RPM 10 minutes at 4°C 
- Transfer the supernatant in a new Epperdorf tube  
 
RNA extraction 
- Add 200  µl of chloroform (Sigma) 
- Shake up and down for 15 seconds 
- Centrifuge 12000 RPM 15 minutes at 4°C 
- Transfer aqueous phase in a new Eppendorf 
 
RNA precipitation and wash 
- Add 250 µl of isopropanol (Carlo Erba) and 1µl of glycogen 20mg/ml (Roche) 
- Vortex 
- Centrifuge 12000 RPM 8 minutes at 4°C 
- Discard the supernatant 
- Add 500 µl of ethanol 75% (Carlo Erba) 
- Centrifuge 7500 RPM 5 minutes at 4°C 
- Discard the supernatant and dry the pellet 
- Add 50 µl of RNAse free water (Sigma) 
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- Run RNA on a 1% gel and quantify it using spectrophotometer 
 
2.5.2 Reverse Transcription  
1 µg of RNA is reverse transcribed using the SuperScript II Reverse Transcriptase kit 
(Invitrogen). For each sample: 
- Add 1 µl of random primers 
- Add 1 µl of dNTPs 10 mM 
- Put the sample 5 minutes at 70°C  
- Put the sample 2 minutes at 4°C 
- Add 4 µl of buffer 5X 
- Add 1 µl dTT 
- Add 1 µl of SuperScript II 
- Leave the sample 1 hour at 50°C 
- Put the sample 15 minutes at 70°C 
 
2.5.3 PCR 
actb1 PCR is performed to control the cDNA quality and to check whether samples have 
comparable concentrations. Then a PCR for the gene of interest is performed.  
 
The following primers are used:  
 
actb1-F: 5’- TGTTTTCCCCTCCATTGTTGG- 3’ 
actb1-R: 5’- TTCTCCTTGATGTCACGGAC- 3’ 
sox13-ex9-F: 5’- CCAACCTCTCAACCTCACCG- 3’ 
sox13-ex11/12-R: 5’- GCCATCTGCCCCTCAGAATC- 3’ 
 
The PCR reaction is made in a volume of 25µl of a mix, which is composed of: 
- DNA template                                            2 µl    
- dNTPs 2 mM                                              2.5 µl 
- primer F 100 mM                                       0.2 µl 
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- primer R 100 mM                                       0.2 µl 
- BufferI 5X                                                  5 µl 
- Go Taq G2 (Promega), 5 U/µl                    0.125 µl 
- mQ H2O                                                      15 µl 
 
The PCR conditions for actb1 are the following: 
 
Phase Temperature (°C) Duration Number of 
cycles 
Initial denaturation 95 2 min 1 
Denaturation 95 30 s  
25 Annealing 58 30 s 
Elongation 72 30 s 
Final elongation 72 10 min 1 
 
The PCR conditions for sox13 are the following: 
 
Phase Temperature (°C) Duration Number of 
cycles 
Initial denaturation 95 2 min 1 
Denaturation 95 30 s  
30 Annealing 56 30 s 
Elongation 72 30 s 
Final elongation 72 10 min 1 
 
2.5 µl of PCR are run on a 2% gel. 
 
 
 
 
Materials and methods 
	 45	
2.6 MORPHANTS AND MUTANTS ANALYSES 
sox18sa12315 mutants, uninjected or injected with subcritical doses of sox7 morpholino, are 
analyzed by ISH to evaluate the expression of some interesting genes (sox7, sox18, vsg1, cdh5, 
flt1, notch1b and sox13) involved in vascular development. In vivo analyses are also performed 
in mutant embryos to detect vascular defects.  
Analyses of ISV defects are performed in tg(fli1al:EGFP) embryos injected with stdMO and 
sox13MO4. 
The transgenic line tg(kdrl:EGFP; gata1:dsRed) is used for SPIM analysis, performed in 
collaboration with professor Andrea Bassi. 
TD analyses are performed in the sox18sa12315/+; tg(lyve1:dsRed) and sox18sa12315/+; tg(fli1a:EGFP) 
lines. The second line is used also for PL analysis. 
Before the analysis, the chorion is mechanically removed and embryos are anesthetized with 
tricaine 1X (ethyl 3-aminobenzoate methane sulfonate salt; Sigma) in PTU 1X (1-Phenyl-2-
thiourea; Sigma). Only fluorescent transgenic embryos are selected for the analysis. 
 
Tricaine 25X 
- 0.08 g tricaine (Sigma) 
- 20 ml deionized H2O 
 
2.6.1 Genotyping 
The sox18sa12315 zebrafish mutant line is characterized by a G to A transition in the HMG box 
domain coding sequence of the sox18 gene. This mutation causes the formation of a premature 
stop codon and the disruption of a restriction site for the BstNI/MvaI enzymes.  
A standardized procedure is followed to determine the embryos genotype.  
The genomic DNA is extracted and the sox18 region is amplified via PCR. Then, the PCR 
product is digested with BstNI/MvaI restriction enzymes. It is possible to determine the embryo 
genotype analyzing the digestion pattern on a gel. This genotyping procedure can be used both 
for embryos analyzed in vivo and for fixed embryos after ISH.  
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Genomic DNA extraction 
To obtain the genomic DNA from embryos, the following procedure must be followed: 
- Anesthetize embryos in tricaine 1X (160 µg/ml)  
- Digest single embryos in 25 µl of Proteinase K working solution for at least 4 hours at 
55°C 
- Inactivate Proteinase K keeping the solution for 10 minutes at 95°C 
- Centrifuge for 30 s at 5000 RPM to pellet cellular debris  
- Transfer the supernatant in a new Eppendorf tube.            
 
Proteinase K working solution    
Proteinase K 10 mg/ml diluted 1:10 in TE Buffer pH 8  
  
Tricaine 25X  
Dissolve 0.08 g of tricaine powder (Sigma) in 20 ml of deionized H2O. Prepare aliquots and store 
at -20°C. 
 
Polymerase chain reaction (PCR)  
For genotyping, the PCR reaction is made in a volume of 25µl of a mixture which is composed 
of: 
- DNA template                                            2 µl    
- dNTPs 2 mM                                              2.5 µl 
- sox18-BstNI-F2/F1 100 mM                      0.2 µl 
- sox18-BstNI-R2/R1 100 mM                     0.2 µl 
- BufferI 5X                                                  5 µl 
- Go Taq G2 (Promega), 5 U/µl                    0.125 µl 
- mQ H2O                                                      15 µl 
  
The PCR conditions are the following: 
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Phase Temperature (°C) Duration Number of 
cycles 
Initial denaturation 95 10 min 1 
Denaturation 95 30 s  
35 Annealing 57 30 s 
Elongation 72 30 s 
Final elongation 72 10 min 1 
 
For PCR reactions performed directly on genomic DNA, sox18-BstNI-F2/R2 primers is used. 
When the PCR products were not enough, a nested-PCR using the sox18-BstNI-R1/F1 internal 
primers is made to further amplify the PCR product. Primer sequences are reported here:   
 
Primer Melting 
temperature 
(°C) 
Sequence (5’-3’) 
sox18-BstNI-F1 60.1 GATTGCATTTAGATGATGTTGTCCTG 
sox18-BstNI-R1 61.3 CATCTTCTTGGGTTGTTTCTTCCTC 
sox18-BstNI-F2 59.8 CAGTGCTCTGGCACTAGATTG 
sox18-BstNI-R2 59.4 AAGCCTTGGAGAAGGAGACC 
 
2.5 µl of the PCR products are loaded on a 2% agarose gel. The PCR product has a different size 
depending on the primers couple (F1/R1 or F2/R2): 
- 305 bp (base pairs) for BstNI F2/R2 primers 
- 254 bp for BstNI F1/R1 primers 
 
Restriction enzyme digestion 
BstNI restriction enzyme (10 U/µl, New England BioLab) or its isoschizomer MvaI (10 U/µl 
Thermo Fisher) can be used for the digestion reaction. In both cases, a total volume of 15 µl is 
prepared for each sample.  
For BstNI digestions, the reaction mix for each sample is composed as follows: 
- Template  5 µl 
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- Buffer3.1 10X  1.5 µl 
- BstNI 10 U/µl  0.9 µl 
- H2O mQ  7.4 µl  
 
Samples are incubated at 60°C for 2 hours. 
For MvaI digestion, the reaction is performed at 37°C for 2 hours or overnight. Depending on 
the chosen incubation time, different volumes of the enzyme are mixed in the reaction solution: 
 
 2 hours at 37°C Overnight at 37°C 
Template 5 µl 5 µl 
Buffer3.1 10X 1.5 µl 1.5 µl 
Mva1 10U/µl 0.9 µl 0.5 µl 
H2O mQ  7.4 µl 7.9 µl 
 
 
After the enzymatic digestion, the entire reaction volume (15 µl) is loaded on a 3% agarose gel. 
Different genotypes generate different digestion patterns, characterized by DNA bands of 
different size, as reported in the following table: 
 
 
 sox18-BstNI-R1/F1 sox18-BstNI-R2/F2 
sox18 +/+ 125 bp; 73 bp; 56 bp 141 bp; 91 bp; 73 bp 
sox18 +/- 198 bp; 125 bp; 73 bp;  56 bp 214 bp; 141 bp; 91 bp;   73 
bp 
sox18 -/- 198 bp; 56 bp 214 bp; 91 bp 
 
Materials and methods 
	 49	
 
 
Figure 2.1. Digestion pattern of wild-type and mutant conditions for sox18-BstNI-F2/R2 PCR products. From left 
to right: Low Molecular Weight DNA ladder (M), uncut control, sox18 wild type control (sox18 +/+), sox18 
heterozygous mutant (sox18 +/-), sox18 wild type (sox18+/+), sox18 homozygous mutant (sox18 -/-). 
 
2.6.2 Lymphatic precursors (PL) analysis 
For lymphatic precursors (PL) analysis, the offspring of intercrosses of sox18sa12315/+ mutants, in 
a tg(fli1a:EGFP) background, is analysed at  52 hpf. The analysis is performed using the Leica 
DFC 405C stereomicroscope; selected embryos are analyzed also at a confocal microscope to 
acquire images. Only circulating larvae are analyzed. They are anesthetized and positioned 
laterally in Petri dishes. Larvae analyzed at the confocal microscope are positioned in Petri dishes 
specific for confocal microscopy (“Glass Bottom Culture Dishes”; MatTek Corporation). Here, 
they are included in a solution of 1% low-melting agarose in PTU 1X and Tricaine 1X to keep 
them fixed in the right position. This solution is kept at 37°C in order to maintain the agarose 
melted. We analyze the PL in a region of ten trunk segments. The observed area starts with the 
first segment above the end of the yolk extension, in the anal region, and continues for ten 
segments toward the head.  
The presence or absence of the PL in each of the ten segments is registered for all the larvae; 
representative images are acquired. 
 
2.6.3 Thoracic Duct (TD) analysis 
For thoracic duct (TD) analysis, the offspring of intercrosses of sox18sa12315/+ mutants, in  
tg(lyve1:dsRed) and in tg(fli1a:EGFP)  backgrounds, are analyzed at 5 dpf. The analysis is 
performed using a confocal microscope. Only circulating larvae are analysed; they are 
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anesthetized and positioned laterally in Petri dishes specific for confocal microscopy as 
described before.  
The analyzed area of the trunk is the same as for PL analysis. The presence or absence of the TD 
in each of the ten segments is scored for all the larvae.  
Then, larvae are divided in three different categories, depending on the number of TD-positive 
segments:  
1. TD-positive segments: 10/10 à  normal TD (100%) 
2. TD-positive segments: 1-9/10 à 10-90% TD  
3. TD-positive segments: 0/10 à absent TD (0%) 
 
For each category, representative images are acquired.  
 
2.6.4 Intersomitic vessels (ISVs) analysis 
std control embryos and embryos injected with sox13MO4 are analyzed in the tg(fli1a:EGFP)y1 
background at 2 dpf. All the embryos are analyzed on the same side, the left one. We analyze 
the intersomitic vessels (ISVs) in the same region described for PL analysis. 
For each segment along the analyzed area we score the presence or absence of the corresponding 
ISV or its incomplete formation; the arterial or venous origin of each ISV is registered as well. 
Analyses are performed using the Leica DFC 405C stereomicroscope and pictures are taken with 
Leica Digital Camera DC200. 
 
2.6.5 Statistical analysis 
Statistical analyses are performed with Student’s t-test or one-way ANOVA followed by 
Dunnett’s Multiple Comparison post-test, when needed, using GraphPad PRISM version 5.0 
(GraphPad, San Diego, CA). In the graphs, statistically highly significant data, with a p value 
<0.001, are marked by ***, p value<0.05 are marked by ** while p value <0.5 are marked with 
*. 
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2.7 In situ HYBRIDIZATION (ISH) 
In-situ hybridization (ISH) is a technique used to visualize the spatial expression of a gene 
through a colorimetric reaction. A specific antisense RNA probe hybridizes with the transcript 
of the gene of interest. Some of the uridines in the probe are covalently linked to digoxygenin 
(DIG) molecules: they are recognized and bound by a specific antibody which is conjugated to 
alkaline phosphatase (AP). Once appropriate substrates are provided, AP catalyzes reactions 
which lead to a coloured precipitate. In this way, it is possible to directly visualize where and 
when a specific gene is expressed. ISH can be performed on tissue sections or on entire 
organisms (whole-mount ISH). In zebrafish, whole-mount ISH gives good results thanks to the 
transparency of the embryos. 
 
2.7.1 Probes preparation for whole mount ISH 
Plasmid DNA containing the cDNA of the genes of interest is used to transform E.coli bacterial 
cells. Then, DNA is extracted, purified, and linearized. For linearization, it is important to 
consider the orientation of the insert in the plasmid. In fact, appropriate phage polymerase and 
restriction enzymes must be chosen to generate an antisense probe. The following table 
summarizes the utilized probes and their characteristics. 
 
PROBE VECTOR RESTRICTION ENZYME RNA 
POLYMERASE 
sox18 pBSKS SmaI T7 
sox7 pExpress BamHI T7 
cdh5 pCR$-TOPO NotI T3 
vsg1 pGEMTeasy NcoI SP6 
sox13 pBS-KS+ Sal1 T3 
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notch1b pPCR-Script BamHI T3 
flt1 pGEM-T NcoI Sp6 
  
 
Restriction enzymes digestion 
Specific restriction enzymes are used to linearize plasmid DNA prior to in vitro transcription. 
The digestion reaction occurs in a solution containing:  
- 10 µg of plasmid DNA in 5-10 µl di TE1X  
- Digestion Buffer (specific for each restriction enzyme; dilute 1:10, stock 10X)  
- BSA (if necessary and not yet contained in the digestion buffer) 
- 1 U of restriction enzyme/µg of DNA to digest 
- deionized H2O to reach the final volume  
 Samples are incubated at the optimal enzyme activity temperature until all DNA is digested. 
 
Phenol/chloroform/isoamyl alcohol purification and DNA precipitation  
After the enzymatic digestion, the linearized DNA must be purified from the proteins, which are 
still present in the solution and it must be precipitated and concentrated.  
 
Purification : 
- Add to the digestion mix TE Buffer 1X to reach a final volume of 200 µl. 
- Add 1 V (volume) of phenol/chloroform/isoamyl alcohol 25:24:1 (Ambion). 
- Mix vigorously  
- Centrifuge at RT for 3 min at 11000 RPM 
- Take the upper aqueous phase and transfer it into a new tube 
 
 Precipitation: 
- Add 1 µl glycogen 20 mg/ml 
- Add 1/9 V NaAc 3M 
- Mix and add 2.5 V EtOH 100% 
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- Incubate on ice for at least 10 min 
- Centrifuge at 4°C, for 30 min, at 11000 RPM 
- Remove the supernatant 
- Add 1 V EtOH 80%  
- Centrifuge at 4°C, for 5 min, at 11000 RPM 
- Remove the supernatant and dry the pellet at RT 
- Resuspend the pellet in 10 µl H2O DEPC 
  
DEPC H2O 
DEPC (diethylpyrocarbonate: Sigma) diluted 1:1000 in deionized H2O. Let in agitation at RT 
for few hours, then autoclave. 
 
TE 1X 
- 10 mM Tris-HCl pH 7.5  
- 1 mM EDTA pH 8.0 
 
In vitro transcription 
During transcription, the RNA polymerase incorporates digoxygenin-conjugated uridine 
triphosphate nucleotides (DIG-UTP) in the nascent RNA. The transcription mix is composed as 
follows:  
- x µl of DNA to have 1µg 
- 2 µl DIG RNA labelling mix 10X (ATP, CTP, GTP  10 mM; UTP 6.5 mM; DIG-UTP 
3.5 mM; Roche)  
- 2 µl Transcription Buffer 10X (Roche) 
- 2 µl RNA polymerase 2 U/µl  
- 0.5 µl RNase inhibitor 40 U/µl (Promega) 
- H2O DEPC to a final volume of 20 µl  
 
The transcription mixture is incubated at 37°C for 2 hours. After this incubation, 2 µl DNase I 
RNase-free (Roche) are added to remove DNA and the mixture is incubated at 37°C for 15 
minutes. 
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To precipitate RNA the following reagents are added, in order: 
- 1 µl EDTA 0.5 M pH 8 
- 1/10 V NaAc 3M 
- 1 µl glycogen (1 mg/ml) 
- 2.5 V cool 100% EtOH  
 
RNA is precipitated o/n at -20°C (or for 1 hour at -80°C). Then the following steps are required:  
- centrifuge at 11000 RPM for 30 min at 4°C 
- wash with ethanol 80% 
- centrifuge at 11000 RPM for 5 min at 4°C 
- remove the supernatant and dry the pellet at RT 
- resuspend the pellet in 20 µL H2O DEPC. 
 
To test the concentration and the quality of the probe, an aliquot is run on a 1% agarose gel and, 
finally, its absorbance is measured at the spectrophotometer. For RNA absorbance, the following 
relation is considered: 1 O.D. at 260nm = 40 µg/ml for RNA 
For RNA, the optimal values of O.D.260/O.D.280 ratio range between 1.9 and 2.0. 
 
2.7.2 Embryos fixation 
Once embryos have reached the desired developmental stage, they must be fixed to preserve the 
integrity of their tissues. Fixation is made in paraformaldehyde 4 % (PFA) in PBS (Phosphate 
Buffered Saline) 1X, o/n at 4°C or for 2 hours at RT. PFA causes the formation of cross-links 
between proteins in the tissues preserving them. Before fixation of embryos at 24 hpf or more, 
the chorion must be mechanically removed with needles. If embryos must be fixed at earlier 
developmental stages, the chorion can be removed after fixation. Then, fixed embryos are treated 
as follows:  
- wash twice with PBS1X 
- dehydrate embryos through incubation for 5 min in solutions with increasing methanol 
concentration: 
• 25%-MeOH/75%-PBS1X  
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• 50%-MeOH/50%-PBS1X  
• 75%-MeOH/25%-PBS1X  
• 100% MeOH  
Embryos are stored in 100%MeOH at -20°C for at least one night. 
 
PBS 4X 
- Dissolve 2 "Phosphate Buffered Saline" tablets (Sigma # P4417) in 100 ml di deionized 
H2O  
- Add DEPC (final dilution 1:1000)  
- Let in agitation for at least 2 hours and then autoclave 
 
PFA 4% 
Dissolve at 60°C 2 g of PFA (Sigma) in 50 ml PBS 1X. Aliquot and store at -20°C. 
 
2.7.3 Protocol used for whole mount ISH 
The ISH experiments follow four main steps in four different days: 
1. Hybridization with digoxigenin-labelled RNA probes 
2. Incubation with anti-dig antibody conjugated with alkaline phosphatase (AP) 
3. PBT washings 
4. Colorimetric reaction to visualize the precipitate  
The protocol is an adaptation of the C. Thisse e B. Thisse protocol, 2008. 
 
First day: 
Embryo rehydration: 
- rehydration through incubations of 5 min in solutions with decreasing methanol 
concentration in PBS 1X (100%, 75%, 50%, 25%) 
- 4 washes in PBT, each of 5 min 
Embryos permeabilization: 
Embryos are incubated in Proteinase K (10 µl/ml from a stock of 10 mg/ml) for different times 
depending on their developmental stage: 
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• 1 cell – tailbud                                                no PK 
• early somitogenesis    1 min 
• advanced somitogenesis   3 min 
• 24 hpf (hours post fertilization)  5 min 
• 29 hpf      10 min 
• 32 hpf      12 min 
• 36 hpf      15 min 
• 2 dpf (days post fertilization)   30 min 
• 3 dpf      40 min 
• 4 dpf      50 min 
• 5 dpf      1 h 
Post-proteinase fixation and washing in PBT: 
- remove PK/PBT solution  
- incubate in PFA 4% in agitation, 20 min at RT  
- wash embryos 5 times in PBT, 5 min each washing at RT  
Prehybridization and hybridization of the embryos: 
- Prehybridize embryos in 800 µl of prehybridization mix (pre-HM) at 65°C for 2-5 h 
- Remove the prehybridization mix  
- add 400 µl of new hybridization mix (HM) containing 200-400 ng of RNA antisense 
probe, previously heated at 65 °C 
- Hybridize embryos o/n at 65 °C. The hybridization temperature varies depending on the 
stringency required by each probe. 
  
Second day: 
Washes at the hybridization temperature (65°C): 
- wash briefly in 100% HM 
- incubation in solutions of increasing concentration of SSC 2X in HM (each of 15 min) 
• 75% HM-/25% SSC2X 
• 50% HM-/50% SSC 2X 
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• 25% HM-/75% SSC 2X 
•  SSC 2X 
- 2 washes of 30 min in SSC 0.1X 
 
Washes at RT: 
- Incubation in solutions of increasing concentration of PBT in SSC 0.1X (each of 10 min, 
in agitation): 
• 25% PBT/75% SSC 0.1X 
• 50% PBT/50% SSC 0.1X 
• 75% PBT/25% SSC 0.1X 
• 100% PBT 
 
Incubation with anti-DIG antibody: 
- Incubate embryos for 2 hours at RT in agitation in 1 ml of preincubation solution 
(PBT/2% sheep serum/2 mg/ml BSA) to saturate and avoid subsequent binding of the 
antibody to non-specific sites 
- Substitute the incubation solution with a new one containing the anti-DIG antibody 
(Roche; final dilution 1:5000)  
- Incubate o/n in the dark 
 
 
Third day:  
After seven washes in PBT at RT (each of 15 min), embryos are kept in PBT o/n at 4°C. This 
additional step allows getting a clearer and cleaner staining of the embryos. 
 
Fourth day: 
Staining: 
To develop the coloration, the chromogenic substrates must be added to the staining buffer. 
Embryos must be constantly monitored during the staining step, which is performed as follows 
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- 3 washes of 5 min at RT in the staining buffer 
- Removal of the staining buffer and addition of the staining solution 
 
Stop of the coloration: 
- Removal of the staining solution 
- Post-fixation in PFA 4% for 2 hours at RT  
- Removal of the fixation solution   
Embryos are stored in PBS at 4°C. 
 
PBT 
- PBS 1X  
- 1% Tween 20 (Sigma) 
 
SSC 20X 
- 3 M NaCl 
- 0.3 M NaCitrate 
 
Proteinase K (10 mg/ml) 
Dissolve 10 mg of powder (Sigma) in 1 ml of sterile water (aliquot and store at -20°C). 
 
Heparin (15 mg/ml) 
Dissolve 15 mg of powder in 1 ml SSC 4X. Filter the solution, aliquot and store at -20°C. 
 
tRNA (500 mg/ml) 
Dissolve in water bath 25 g yeast tRNA in 50 ml of DEPC water until the suspension becomes 
translucent. Aliquot and store at -20°C. 
 
Pre-hybridization Mix (pre-HM) 
- 60% Formamide (Roche) 
- SSC 5X  
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- 0.1% Tween20 
- Citric acid 4.6 mM pH 6.0 
- tRNA 500 µg/ml 
- heparin 50 µg/ml 
- deionized H2O  
  
 Hybridization Mix (HM) 
Add 200-400 ng of the probe to the pre-hybridization mix. 
 
HM wash 
- 60% Formamide (Roche) 
- SSC 5X 
- 0.1% Tween20 
- Citric acid 4.6 mM pH 6.0 
- deionized H2O 
 
Pre-incubation solution  
- 2% sheep serum (Sigma) 
- 2 mg/ml BSA (Sigma) 
- PBT  
 
Incubation solution with antibody 
Add the anti-DIG antibody (Roche) diluted 1:5000 to the pre-incubation solution. 
 
Staining buffer 
- 100 mM Tris HCl pH 9,5 
- 50 mM MgCl2 
- 100 mM NaCl 
- 0.1% Tween 20 
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Staining solution 
- 2.3 µl NBT (Nitro Blu Tetrazolium, Roche; stock 100 mg/ml) 
- 3.5 µl BCIP (5-bromo-4-chloro-3-indolyl phosphate, Roche; stock 50 mg/ml) 
- 1 ml of staining buffer   
 
Embryos have been analyzed with stereomicroscope Leica MZFLIII and pictures have been 
taken with Leica Digital Camera DC200. 
 
2.8 SPIM 
SPIM (single plane illumination mycroscopy) technique allows a long term time-lapse 
acquisition of fluorescent samples (Bassi et al. 2015).  
 
2.8.1 Cleaning of FEP tubes  
For SPIM analysis embryos are included in FEP (fluorinated ethylene propylene) tubes with a 
diameter of 0.8x1.6 mm. Tubes must be washed with the following specific protocol before being 
used. 
 
Cleaning tubes protocol: 
  -  flush with NaOH 1M  
  -  place in NaOH 0.5 M  
  -  Sonicate 10 min RT in water  
  -  flush with double-distilled water 
  -  flush with EtOH 70%  
  -  place in EtOH 70%  
  -  Sonicate 10 min RT in water  
  -  flush and store in double-distilled water 
  -  cut tubes in segments of 2.5 cm in length  
  -  stock in deionized and distilled water.  
All solutions are degassed and filtered using a syringe filter (Millex-HV PVDF 0.45 µm).  
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Before embryos inclusion, tubes must be lubricated with methylcellulose 3% and wash with 
deionized and distilled water.  
 
2.8.2 Mounting of the embryos  
The mounting medium is composed of 0.1% agarose LMP (low melting point; Sigma) and 
tricaine 160 μg/ml. Embryos are placed in the mounting medium and drawn into the tube with a 
needle and syringe. Once the position of the embryos has been controlled, the tube is plugged 
with solid 1.5% agarose. After that, tubes are cut away from the syringe and positioned in an 
Eppendorf tube containing E3-1X, PTU1X and tricaine 160 μg/ml. The so mounted embryos are 
positioned in the SPIM machinery, ready for the acquisition. The SPIM machinery is equipped 
of a thermostat to maintain temperature at 28°C that is the optimal temperature for zebrafish 
embryo development. 
 
PTU10X in E3-1X  
  -  0.3 g PTU (1-Phenyl-2-Thiourea; Sigma)  
  -  1 l E3-1X E3-60X  
  -  34.8 g NaCl  
  -  1.6 g KCl  
  -  5.8 g CaCl2·2H2O  
  -  9.78 g MgCl2·6H2O  
  -  add double-distilled water until 2l volume is reached.  
Adjust the pH to 7.2 and autoclave. The medium is conserved at RT. 
 
Tricaine 160 μg/ml in PTU1X in E3-1X  
Dilute Tricaine 25X (1:25) in E3-1X with PTU1X. 
 
0.1% agarose LMP  
Dissolve 0.1 g of LMP agarose (Sigma) in 100 ml of PTU1X in E3-1X with tricaine. Dissolve 
at high temperature and let the medium solidify at RT. 
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1.5% agarosio LMP  
Dissolve 1.5 g of LMP agarose (Sigma) in 100 ml of PTU1X in E3-1X with tricaine. Dissolve 
at high temperature and let the medium solidify at RT. 
 
2.8.3 Acquisition of the embryos  
The embryo of interest is mounted in a little cell of the SPIM machinery containing E3-1X with 
PTU1X and tricaine 1X. The cell is equipped of a thermostat to maintain temperature at 28°C 
that is the optimal temperature for zebrafish embryo development. Every 5 minutes, a “z-
spacing” of 5 μm between two consecutive frames is acquired. The acquisitions are converted 
in photograms and mounted in videos. The software saves a stack every 50 acquisitions in order 
to allow 3D reconstruction of the image. 
 
2.8.4 Data analysis  
Acquisitions are analyzed with the ImageJ software adjusting brightness and contrast 
parameters. With ImageJ is also possible to mount single acquisition in a video. 
 
2.9 ANALYSES OF ENDOTHELIAL CELLS OVEREXPRESSING Sox13  
2.9.1 Overexpression of Sox13 in immortalized endothelial cells  
We use the pCMV5-Sox13 plasmid published in Stolt C., 2005.  
Endothelial cells, immortalized with polyomavirus T, are seeded in Petri dishes of 60 mm of 
diameter in order to be 3.2*104 cells/cm2 in MCDB 131 (Gibco) supplemented with glutamine, 
20% FBS NA, heparin and ECGS.  The second day, cells are washed 2 times with OPTIMEM 
(Life Technologies) and finally 4 ml of OPTIMEM are added; these passages must be done in 
the dark because OPTIMEM is photosensitive. Then the transfection solution, containing 
lipofectamine 2000 (Life Technologies) and Sox13 plasmid, is prepared as described by the 
following protocol.  
- Mix A: 0.5 ml of OPTIMEM+ 8 μg of DNA 
- Mix B: 0.5 ml of OPTIMEM+ 17 μl of lipofectamine 
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Mix A and mix B are mixed within 30 minutes and incubated for 20 minutes in the dark and at 
RT. Eventually cells are incubated for 5.5 hors at 37°C with 1 ml of transfection medium. At the 
end of the incubation the medium is changed and ampicillin is added to the medium. The day 
after, medium is changed and only transfected cells manage to survive because they have 
acquired ampicillin resistance.  
 
2.9.2 Transwell 3D migration assay  
Endothelial cells are seeded 50.000 ECs/well in 6 well plate. The day after, they are transfected 
with 15 ug of Sox13 plasmid using lipofectamine 2000. The third day medium is changed and, 
at day 4, cells are seeded for transwell migration. After 8 hours, cells are extracted for WB 
analysis and/or fixed with 4% PAF and stained for DAPI to acquire images. Cell count is 
performed with ImageJ. 
 
2.9.3 Western blot  
Total proteins are extracted by lysing cells in boiling sample buffer 2X. Lysates are incubated at 
100°C for 10 minutes, to allow protein denaturation, then they are centrifuged 5 minutes at 1500 
RPM to eliminate cellular residues. Protein concentration of the samples is measured with the 
bicinchoninic acid assay (BCA assay, Thermo Fisher Scientific). 
Buffer 4X is added to protein samples before loading them on 8% SDS-polyacrylamide gel 
(Biorad mini-protean 3 kit) to the electrophoresis. Protein are then transferred on a nitrocellulose 
filter for 3 hours at 240 mA in transfer buffer additioned with 20% of MeOH. The filter is 
incubated 1 hour with the blocking solution at RT in PBST with 5% milk and then with the 
opportune primary antibody (Vinculin antibody, Sigma; for Sox13 antibody see Baroti et al., 
2016) for 4 hours at RT in PBST with 5% milk.  
Finally the filter is washed with PBST and incubated with the opportune secondary antibodies 
for 45 minutes at RT. Secondary antibodies are coniugated with peroxidase and can be revealed 
using a chemiluminescence kit (ECL kit; GE Healtcare). The intensity of the so obtained bands 
is quantified using ImageJ software. 
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3.1 CHARACTERIZATION OF A NEW sox18 MUTANT: the sa12315 ALLELE 
Our data on zebrafish morphants demonstrated that sox7 and sox18 have a redundant role in 
arterio-venous differentiation (Cermenati et al. 2008) and that Sox18 has a conserved role in 
zebrafish lymphangiogenesis (Cermenati et al. 2013). However, data published on mutants 
then questioned the evolutionary conservation of the entire Sox18/Prox1/Coup-TFII 
regulatory axis (van Impel et al. 2014).  
In this context, we re-evaluated the role of Sox18 in zebrafish by making use of a new, 
independent mutant allele: sox18sa12315, that should behave as a null allele. 
The new sox18 sa12315 mutant line, coming from the Sanger Institute, carries a non-sense 
mutation within the HMG-box coding region that leads to a putative null allele encoding a 
truncated protein (fig.3.1A). 
In sox18sa12315, the mutation was kept in heterozygosity and the line was manteined by 
outcrossing with an AB wild-type line. For this reason we performed genotyping to identify 
heterozygotes. Genotyping could be done directly on adult fish, by fin clip, or through the 
analysis of the progeny, by extracting DNA from single embryos. 
We designed primers to amplify by PCR the region of sox18 gene carrying the mutation, then 
we could proceed by following two strategies. The former is to sequence the PCR product 
and to look at the pherograms to understand the genotype (fig.3.1B); the latter is the digestion 
of the PCR product. In this case, we took advantage of the fact that the mutation destroys a 
BstNI/MvaI restriction site, so the genotype of the embryos can be deduced from the 
digestion pattern. Genotyping can be performed on both non-fixed embryos and on embryos 
after ISH or in vivo analysis.   
	
	
Fig.3.1 The sox18sa12315 allele. A) Scheme of the sox18sa12315 allele that carries a non-sense mutation within the 
HMG-box coding region. The mutation converts the tryptophan in position 132 in a stop codon. B) Pherograms 
of a sox18+/+, sox18+/- and a sox18-/- mutant; the box indicates BstNI/MvaI restriction site in wild type and the 
corresponding region in heterozygotes and homozygotes. Red arrows indicate the mutated base.  
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3.1.1 Analysis of soxF expression in sox18sa12315 mutants 
sox7 
It is known from literature that, in mouse, Sox7 and Sox17 are ectopically expressed to 
compensate Sox18 mutation and restore a correct lymphatic development in a mixed 
background (Hosking et al., 2009). It is also known that the zebrafish sox18hu10320 mutant 
described by van Impel does not show lymphatic defects, but the authors of the article did 
not investigate about sox7 and sox17 expression pattern (van Impel et al., 2014). For this 
reason, we decided to evaluate sox7 expression in sox18sa12315 mutant by ISH analysis on the 
offspring of heterozygous mutants at 30 hpf. At this stage, sox7 is mainly expressed in the 
DA and in the caudal vein (CV), together with sox18, but its expression is detectable also in 
rhombomers in correspondence to the optic vesicle (fig.3.2). Genotyping, performed after 
ISH analysis, reveals that there are not significant differences in sox7 expression among wild-
type, heterozygous and homozygous embryos at 30 hpf in the AB background. To confirm 
that sox7 is not ectopically expressed in sox18sa12315 mutant line, my colleagues expanded 
ISH analysis to other developmental stages and other backgrounds since it is known from 
literature that, in mouse, the fine regulation of soxF depends on the genetic background 
(Hosking et al., 2009). sox7 ISH signal is upregulated in homozygous mutant embryos in the 
tg(lyve1:dsRed) background (see discussion). 
	
	
Fig. 3.2 sox7 expression is not grossly altered in sox18sa12315 mutants. ISH analysis followed by genotyping 
shows that sox7 expression is not grossly altered in the trunk region of sox18sa12315 in a AB background at 30 
hpf. Red arrowheads indicate the DA. 
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sox18 
 
We decided to evaluate if sox18sa12315 mutation causes variation in sox18 expression profile. 
To understand if sox18 RNA was eventually destabilized, we performed ISH analysis on the 
offspring of heterozygous mutants at 30 hpf in the AB background (fig.3.3). At this stage 
sox18 is mainly expressed in the posterior cardinal vein (PCV) and in the dorsal aorta (DA) 
but also in the eye. All the embryos show a comparable sox18 staining in non-vascular 
territories while in 15/18 embryos the vascular signal seems to be slightly reduced. We 
genotyped a pool of embryos with high and low signal and we found that there is not a 
correspondence between the genotype and the slight reduction of sox18 staining. Only 2/5  
sox18-/- embryos show a slight reduced sox18 expression while in 3/5 the expression is 
comparable to that of sox18+/+ embryos. So, we can conclude that, in the AB background, 
sox18sa12315 mutation does not cause variation in sox18 expression profile. 
 
 
 
	
Fig. 3.3 sox18 ISH signal is still detectable in sox18sa12315 mutants at 30 hpf. ISH analyses followed by 
genotyping show that sox18 signal is not grossly reduced in sox18sa12315 in a AB background at 30 hpf. Red and 
blue arrowheads: DA and PCV respectively.	
 
 
 
 
 
 
 
 
sox18	+/+ sox18	-/- 
1/1 2/5 sox18 
30 hpf 
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3.1.2 sox18sa12315 behaves as expected for a null mutant 
In vivo analysis of blood circulation 
To understand if sox18sa12315 behaves as expected for a null mutant, we decided to analyze 
the circulatory phenotype of the offspring of heterozygous mutants.  
We analyzed three groups of embryos:  
• uninjected mutant embryos, to evaluate the effect of sox18 mutation; 
• sox18 mutant embryos injected with subcritical doses of sox7 morpholino to compare 
the phenotype caused by sox7 knockdown in a sox18 mutant background with the 
circulatory phenotype observed in sox7/sox18 double partial morphants (fig 3.4A). 
The doses of sox7MO were selected as they were shown to be subcritical in previous 
studies (Cermenati et al., 2008); 
• embryos injected with a control morpholino (std-MO) to exclude that the circulatory 
phenotype was caused by the microinjection itself. 
Embryos were followed from 1 dpf to 3 dpf and, in general, they do not show severe 
morphological alterations or developmental delays. We analyzed the circulation of the trunk-
tail region because this is the region in which sox7/sox18 double partial morphants show 
circulatory defects (Cermenati et al., 2008). We defined three different phenotypic classes: 
normal, reduced or absent trunk-tail circulation. 
At 2 dpf, most of uninjected and std-MO embryos show a normal trunk-tail circulation, while 
only a small number of embryos have absent trunk-tail circulation. Most of the embryos 
having absent trunk-tail circulation show a “short circulatory loop” involving the heart region 
and the Cuvier duct. The number of embryos showing circulatory defects becomes higher 
after the injection of low doses of sox7 morpholino; the circulatory phenotype is dose-
dependent since it is more evident when the higher dose of sox7MO (0.25 pmol) is used (fig. 
3.4B and 3.4C). Since it is known from literature that sox7/sox18 double partial morphants 
(Cermenati et al. 2008) and sox7/sox18 double mutants have circulatory defects (Hermkens 
et al. 2015), it is interesting to notice that a significant number of sox18 mutant embryos 
show a “short circulatory loop” after sox7 perturbation. 
At 3dpf, we have a similar situation (fig.3.4D); most of uninjected and std control embryos 
show normal trunk-tail circulation, while injection of subcritical doses of sox7MO causes the 
absence of trunk tail circulation and the presence of the “short circulatory loop”. 
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We focused our interest on embryos showing absent trunk-tail circulation to understand if 
this phenotypic class was enriched in heterozygous and homozygous embryos. Genotyping 
analyses, performed at 3 dpf, of 9 uninjected embryos with absent circulation reveal that this 
phenotype is typical of sox18 heterozygotes (7/9) and regards only few wild type embryos 
(2/9). Among the 20 genotyped embryos with absent circulation and injected with 0.25 pmol 
of sox7MO, 15/20 are sox18+/- and 1/20 is sox18-/-. Those numbers become more interesting 
in embryos injected with 0.125 pmol of sox7MO and showing absent circulation; in this case, 
we found 4/14 heterozygotes and 10/14 homozygotes. So, genotyping reveals that 
perturbation of sox7 expression exacerbates the circulatory defects in heterozygous and 
homozygous embryos.   
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Fig. 3.4 In vivo analysis of trunk-tail circulation in the offspring of sox18 heterozygous adult fish. A) 
Experimental scheme: two subcritical doses of sox7-MO (0.25 pmol and 0.125 pmol) are injected in the 
offspring of sox18 heterozygous adult fish. B) The new allele sox18sa12315 behaves as expected for a null mutant: 
genotyping analysis indicates that sox18sa12315 homozygous mutants are enriched in the “absent circulation” 
category of embryos when sox7 expression is perturbed. C) and D) Tables showing the number of embryos 
analyzed for each experimental condition at 2 dpf and 3 dpf, respectively. 
 
Molecular analysis of sox18sa12315 mutants 
We decided to analyze the structure of the vascular tree by performing ISH analysis for some 
interesting markers on the offspring of sox18sa12315 heterozygotes in order to understand the 
effect of sox18 mutation at a molecular level and to identify possible targets of Sox18. 
In each experiment, fertilized eggs have been divided stochastically in 3 experimental groups: 
uninjected, injected with subcritical doses of sox7MO and injected with a control morpholino 
(std-MO). For each embryo, the ISH signal of the marker of interest has been analyzed and 
genotyping analyses were performed after ISH to score for any correlation between the 
intensity of the ISH staining of the marker and the genotype of the embryo. 
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• vsg1 
Zebrafish vsg1 (vessel specific gene1) is the homologue of human PLVAP (plasmalemma 
vescicle associated protein) gene and, in zebrafish, it has a panendothelial expression around 
30 hpf when it becomes to be expressed preferentially in the PCV.  We focused our attention 
on vsg1 because it is the most downregulated marker in sox7/sox18 double partial morphants 
both in ISH analysis (fig. 3.5A, Cermenati et al. 2008) and in RNA sequencing data 
(unpublished results in collaboration with Giulio Pavesi from the University of Milan). 
To understand if sox18sa12315 mutants behave as sox18 morphants, we analyzed vsg1 
expression at 30 hpf by ISH in mutants and siblings either uninjected or injected with a 
subcritical dose of sox7MO and a std-MO (fig. 3.5C). According to the intensity of vsg1 
signal in the PCV, we divided embryos in three phenotypic classes: strong, intermediate and 
very faint/absent vsg1 signal.  
In mutants and siblings either uninjected or injected with a std-MO, there are only the first 
two phenotypic classes, while embryos injected with a subcritical dose of sox7MO show also 
a faint/absent vsg1 signal (fig. 3.5B and C).  
All the embryos have been genotyped to look for a correlation between the genotype and 
vsg1 expression level. Genotyping reveals that vsg1 expression in the PCV is not altered in 
most wild-type embryos in all the three experimental conditions.  
As for sox18sa12315 homozygous mutants, there is a close correlation between the phenotype 
and the genotype. Indeed, uninjected and stdMO homozygotes show a slight reduction of 
vsg1 signal in the PVC and this reduction becomes stronger when we perturbed sox7 
expression by injecting a subcritical dose of morpholino (fig. 3.5B and C). 
Heterozygotes, instead, show a more variable phenotype in all the experimental conditions 
analyzed: most of them have a slightly reduced vsg1 signal in the PCV, while in a small 
number of embryos, vsg1 signal is comparable to that of wild type.  
In conclusion, vsg1 signal is strong in wild-type embryos, slightly reduced in heterozygotes 
and extremely faint or completely absent in homozygous embryos when sox7 is perturbed, 
as expected from redundancy of soxF genes (fig. 3.5B and C). 
To demonstrate that the absence of vsg1 signal was not due to alterations in the structure of 
the vascular tree, we performed ISH for the panendothelial marker cdh5 (vascular endothelial 
cadherin). Genotyping analyses show that cdh5 expression does not change in wild-type, 
heterozygous and homozygous mutant embryos at 30 hpf (fig. 3.5D). 
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Fig. 3.5 vsg1 expression is strongly downregulated both in sox7/sox18 double partial morphants and in 
sox18sa12315 embryos injected with subcritical doses of sox7-MO. A) vsg1 is the most downregulated gene in 
sox7/sox18 double partial morphants as shown by ISH analysis at 29 hpf (Cermenati et al., 2008). B) Table 
showing the results of genotyping analysis; prevalent categories are highlighted in yellow. C) At 30 hpf, vsg1 
expression is slightly downregulated in sox18 heterozygotes mutants, while it is strongly downregulated in 
homozygotes after sox7 perturbation. D) vsg1 downregulation is not caused by gross alteration in axial vessels 
that are normally formed as shown by cdh5 staining at 30 hpf. 
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• notch1b	
notch1b is one of the two paralogues of mammalian Notch1 (the other is notch1a).  I focused 
my interest on Notch1 because Notch signaling is involved in arterio-venous differentiation 
of endothelial cells, and it is important for intersomitic sprouts. 
Moreover, notch1b has been linked to lymphangiogenesis, indeed, a recent work shows that 
lymphatic vessels arise from specialized angioblasts of the ventral wall of cardinal vein that 
express notch1b together with nr2f2 and fzd7a (Nicenboim J. et al. 2015). The analysis of 
RNA sequencing data performed during my first PhD year pointed to a statistically 
significant downregulation of notch1b in sox7/sox18 double partial morphants at 22 somites 
stage (unpublished results, in collaboration with Giulio Pavesi from the University of Milan). 
My first aim was to validate the results obtained in RNA sequencing by in situ hybridization. 
I chose this technique because, differently from others such as Real-Time PCR, it gives 
spatial information about gene expression.  In situ of sox7/sox18 double partial morphants at 
22 somites stage did not give informative results (data not shown) because at this stage 
notch1b signal in the somites masks the signal in the axial vessels.  
However, I expanded the analysis of notch1b expression in std control embryos and in 
sox7/sox18 double partial morphants at 24hpf (fig.3.6A). 
At this stage, in control embryos, notch1b is expressed not only in the DA and in the 
intersomitic vessels (ISVs) but also in the central nervous system. sox7/sox18 double partial 
morphants show a very strong vessel-specific notch1b downregulation. notch1b 
downregulation is not due to alteration of the vascular system because the signal of the 
panendothelial marker cdh5 and of the arterial one flt1 is comparable among control embryos 
and sox7/sox18 double partial morphants. In RNA sequencing probably we do not see the 
strong vascular reduction of notch1b at 24 hpf because the strong signal in the nervous system 
masks the downregulation in the vascular one.  
To understand if the sox18sa12315 mutant behaves as a null mutant, I analyzed notch1b 
expression pattern at 24 hpf in mutants and siblings either uninjected or injected with a 
subcritical dose of sox7MO and a stdMO (fig.3.6B). ISH analyses, followed by genotyping, 
show that notch1b expression is comparable in wild type, heterozygotes and homozygotes 
uninjected or injected with stdMO. The perturbation of sox7 expression causes a strong 
specific vascular notch1b downregulation in the vascular district of most homozygotes (6/7), 
while wild-type and heterozygous embryos show a comparable and vastly unchanged 
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notch1b signal. So, sox18sa12315 mutant behaves as sox7/sox18 double partial morphants when 
sox7 is perturbed.  
All this data about notch1b are part of an article published this year and stating that, in 
zebrafish, SoxF proteins positively regulate notch1b.  Indeed, notch1b mRNA expression is	
strongly downregulated both in sox7/sox18 double partial morphants and in sox7/sox18 
double knockout.  This work identifies SoxF responsive enhancers in Notch1 and notch1b 
loci in mouse and in zebrafish, respectively, demonstrating for the first time that Sox7 and 
Sox18 physically interact with Notch1/notch1b enhancers (Chiang et al. 2017).  
 
 
Fig. 3.6 SoxF TFs regulate notch1b endothelial expression. A) At 24 hpf, notch1b ISH signal is 
downregulated in sox7/18 double partial morphants. This downregulation is not caused by alteration in axial 
vessels that are normally formed as shown by flt1 and cdh5 staining. B) At 24hpf, nocth1b is strongly 
downregulated in the vascular district of sox18-/- mutants when sox7 is partially knocked down. 
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3.1.3 sox18sa12315 mutants show subtle lymphatic defects, highly enhanced under perturbed 
Vegf-C signaling  
In mammals, Sox18, with Prox1 and Coup-TFII, is at the top of the molecular hierarchy that 
drives lymphatic development. Sox18-null mice develop lymphedema only in certain genetic 
backgrounds (Hosking et al., 2009) and only a subset of patients carrying SOX18 mutations 
show signs of lymphatic dysfunction (Slee, 1957; Irrthum et al., 2003).  
My laboratory demonstrated that sox7/sox18 double partial morphants show defects in 
arterio-venous differentiation (Cermenati et al. 2008) and that sox18 morphants have 
impaired lymphangiogenesis (Cermenati et al. 2013). However, the entire 
Sox18/Prox1/Coup-TFII regulatory axis has been questioned by data published on mutants 
(van Impel et al. 2014).  
In this context, we tried to clarify the role of Sox18 in zebrafish lymphangiogenesis by 
analyzing lymphatic development in sox18sa12315 mutants. 
There are two critical phases during lymphatic system development. In the former, lymphatic 
precursors (PLs) migrate along the arterial intersomitic vessels to reach the horizontal 
myoseptum following Vegf-C signaling; PLs reside at the horizontal myoseptum at 2.5 dpf.  
The latter phase is the formation of the thoracic duct (TD) which starts around 3.5 dpf and is 
complete by 5 dpf. 
In order to follow lymphatic system development in vivo, we crossed sox18 heterozygous 
mutants with two endothelial-specific transgenic lines: lyve1:dsRed and  fli1a:EGFP .  
In the lyve1:dsRed line, reporter gene expression is driven by a venous/lymphatic regulatory 
region; this line is useful to analyze TD formation. In fli1a:EGFP transgenic line, the 
expression of the reporter gene is detectable in the whole vasculature and it is interesting to 
study PL migration at the horizontal myoseptum. 
sox18sa12315 mutants show a subtle decrease in lymphatic precursors (PLs)  
We started to analyze PL migration in uninjected sox18 mutant embryos at 52 hpf in the 
transgenic background fli1a:EGFP.  The number of PL+ segments on one side of each embryo 
was counted and plotted after genotyping (Fig.3.7 A and B). 
As shown by confocal images (fig.3.7A), in sox18 mutants there is a wide range of 
phenotypes. At 52 hpf, the mean value of PLs that manage to reach the horizontal myoseptum 
is lower in heterozygotes and homozygotes if compared to wild-type embryos. 
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The partial decrease in PL+ segments at the horizontal myoseptum in heterozygous and 
homozygous mutant embryos is subtle but statistically significant (fig. 3.7B). 
Taken together these data confirmed the phenotype observed in sox18 morphants and 
reinforce the notion of an involvement of sox18 in zebrafish lymphatic development.  
Since data gathered in my laboratory pointed to a genetic interaction between sox18 and vegfc 
in lymphatic development (Cermenati et al., 2013), we tried to clarify this point by 
performing PL analysis also in sox18 mutant embryos injected with vegfc morpholino, using 
doses which were shown to be subcritical in other genetic backgrounds (Cermenati et al., 
2013). Unfortunately, we had some problems in defining the dose of vegfcMO because the 
dose we used (0.045 pmol) affected PL migration independently from the genotype of the 
embryos (fig. 3.7C). Preliminary data, using a lower dose of vegfcMO (0.03 pmol), suggest 
that this dose affects PL migration in a genotype-dependent manner (data not shown). 
 
 
Fig. 3.7 sox18 mutants show PL defects at 52hpf in a fli1a:EGFP transgenic background. A) Confocal 
images of PL defects in uninjected sox18 mutants at 52 hpf. Arrows indicate the presence of PLs, while 
asterisks indicate PL- segments. B) and C) The number of PL+ segments from one side of each embryo was 
counted and plotted after genotyping. B) At 52hpf, heterozygous and homozygous mutants have a slight but 
statistically significant reduced number of PLs if compared to wild-type embryos. C) 0.045 pmol of vegfcMO 
affected PL migration independently from the genotype of the embryos, so it is not a subcritical dose in this 
genetic background. n=number of analyzed embryos. 
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sox18sa12315 mutants show subtle defects in TD formation, exacerbated when Vegf-C 
signaling is perturbed 
To better characterize the role of Sox18 in zebrafish lymphangiogenesis and to clarify if 
Sox18 genetically interacts with Vegf-C during this process, we analyzed TD formation at 5 
dpf in mutant and sibling larvae either uninjected or injected with a subcritical dose of vegfc 
morpholino. We performed the analysis in both lyve1:dsRed and  fli1a:EGFP transgenic 
backgrounds. The number of TD+ segments on one side of each embryo was counted and 
plotted after genotyping. 
Data obtained in uninjected tg(lyve1:dsRed);sox18sa12315 line reveal that the mutation does 
not cause strong alterations of lymphatic system development, but  larvae show a very 
heterogeneous range of phenotypes. In general, most of wild-type larvae show a completely 
formed TD (fig. 3.8A) but some of them can have defects in TD formation. The number of 
larvae with TD defects becomes significantly higher in homozygotes, while heterozygotes 
show an intermediate phenotype (fig. 3.8B). 
Perturbation of vegfc signaling, injecting a subcritical dose of vegfcMO, exacerbates TD 
defects in a genotype-dependent manner (fig. 3.8B). TD analysis performed in the 
tg(fli1a:EGFP);sox18sa12315 line confirmed the phenotype observed in the previous line (fig. 
3.8C). Even in this case, wild-type larvae show a heterogeneous TD phenotype, with most 
larvae showing a completely formed TD and some others showing TD defects. TD alterations 
are more common in homozygotes, while heterozygotes have a phenotype comparable to that 
of wild-type larvae in this line. 
Also in tg(fli1a:EGFP);sox18sa12315 , injection of a low dose of vegfcMO is crucial in 
highlighting TD defects in sox18sa12315 mutants. This is true even if the dose of vegfcMO used 
is not a truly subcritical dose because it exacerbates TD defects also in injected wild-type 
larvae (fig. 3.8C). However, TD defects caused by this dose of vegfcMO are not comparable 
to the strong phenotype observed after injection of high doses of vegfcMO.  
Taken together, these data confirmed the phenotype observed in sox18/vegfc compound 
double morphants and reinforce the notion of a sox18-vegfc genetic interaction that had 
been suggested by previous knockdown studies (Cermenati et al, ATVB 2013).	
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Fig. 3.8 sox18 homozygous mutants show statistically significant TD defects at 5 dpf in two different 
transgenic backgrounds. A) Confocal images of TD defects in uninjected sox18 mutants in the transgenic 
background lyve1:dsRed. Arrows indicate TD+ segments, while asterisks indicate TD- segments. B) and C) 
The number of TD+ segments from one side of each embryos was counted and plotted after genotyping. 
Analyses were performed respectively in a lyve1:dsRed and in a fli1a:EGFP transgenic background. 
TD defects are exacerbated in sox18 heterozygous and homozygous mutants under slightly perturbed VegfC 
signaling. n=number of analyzed embryos. 
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3.1.4 Hierarchy of SoxF and SoxD transcription factors 
I decided to evaluate sox13 expression in sox18sa12315 mutants because my laboratory had 
recently shown that sox13 is transiently expressed in the endothelial cells of the dorsal aorta 
(DA) and that, in sox7/sox18 double partial morphants, sox13 vascular expression is strongly 
downregulated while its expression in the central nervous system is unchanged (fig. 3.9A) 
(Boezio et al., unpublished). 
Since sox13 expression in the DA is detectable until 24 hpf, we chose the stage of 22 hpf to 
perform ISH analysis on the offspring of sox18sa12315 heterozygotes injected with a subcritical 
dose of sox7MO. Embryos injected with a stdMO were used as a control of the microinjection 
and uninjected embryos were analysed to understand the effect of the sox18 mutation only 
on the expression of sox13. Genotyping was performed after ISH analysis. 
All the embryos show a comparable level of sox13 expression in the central nervous system, 
while some of them show a slightly reduced sox13 signal in the DA (fig. 3.9B). We classified 
embryos in three phenotypic classes according to sox13 signal in the DA: strong, reduced 
and faint/ absent signal and we genotyped some embryos for each phenotypic class and for 
each experimental condition. 
Genotyping reveals that in mutants and siblings either uninjected or injected with a stdMO, 
the vast majority of wild-type embryos and most heterozygotes show a strong level of sox13 
in the DA. Homozygotes show a slight reduction of sox13 signal in the DA; this reduction 
becomes stronger when sox7 is perturbed in heterozygotes and homozygotes (fig. 3.9D).  
sox13 reduction in the DA it is not caused by alteration of the vascular system because cdh5 
staining at 22 hpf is comparable among the three experimental conditions (fig. 3.9C), we 
therefore decided to not genotype embryos hybridized with the cdh5 probe. 
 
Fig. 3.9 Endothelial expression of sox13 is strongly downregulated both in sox7/sox18 double partial 
morphants and in sox18sa12315 embryos injected with subcritical doses of sox7-MO. A) At 22 hpf, sox13 
ISH signal is downregulated in sox7/18 double partial morphants (Boezio et al., unpublished). B) At 22 hpf, in 
mutants and siblings, either uninjected or injected with a stdMO, the vast majority of wild-type embryos and 
most heterozygotes show a strong level of sox13 in the DA. Homozygotes show a slight reduction of sox13 
signal in the DA. After sox7 perturbation, most of the heterozygotes show an intermediate or a low sox13 signal 
in the DA, while all the homozygotes show a faint or absent sox13 staining in the DA. Red arrowheads indicate 
the DA C) sox13 downregulation is not caused by alteration in the DA that is normally formed as shown by 
cdh5 staining at 22 hpf. D) Table showing the results of genotyping analysis; prevalent categories are 
highlighted in yellow. 
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3.2 CHARACTERIZATION OF SOX13 ROLE IN ANGIOGENESIS 
3.2.1 A dynamic characterization of ISV defects in sox13 morphants using SPIM 
technique 
In my laboratory, there is the evidence that also sox13 is involved in zebrafish vascular 
development, indeed it is transiently expressed in the DA and sox13 morphants show defects 
in the ISVs (Omini et al., unpublished; Boezio et al., unpublished). 
However, the analyses performed on sox13 morphants have been limited to a static 
observation of ISVs defects at different time points. sox13 morphants show a compromised 
primary angiogenesis, with a wide range of ISV defects. Some ISVs are blocked at the 
horizontal myoseptum while some others are completely absent. Moreover, some possible 
defects in ISVs maturation during secondary angiogenesis have been hypothesized (Boezio 
et al., unpublished).   
To dynamically characterize the angiogenic phenotypes of sox13 morphants in vivo, we 
collaborated with Professor Andrea Bassi, from the Politecnico di Milano”, to perform 
long-term time-lapse analysis of sox13 morphants with SPIM. 
SPIM (single plane illumination microscopy) technique had never been used in my laboratory 
and my colleagues set up the experimental conditions on the base of the information available 
in literature (Kaufmann et al. 2012).  
After setting up the best experimental conditions (well described in the material and methods 
section), we started the in vivo analysis of sox13 morphants in the kdrl:EGFP;gata1:dsRed 
transgenic background. This transgenic line allows the visualization of the whole vascular 
tree since the EGFP is under the control of the endothelial regulatory region of kdrl.  
sox13 morphants and uninjected control embryos were acquired from 26 hpf to 3 dpf. Our 
initial aim was to acquire embryos at 22 hpf in order to characterize the events occurring 
during both primary and secondary angiogenesis. However, some technical problems 
prevented us from doing this: sox13 morphants are too fragile to be included at 22 hpf. The 
advantage of including sox13 morphants at 26 hpf is that we can select and include only the 
embryos with the most interesting phenotype. 
The acquisitions are converted in photograms, mounted in videos and analyzed. Data analysis 
confirmed developmental delay of sox13 morphants and allowed a better characterization of 
the ISV defects. 
Control embryos develop a completely normal vascular tree in which all the ISVs manage to 
reach the dorsal portion of the embryo and form complete dorsal longitudinal anastomotic 
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vessels (DLAVs). On the contrary, sox13 morphants show a wide range of ISV defects: some 
ISVs are blocked at the myoseptum, others migrate slowly and some others merged together 
(fig. 3.10B). We also saw a new type of event that can be seen only in a dynamical in vivo 
analysis: some ISVs first migrate up to the DLAV and then regress in a ventral to dorsal 
direction after detaching from the axial vessel (fig. 3.10A). 
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Fig. 3.10 In vivo dynamic characterization of the angiogenic phenotypes of sox13 morphants in 
tg(kdrl:EGFP;gata1:dsRed) line. A) In sox13 morphants, there are a wide range of ISV defects. Yellow 
arrowheads indicate an ISV blocked at the horizontal myoseptum. Red arrows and asterisks indicate an ISV 
that first migrates up to the DLAV (red arrows) and then regresses in a ventral to dorsal direction after 
detaching from the axial vessel (asterisks). Control embryos do not show ISV defects. B) Table showing the 
type of ISV defects found in three sox13 morphants analyzed along ten consecutive segments rostral to the 
anus. Uninjected control embryos show a perfectly formed vascular tree. n= number of analyzed ISVs. 
3.2.2 Knockdown experiments using an independent sox13 morpholino confirmed Sox13 
involvement in ISV angiogenesis 
In my laboratory, it had been demonstrated that, in sox13 morphants, primary and secondary 
angiogenesis are compromised. In particular, sox13 morphants show a lower number of 
venous ISVs at 2.5 dpf (Omini et al., unpublished; Boezio et al., unpublished). 
To reinforce these data, we performed in vivo analysis of ISV defects in embryos injected 
with an independent sox13 morpholino (see the material and methods section for details). 
First, we tested morpholino efficacy using reverse transcriptase (RT) PCR to measure sox13 
expression levels at 22 hpf in embryos of the AB line injected with sox13MO and in control 
embryos. As expected, sox13 RNA expression level is lower in sox13 morphants than in 
stdMO embryos. This is not due a lower concentration of the RNA extracted by sox13 
morphants as the actb1 RT-PCR points out (fig. 3.11A). 
Then we started in vivo analysis of ISV defects at 2.5 dpf to confirm the phenotype observed 
in previously analyzed sox13 morphants. sox13 morpholino and stdMO control embryos 
were analyzed in a tg(fli1a:EGFP) background.  
ISVs on one side of each embryo were counted and classified as arterial (aISVs) or venous 
(vISVs) ISVs, depending on their sprouting from the DA or from the PCV. 
At this stage, in std control embryos there is a comparable number of arterial and venous 
ISVs, as expected. sox13 morphants show the absence of some ISVs. The number of arterial 
and venous ISVs are reduced, in a highly significant way (fig. 3.11B). So, this independent 
sox13 morpholino causes the reduction of both arterial and venous ISVs, thus affecting both 
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primary and secondary angiogenesis, as previously hypothesized (Boezio et al., 
unpublished). Taken together, these data support the involvement of sox13 in angiogenesis.  
 
 
 
Fig. 3.11 Characterization of sox13MO4 morphants phenotype. A) RT-PCR on total RNA extracted from 
sox13 morphants injected with sox13MO4 and control embryos. The size sox13 PCR fragments is 454 bp in 
both sox13 morphants and controls. actb1 PCR fragment is 560 bp.  sox13MO4 causes the decrease of sox13 
RNA, as expected. Embryos of the AB line were injected with 0.8 pmol of sox13MO4 and 0.8 pmol of stdMO. 
B) sox13-MO4 injection in tg(fli1a:EGFP) line causes a statistically significant reduction of both arterial ISVs 
and venous ISVs. In the upper graph, absent (white bars), arterial (red patterned bars) and venous	(blue patterned 
bars) ISVs are plotted.  In the bottom graph, full length aISVs (red bars) and full length vISVs (blue bars) are 
separated from ISVs blocked at the myoseptum to better describe the range of ISV defects detectable in sox13 
morphants. White bars indicate absent ISVs, light red bars reduced in length aISVs, light blue bars reduced in 
length vISVs. n= number of analyzed embryos. 
 
3.2.3 Sox13 overexpression increases endothelial cell migration 
To understand if ISV defects found in sox13 morphants was due to a problem in endothelial 
cells migration, our collaborator Costanza Giampietro, a former member of our Department, 
currently at ETH of Zurich, performed some in vitro experiments. We transfected Sox13 
plasmid in immortalized mouse lung endothelial cells and performed an in vitro migration 
assay; non-transfected cells were used as control. Western blot analysis confirmed that Sox13 
protein level was higher in endothelial cells in which Sox13 had been overexpressed 
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compared to controls (fig. 3.12A). So, we started the transwell migration assay for 8 hours 
and then we fixed cells and counted them with ImageJ (fig. 3.12B). Statistical analysis 
revealed that Sox13 overexpressed cells migrate more than control cells (fig. 3.12C). These 
data suggest an involvement of Sox13 in endothelial cell migration. In particular, we can 
speculate that, if Sox13 overexpression increases endothelial cells migration, Sox13 absence 
could cause migration problems. Therefore, ISV defects found in sox13 zebrafish morphants 
could be caused by the fact that sox13 absence in endothelial cells affects their migration.   
 
 
Fig. 3.12 sox13 overexpression increases endothelial cell migration. A) Western blot analysis confirmed that 
Sox13 protein level was higher in endothelial cells in which Sox13 had been overexpressed compared to control 
cells. B and C) In vitro transwell migration assay of Sox13 overexpressed endothelial cells and control cells. 
B) DAPI staining; C) Statistical analysis of the number of cells/field. 6 experiments have been performed, each 
in duplicate. ImageJ software has been used for automated count of cell nuclei in 1 field/sample. 
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An accurate knowledge of the players, the signaling pathways and the mechanisms that 
regulate the correct patterning of the cardiovascular system is very relevant, especially 
because the molecular mechanisms involved in pathological processes could be sometimes 
similar or identical to those used during embryogenesis (Folkman, 1995). 
SOXF transcription factors are crucial for vascular and lymphatic system 
development (François et al. 2010; Lilly et al. 2016). Several laboratories, including ours, 
have shown with knockdown approaches that sox7 and sox18 play redundant roles in arterio-
venous differentiation of endothelial cells (Cermenati et al. 2008; Herpers et al. 2008; 
Pendeville et al. 2008). In sox7/sox18 double partial morphants endothelial cells fail to 
acquire a full arterio-venous identity. This causes the formation of anomalous shunts between 
arteries and veins leading to the block of circulation in the trunk- tail region of the embryo. 
The same phenotype has been recently observed in sox7/sox18 double mutants (Hermkens et 
al. 2015). The correspondence between the mutants and the morphants phenotype is of crucial 
importance since morpholino reliability has been recently questioned. 
Morpholino (MO) based knockdown approach has revolutionized the study of gene 
function and a lot of work has been done by using this technique. However, the recent 
development of new genome engineering techniques has allowed the easy generation of a lot 
of mutants. The problem is that not all the zebrafish mutants show the same phenotype of the 
corresponding morphants, so the use of MOs has been debated. Moreover, MO injection can 
induce p53-dependent apoptosis and off-target cell-type-specific changes in gene expression 
that confound phenotypic analysis (Ekker and Larson 2001). The mechanism of p53 
activation after MO injection has not been fully understood, but it is demonstrated that off-
target phenotypes can be avoided by coinjecting the MO of interest with p53MO (Robu et al. 
2007). Since several hypotheses can explain the phenotypic differences among mutants and 
morphants, morpholino reliability is still recognized but there are some recommendations to 
take into account when using MO, as described in the introduction. 
In humans, mutations in SOX18 are associated with the Hypotrichosis-Lymphedema-
Telangiectasia (HLT) syndrome, characterized by defects in hair, blood vessels and 
lymphatic development (Irrthum et al., 2003); a renal failure associated with SOX18 mutation 
(HLT-renal defect syndrome or HLTRS) has also been reported (Moalem et al., 2014). 
The murine counterpart of the disease is represented by the ragged phenotype (Slee, 1957) 
due to the spontaneous mutations in Sox18 (Pennisi et al., 2000). The most severe allele, 
ragged-opossum (RaOp), causes the production of a truncated SOX18 protein which acts in 
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a dominant-negative manner (Pennisi et al., 2000a; Downes and Koopman, 2001). This allele 
causes embryonic lethality before E11.0 in homozygous mutant mice (Green and Mann, 
1961; Pennisi et al., 2000b; Downes and Koopman 2001). On the other hand, Sox18-null 
mice were originally described as viable and presented only a mild coat defect (Pennisi et al., 
2000a). This happens because, Sox7 and Sox17 are ectopically upregulated during mouse 
lymphangiogenesis and they act as strain specific modifiers compensating lymphatic defects 
caused by Sox18 dysfunction in a mixed 129-CD1 background (Hosking et al., 2009). Indeed, 
Sox18 null mice show gross subcutaneous edema at E13.5 and died after E14.5 in a pure B6 
background  (Francois et al., 2008).  
In zebrafish, the role of sox18 in lymphangiogenesis is now debated. Indeed, 
sox18hu10320 mutants (van Impel et al. 2014) do not show the lymphatic phenotype observed 
in sox18 morphants (Cermenati et al., 2013). However, van Impel and colleagues did not 
check if the absence of lymphatic phenotype was due to sox7 or sox17 ectopic expression. 
To clarify Sox18 role in zebrafish lymphangiogenesis, we made use of a new, 
independent mutant allele: sox18sa12315, that should behave as a null allele.  In sox18hu10320 
mutant, a 1-bp insertion preceding the HMG-box causes a frame-shift leading to a premature 
stop codon after additional 50 amino acids. The new sox18 sa12315 mutant line, generated at 
the Sanger Institute, carries a non-sense mutation within the HMG-box coding region that 
leads to a putative null allele encoding a truncated protein. 
We started the characterization of this sox18 mutant to understand if it behaves as a null.  
As first step, we decided to evaluate sox18 and sox7 expression profile at 30 hpf in 
the mutant background. We chose this developmental stage because it is the moment in 
which sox7 expression starts to be restricted to the dorsal aorta (DA), while sox18 continues 
to be expressed both in the DA and in the posterior cardinal vein (PCV). The offspring of 
heterozygous mutants in the AB background was analyzed by ISH. Genotyping reveals 
that, in this background, sox18sa12315 mutation does not cause gross variation in sox18 
expression profile and that sox7 is not overexpressed in sox18sa12315 mutant line. However, 
in the laboratory, my colleagues expanded ISH analysis to other developmental stages and 
other backgrounds, finding that sox7 signal is higher in the caudal vein (CV) of 
homozygous embryos in a tg(lyve1:dsRed)nz101 background, at 24 hpf. They checked also 
for sox17 expression profile, showing that it is not upregulated at this stage and in this 
background. Taken together, these data confirm that, also in zebrafish as in mouse, the fine 
regulation of soxF genes expression depends on the genetic background.  
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In vivo analyses of sox18sa12315 mutants show that they behave as expected for a null 
mutant and they recapitulate the circulatory phenotype observed in sox7/sox18 double partial 
morphants, after perturbation of sox7 expression with subcritical doses of sox7MO.  
We analyzed, at 2 dpf and 3 dpf, mutants and siblings either uninjected or injected with 
subcritical doses of sox7 morpholino and stdMO, as a control for unspecific effects. 
Genotyping reveals that most of wild-type and heterozygous uninjected and std control 
embryos show a normal circulation; only a small number of heterozygotes show absent 
circulation. This means that the sox18 mutation only is not sufficient to cause circulatory 
defects, because Sox7 can compensate Sox18 absence as shown in literature through 
knockdown studies (Cermenati et al. 2008; Herpers et al. 2008; Pendeville et al. 2008). 
In embryos injected with subcritical doses of sox7MO, circulatory defects are exacerbated, 
indeed most of heterozygotes and homozygotes show absent circulation. These data are in 
agreement with literature, where it has been shown that both sox7/sox18 mutants and 
sox7/sox18 double partial morphants show defects in trunk-tail circulation (Cermenati et al. 
2008; Herpers et al. 2008; Pendeville et al. 2008; Hermkens et al. 2015). 
My laboratory performed a molecular analysis of sox7/sox18 double partial 
morphants by ISH (Cermanati et al. 2008) and by RNA sequencing (unpublished data, in 
collaboration with Giulio Pavesi from the University of Milan) with the aim to identify 
possible Sox18 direct or indirect targets. The most promising gene is vsg1 because it is the 
most downregulated marker in sox7/sox18 double partial morphants both in ISH and in RNA 
sequencing data. 
vsg1 (vessel specific gene1) is the homologue of human PLVAP (plasmalemma 
vescicle associated protein) gene that codifies for PV1, a transmembrane glycoprotein 
associated to the fenestrated endothelium (Hnasko et al. 2002; Strickland et al., 2005). In 
mammals, PLVAP is crucial for the development of diaphragms in fenestrated blood vessels 
(Guo et al., 2016), indeed homozygous Plvap-deficient mice lack diaphragms (Herrnberger 
et al., 2012; Stan et al., 2012; Herrnberger et al., 2014) and, in a pure background, die before 
birth because of subcutaneous edema, hemorrhages, and defects in the vascular wall of 
subcutaneous capillaries. Plvap-/- mice, in a mixed genetic background, are born and survive 
at the most for 4 weeks (Herrnberger et al., 2012; Herrnberger et al., 2014). 
Furthermore, Plvap interacts with chemoattractants and adhesion molecules and regulates the 
extravasation of macrophage and leucocyte from fenestrated endothelium. Rankatari and 
colleagues showed that Plvap selectively controls the exit of macrophage precursors from the 
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fetal liver (Rankatari et al., 2016) and that it facilitates lymphocyte migration, presumably 
by sustaining the selective entry of lymphocytes into the parenchyma, in addition to offering 
the path of least resistance through cell bodies (Rankatari et al., 2015).  
Different studies have also suggested that, in humans, PLVAP is upregulated in various 
pathophysiological processes associated with angiogenesis, including tumorigenesis 
(Carson-Walter et al., 2005). In a recent study, PLVAP was shown to be a preferable 
therapeutic target for cancer therapy, since administration of PLVAP antibodies effectively 
suppressed tumor growth and had minimal systemic toxicity (Wang et al., 2014). 
In zebrafish, a very recent study shows that vsg1/plvap behaves as mammalian Plvap: 
it is initially expressed in brain endothelial cells, subsides during development, and is absent 
from adult brain vasculature (Umans et al., 2017). 
As for other vascular districts, vsg1 has a panendothelial expression around 30 hpf when it 
becomes to be expressed preferentially in the venous vessels (Qian et al. 2005; Covassin et 
al. 2006).  vsg1 is strongly downregulated in sox7/sox18 double partial morphants, as 
mentioned before, but it is slightly downregulated also in sox18 morphants and this suggest 
that vsg1 can be a direct or indirect target of Sox18 (unpublished data). For all these reasons, 
we analyzed vsg1 expression at 30 hpf by ISH in mutants and siblings either uninjected or 
injected with a subcritical dose of sox7MO and a std-MO. Genotyping reveals that there is a 
perfect correlation between vsg1 signal intensity and the genotype of the embryos: vsg1 
signal is strong in wild-type embryos, slightly reduced in heterozygotes and faint or 
completely absent in homozygous embryos after sox7 partial knockdown. These data are in 
agreement with those obtained in sox7/sox18 double partial morphants (Cermenati et al. 
2008) and sox18 morphants (unpublished data) and confirm vsg1 as a possible target of 
Sox18.  
PLVAP has been recently linked to lymphatic structures: PLVAP forms a physical sieve that 
regulates the parenchymal entry of lymphocytes and soluble antigens (Rankatari et al., 2015).  
Considering vsg1 expression pattern and the fact that it seems to be a promising direct target 
of Sox18, in future, it will be very interesting to investigate the role of vsg1 in zebrafish 
lymphatic development. 
RNA sequencing data pointed our attention also on another possible interesting marker of 
Sox18: notch1b, one of the two paralogues of Notch1 (the other is notch1a).  
It is very interesting to understand if Sox18 could modulate in some way the Notch pathway 
because Notch signaling is involved in arterio-venous differentiation of endothelial cells, and 
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it is important for intersomitic sprouts. Moreover, notch1b has been linked to 
lymphangiogenesis, indeed, a recent work shows that lymphatic vessels arise from 
specialized angioblasts of the ventral wall of the cardinal vein that express notch1b together 
with nr2f2/couptfII and fzd7a (Nicenboim et al., 2015).  
RNA sequencing analysis pointed to a statistically significant downregulation of notch1b in 
sox7/sox18 double partial morphants at 22 somites stage. Even if ISH analysis at this stage 
did not give informative results (data not shown), I expanded the analysis of notch1b 
expression in std control embryos and in sox7/sox18 double partial morphants at 24 hpf. 
At this stage, notch1b is expressed not only in the DA and in the intersomitic vessels (ISVs) 
but also in the central nervous system. sox7/sox18 double partial morphants show a very 
strong vessel-specific notch1b downregulation if compared to std control embryos. notch1b 
downregulation is not due to alteration of the vascular system because the signal of the 
panendothelial marker cdh5 and of the arterial one flt1 are comparable among control 
embryos and sox7/sox18 double partial morphants. To understand if sox18sa12315 mutant 
behaves as a null mutant, we analyzed notch1b expression pattern at 24 hpf in mutants and 
siblings either uninjected or injected with a subcritical dose of sox7MO and with stdMO. 
ISH analysis, followed by genotyping, reveals that notch1b vascular signal is strongly 
downregulated in sox18 homozygous embryos after perturbation of sox7, while wild-type 
and heterozygous embryos show a comparable and unchanged notch1b vascular signal. So, 
when sox7 is perturbed, sox18sa12315 mutants behave as sox7/sox18 double partial morphants.  
All this data about notch1b are part of an article published this year and stating that 
SoxF proteins positively regulate notch1b in zebrafish. Indeed, notch1b mRNA expression 
is strongly downregulated both in sox7/sox18 double partial morphants and in sox7/sox18 
double knockout.  This work identifies SoxF responsive enhancers in Notch1 and notch1b 
loci in mouse and in zebrafish, respectively, demonstrating for the first time that Sox7 and 
Sox18 physically interact with Notch1/notch1b enhancers both in zebrafish and in mammals 
(Chiang et al. 2017). In zebrafish, mutations in SoxF responsive enhancer (notch1b-15) affect 
notch1b endogenous expression in both the DA and in ISVs, but not in the neural tube of the 
mutants. RT-PCR analyses confirmed notch1b downregulation in purified flt1-positive 
arterial endothelial cell populations from F3 generation of homozygous fish. No vascular 
defects were observed in homozygotes, suggesting partial enhancer redundancy. However 
vascular defects in homozygous and heterozygous mutants were evident, when Notch 
signaling was perturbed using subcritical doses of notch1b morpholino or by treating mutant 
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embryos with sub-optimal concentration of DAPT, a well characterized inhibitor of the Notch 
signaling. 
In future, it could be of great interest understanding if SoxF factors could regulate other 
members of the Notch pathway. We have some preliminary RNA sequencing and ISH data 
showing that notch3 is downregulated in sox7/sox18 double partial morphants (unpublished 
data), so notch3 could be a candidate gene from which to start the analysis. 
Our data on zebrafish morphants pointed to a conserved role for Sox18 in zebrafish 
lymphangiogenesis and let us to hypothesize that sox18 interacts with vegfc in driving 
lymphangiogenesis (Cermenati et al. 2013). sox18 morphants have a lower number of 
lymphatic precursors (PLs) at 2.5 dpf and they are not able to form a normal thoracic duct at 
5 dpf. Moreover, the combined partial knockdown of sox18 and vegfc, using subcritical doses 
of specific morpholinos, which do not exert a strong effect when injected in the embryos, 
exacerbates defects in both venous and lymphatic sprouting in zebrafish (Cermenati et al. 
2013). However, a recent article questioned the role of Sox18 in zebrafish lymphatic vessels 
development, showing that sox18 mutants do not show a lymphatic phenotype (van Impel et 
al. 2014).  
Since zebrafish is a powerful model to study lymphangiogenesis and for the screening of 
small molecules with potential therapeutic effects, it is of crucial importance to clarify if 
molecular pathways regulating vascular and lymphatic development are conserved in both 
mammals and zebrafish. With this purpose, we analyzed the lymphatic system of sox18sa12315 
mutants. The lymphatic development could not be followed in sox18sa12315 line in the AB 
background, due to the lack of a reporter highlighting lymphatic structures. So we crossed 
sox18 heterozygous mutants with two endothelial-specific transgenic lines: lyve1:dsRed and  
fli1a:EGFP that allow, respectively, the analysis of venous /lymphatic vessels and of the 
whole vasculature. 
Analysis in the tg(fli1a:EGFP);sox18sa12315 line revealed that, at 52 hpf, in most wild-type 
embryos PLs manage to reach the horizontal myoseptum, in homozygotes there is subtle but 
statistically significant reduction in PL number, while heterozygotes show an intermediate 
phenotype. TD analysis, at 5 dpf, pointed out that the mutation does not cause strong 
alterations of lymphatic system development, indeed, in both tg(lyve1:dsRed);sox18sa12315 and 
in tg(fli1a:EGFP);sox18sa12315 line, larvae show a very heterogeneous range of phenotype. 
Most of wild-type larvae show a completely formed TD, but some of them can have defects 
in TD formation. However, TD formation defects are statistically significant in homozygotes, 
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when compared to wild-type larvae. Perturbation of vegfc signaling, injecting a subcritical 
dose of vegfcMO, exacerbates TD defects in a genotype-dependent manner in 
tg(lyve1:dsRed);sox18sa12315. Not only TD defects are more evident in homozygotes, but they 
become more marked and statistically significant also in heterozygotes after vegfc 
perturbation. 
Taken together, analyses of the lymphatic system of sox18sa12315 mutant transgenic lines 
demonstrate that Sox18 has a conserved role in zebrafish lymphangiogenesis, with an 
interplay with VegfC in the formation of the TD. 
These data are in contrast with the work mentioned before, questioning the evolutionary 
conservation of the entire Sox18/Prox1/Coup-TFII regulatory axis, because single prox1a, 
coup-TFII and sox18 mutants did not show lymphatic defects (van Impel et al. 2014). 
However, a recent work showed that prox1a maternal-zygotic mutants show a strong 
lymphatic phenotype demonstrating that Prox1 role in zebrafish lymphangiogenesis is 
conserved (Koltowska et al. 2015).  
There are two hypotheses to explain why the lymphatic defects seen in sox18sa12315 mutants 
are so subtle (and not so easy to see). The first is that sox7 could compensate the absence of 
sox18. It is important to remember that sox7 is upregulated in the tg(lyve1:dsRed) background 
used for TD analysis. The second hypothesis is that mRNA maternal deposition could 
compensate the absence of a functional zygotic Sox18 protein. For this reason, in future, it 
will be of crucial importance to generate a sox18 maternal-zygotic mutant in which the 
lymphatic defect should be more evident. 
Another important point is to try to understand if the Sox18/Prox1 axis is conserved also in 
zebrafish. In this case, we will evaluate prox1a expression levels by ISH and RT-PCR in 
sox18sa12315 mutants. Then, we will perform the same analysis in sox18 mutants after 
perturbation of sox7 or vegfc levels to understand if Sox7 and/or Vegfc may cooperate with 
Sox18 in regulating prox1a. 
It is known that Sox TFs belonging to different subgroups are often involved in 
complex regulatory networks driving developmental processes and that they can modulate 
each other’s function when coexpressed in the same territories (Kamachi and Kondoh, 2013). 
For example, Sox5 and Sox6, of the subgroup D, interact with Sox9, a member of the SoxE, 
to drive chondrocytes differentiation (Lefebvre et al. 1998; Han and Lefebvre 2008). 
Moreover, Sox18 (subgroup F) and Sox2 (subgroup B) are essential for derma papillae 
maturation (Kamachi and Kondoh, 2013; Villani et al., 2017).  
Discussion 
	 94	
The expression of Sox genes themselves is frequently subjected to auto-regulation or 
controlled by other Sox proteins (Kamachi and Kondoh, 2013).  
My laboratory has the evidence that Sox7 and Sox18 regulate the vascular expression of 
sox13, a member of the SoxD subgroup (Boezio et al., unpublished). 
In mice, Sox13 expression pattern during embryogenesis was firstly analyzed by Roose and 
colleagues by in situ hybridization on histological sections. Sox13 is mainly expressed in the 
central nervous system, but it is also detectable in arteries (Roose et al., 1998).  
ISH analysis in Xenopus laevis, revealed that sox13 was detectable in some vascular districts 
and that sox13 knockdown by morpholino injection causes defects in vascular vessels 
(McGary et al. 2010). Furthermore, SOX13 siRNA-mediated knockdown in HUVEC causes 
defects also in HUVECs, which fail to form vessels-like structures when cultured in 2D-
matrigel (McGary et al. 2010). 
In our laboratory, sox13 expression pattern was analyzed by RT-PCR and ISH 
experiments on zebrafish embryos from early somitogenesis to 5 dpf. sox13 expression is 
widely detectable in the developing central nervous system (CNS) at all the analysed 
developmental stages. It is also detectable in the DA until 24 hpf, even if the vascular staining 
is weak if compared to the signal in the CNS (Omini et al., unpublished). 
sox13 expression is strongly reduced in the DA of sox7/sox18 double partial morphants, 
suggesting that sox13 vascular expression could be regulated by SoxF (Boezio et al., 
unpublished). To confirm this possible interaction, we analysed sox13 expression in sox18 
mutants and siblings either uninjected or injected with a subcritical dose of sox7MO and a 
stdMO. Since sox13 expression in the DA is detectable until 24 hpf, I performed ISH analyses 
at 22 hpf. 
ISH analyses, followed by genotyping, reveal that the vast majority of wild-type embryos 
and most heterozygotes show a strong level of sox13 staining in the DA. sox18 mutation 
causes a slight reduction of sox13 signal in the DA and this reduction becomes stronger when 
sox7 is perturbed in heterozygotes and homozygotes. Thus, we can speculate that Sox7 and 
Sox18 positively regulate sox13 expression in the DA. 
To investigate the role of sox13 in angiogenesis, knockdown experiments were 
performed in my laboratory. sox13 morphants were analysed from 22 hpf to 2 dpf, in order 
to cover the events occurring during both primary and secondary angiogenesis (Omini et al., 
unpublished; Boezio et al., unpublished). sox13 morphants show defects in primary 
angiogenesis, indeed, at 30 hpf, some ISVs are blocked to the horizontal myoseptum and 
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some others are completely absent (Omini et al., unpublished). Moreover, at 2 dpf, sox13 
morphants show a lower number of venous ISVs if compared to control embryos, thus, also 
secondary angiogenesis is affected by sox13 knockdown. Preliminary data show that ISVs 
defects are observed at 2 dpf also by using an independent sox13 morpholino; in this case, 
sox13 morphants show a lower number of both arterial and venous ISVs. However, a deeper 
analysis is required to better characterize ISVs defects observed using this independent 
morpholino. We must expand the analysis at 30 hpf to understand how primary angiogenesis 
is affected and at 1.5 dpf to understand if sox13 morphants has defects in secondary sprouts.   
We hypothesize that defects in secondary angiogenesis are a consequence of defects in 
primary angiogenesis. Indeed, it is known from literature that venous ISVs originate from 
the fusion of a venous sprout with an arterial ISV (Ellertsdottir et al. 2010); if arterial ISVs 
are not formed correctly, venous sprouts could have problems in giving rise to venous ISVs.  
Trans-migration assay in immortalized mouse lung endothelial cells performed in 
collaboration with Costanza Giampietro, a former member of our Department, currently at 
ETH of Zurich, points to an involvement of Sox13 in endothelial cell migration. Indeed, 
Sox13 overexpression improves the migratory behavior of endothelial cells in an assay that 
is very similar to physiological conditions. We can speculate that, if Sox13 overexpression 
increases endothelial cell migration, its absence could cause migration problems.  
To dynamically characterize the angiogenic phenotypes of sox13 morphants, we 
collaborated with Professor Andrea Bassi, from the “Politecnico di Milano”, to perform in 
vivo long-term time-lapse analysis of sox13 morphants with SPIM technique. The in vivo 
analysis was performed from 26 hpf to 3 dpf and confirmed the ISV defects seen in sox13 
morphants. While control embryos develop a completely normal vascular tree, in sox13 
morphants some ISVs are blocked at the myoseptum, others migrate slowly and some others 
reach the myoseptum, develop normal but later regress in a ventral to dorsal direction after 
detaching from the axial vessel. These events seem to indicate that not only the formation 
but also the stability of ISVs is compromised in sox13 morphants.  
ISVs regression is the most interesting phenotype observed in sox13 morphants, because 
regression events occur both in physiological and pathological conditions.  For example, ISV 
regression is crucial during secondary angiogenesis when half of venous sprouts connect to 
the preexisting arterial sprouts converting them into venous ISVs. When secondary sprouts 
contact the primary ISVs, blood flow changes its dynamics and the ventral portion of the 
sprout, in proximity to the DA, regresses until disappearing (Isogai et al. 2003). 
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Going into details, blood flow is interrupted in the portion of the ISV connecting the sprout 
to the DA and the thinning of the vessel starts until it regresses and disappears (Franco et al. 
2015). The regression of ISVs observed in sox13 morphants has a similar mechanism, but it 
is anomalous because it happens without the contact of the regressing vessel with other 
vessels. A similar phenotype has been observed in hif-1a  mutants (Gerri et al., 2017) where 
ISV regression from the DA is caused by impaired interactions between macrophages and 
endothelial cells during developmental angiogenesis; in these mutants, macrophages are not 
able to repair vessels after hypoxic conditions leading to ISV regression from the DA (Gerri 
et al., 2017).  
Since sox13 has a role also in hematopoiesis (Omini et al., unpublished), in future it will be 
of great interest to investigate if sox13 morphants show defects in macrophages 
differentiation. It will be also very interesting to generate and characterize a sox13 mutant in 
order to better understanding the role of Sox13 in zebrafish angiogenesis. 
ISV regression is observed also after the perturbation of Notch and Wnt signaling in 
zebrafish, mouse retina and in HUVEC using respectively MO-induced knockdown and 
knockout approaches (Phng et al. 2009; Franco et al. 2015). 
My laboratory collected data suggesting that Sox13 could modulate both Wnt and Notch 
pathway. Sox13 seems to negatively regulate Wnt pathway, because in sox13 morphants the 
ISH staining of ccdn1 (cyclin D1), a target of the Wnt canonical pathway, is upregulated if 
compared to control embryos (Boezio et al., unpublished). 
As for the Notch pathway, sox13 morphants show elevated notch1b staining and their 
angiogenic defects can be rescued by treatment with the Notch signaling inhibitor DAPT 
(Omini et al., unpublished). So, ISV defects of sox13 morphants could be due to alteration of 
the Notch signaling that, together with Vegf signaling, plays a key role in ISV sprouting. 
Taken together these data suggest that Sox13 is a negative regulator of the Notch pathway. 
This is very interesting if we think that sox13 vascular expression seems to be regulated by 
SoxF TFs that are positive regulators of Notch signalling (Chiang et al., 2017).  
Our data suggest that SoxF TFs and Sox13 form a complex regulatory network to fine-tune 
Notch signaling during vascular development. In future, further analyses will be necessary 
to better characterize the network involving SoxF TFs and Sox13; for example, one could 
check for the presence of a Sox18 responsive enhancer in sox13 locus to understand if sox13 
is a direct or indirect target of Sox18.   
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Supplementary Materials and Methods
Generation and analysis of transgenic and mutant mice (final paragraph)
Sox7:tm1 (Sox7+/−) mice were generated through germline transmission in chimaeras, using VGB6 ES cells (of C57BL/6NTac
background) that contained an inactivated Sox7 allele replaced with a ZEN-Ub1 cassette from Velocigene (Sox7tm1(KOMP)Vlcg), and
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obtained from the KOMP repository at University of California at Davis (https://www.komp.org/pdf.php?projectID=VG10649).
Compound Sox7−/−;Sox18−/− mouse embryos were generated on the C57BL/6 background through crossing heterozygous Sox7:tm1 to
Sox18:tm1, generating Sox7+/−;Sox18+/−micewhich were subsequently incrossed (Pennisi et al., 2000a). Genotypewas confirmed by PCR
using the following primers: mSox7(F), TGTAACTTGGAGATCCATAGAGC; mSox7(R), TCATTCTCAGTATTGTTTTGCC;
mSox7lacZ(R), TGGATCAGCTAAGCCAGGT; mSox18(F), CCCGACGTCCATCAGACCTC; mSox18(R), GTCGCTTGCGCTCGT-
CCTTC; mSox18lacZ(R), CGCCCGTTGCACCACAGATG. All animals used were 7-24 weeks old.
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ABSTRACT
Arterial specification and differentiation are influenced by a number of
regulatory pathways. While it is known that the Vegfa-Notch cascade
plays a central role, the transcriptional hierarchy controlling arterial
specification has not been fully delineated. To elucidate the
direct transcriptional regulators of Notch receptor expression in
arterial endothelial cells, we used histone signatures, DNaseI
hypersensitivity and ChIP-seq data to identify enhancers for the
humanNOTCH1 and zebrafishnotch1b genes. These enhancerswere
able to direct arterial endothelial cell-restricted expression in transgenic
models. Genetic disruption of SoxF binding sites established a clear
requirement for members of this group of transcription factors (SOX7,
SOX17 and SOX18) to drive the activity of these enhancers in vivo.
Endogenous deletion of the notch1b enhancer led to a significant loss
of arterial connections to the dorsal aorta in Notch pathway-deficient
zebrafish. Loss of SoxF function revealed that these factors are
necessary for NOTCH1 and notch1b enhancer activity and for correct
endogenous transcription of these genes. These findings position
SoxF transcription factors directly upstream of Notch receptor
expression during the acquisition of arterial identity in vertebrates.
KEY WORDS: Notch1, SoxF, Artery, Arterial enhancer, Endothelial
cell, Transcriptional regulation, Zebrafish, Human, Mouse
INTRODUCTION
Genetic specification of arterial fate has long been attributed to
regulation downstream of the Vegfa and Notch pathways. Vegfa
signalling is essential for arterial specification in both zebrafish and
mammalian models, at least partially by stimulating the expression
of components of the Notch pathway, while activation of Notch
signalling can rescue defects in Vegfa-deficient zebrafish embryos
(Lanahan et al., 2010; Lawson et al., 2002; Liu et al., 2003; Visconti
et al., 2002). The Notch receptors Notch1 and Notch4 and the delta-
like ligands Dll1, Dll4, Jag1 and Jag2 are expressed in endothelial
cells, where they play crucial roles in both arteriogenesis and
angiogenesis (Lawson et al., 2002; Liu et al., 2003; Phng and
Gerhardt, 2009; Roca and Adams, 2007). Ligand binding to the
Notch receptor releases the Notch intracellular domain (NICD),
which translocates to the nucleus and forms a transcriptional
activation complex with the otherwise repressive DNA-bound Rbpj
[CSL, Su(H)] (Bray, 2006). Combined ablation of Notch1 and
Notch4, which are both principally expressed in arterial endothelial
cells during early vascular remodelling (Chong et al., 2011; Jahnsen
et al., 2015), results in severe vascular remodelling defects (Krebs
et al., 2000), as does ablation of the Notch downstream effector
Rbpj or of Dll4, a Notch ligand specific within the vasculature to
arteries (Duarte et al., 2004; Gale et al., 2004; Krebs et al., 2004).
However, loss of Notch signalling does not fully recapitulate the
arterial defects downstream of Vegfa ablation (Carmeliet et al.,
1996; Krebs et al., 2000; Lawson et al., 2002), and the arterially
restricted gene expression patterns of components of the Notch
pathway do not fully overlap with activated Vegfa (Lawson, 2003),
suggesting that additional factors are involved in the regulation of
Notch-mediated arterial fate.
The SoxF group of transcription factors (Sox7, Sox17 and
Sox18) are expressed in endothelial cells from early in development
(Francois et al., 2010). While each SoxF member displays a
subtly different endothelial expression pattern, all three factors are
expressed early in arterial development (Corada et al., 2013;
François et al., 2008; Zhou et al., 2015) and share considerable
functional redundancy, complicating interpretation of the
consequences of gene disruption (Hosking et al., 2009; Zhou
et al., 2015). Combined loss of sox7 and sox18 in zebrafish, both by
morpholino-based knockdown and genetic mutation, resulted in
serious arteriovenous malformations similar to those seen after
Notch ablation, suggesting that SoxF factors might genetically
interact with the Notch pathway in endothelial cells (Cermenati
et al., 2008; Hermkens et al., 2015; Herpers et al., 2008; Lawson
et al., 2001). Further evidence was provided in mice, where
endothelial-specific ablation of Sox17 caused arterial differentiation
and remodelling defects (Corada et al., 2013), and conditional
deletion of SoxF factors in the adult resulted in loss of major vessel
identity in the retina (Zhou et al., 2015). Inhibition of Vegfa
signalling can significantly impact SoxF expression and activity in
both mouse and zebrafish models (Kim et al., 2016; Pendeville
et al., 2008; Duong et al., 2014; Pennisi et al., 2000b), suggesting
that members of the SoxF family lie downstream of Vegfa.
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(Kdr; kdrl in zebrafish) expression (Kim et al., 2016). By contrast,
the ablation of Notch signalling in the vasculature does not
significantly impact the expression of SoxF (Abdelilah et al., 1996;
Corada et al., 2013). Different experimental models have positioned
SoxF genes both upstream (Corada et al., 2013) and downstream
(Lee et al., 2014) of Notch signalling in endothelial cells, suggesting
a complex relationship between these two pathways.
Analysis of the only known enhancers for the Notch pathway,
namely the arterial-specific Dll4-12 (Sacilotto et al., 2013) and
Dll4in3 enhancers (Sacilotto et al., 2013; Wythe et al., 2013), has
demonstrated a crucial role for SoxF factors in the regulation of
expression of the Notch ligand Dll4 in arteries, in combination with
Rbpj/Notch binding and in the presence of Ets factors including Erg
(Sacilotto et al., 2013;Wythe et al., 2013). Although this work clearly
positioned the SoxF and Notch pathways as crucial regulators of
arterial specification, and is supported by analysis placing Sox17
upstream of Notch signalling in mouse models (Corada et al., 2013),
ablation of arterial marker expression only occurs after the removal of
both SoxF factors and Notch signalling in combination (Sacilotto
et al., 2013). Consequently, the precise transcriptional hierarchy of
SoxF and Notch has yet to be fully established. Although studies of
the Notch receptor genes Notch1 and Notch4 also identified SoxF
binding motifs within putative promoter sequences (Corada et al.,
2013; Lizama et al., 2015), a requirement for these SOX motifs in
arterial-specific gene expression of Notch receptors has not been
established. In this study, we have identified and characterised
arterial-specific enhancers directing NOTCH1/notch1b gene
expression in vivo, and used them to demonstrate a direct
requirement for SoxF factors in the transcriptional regulation of
Notch receptors during early arterial differentiation, positioning SoxF
factors upstream of Notch in the acquisition of arterial cell identity.
RESULTS
Identification of an arterial-specific NOTCH1 intronic
enhancer
Previous studies into the transcriptional regulation of the Notch
receptors have not extended to the identification or analysis of gene
enhancers (cis-regulatory elements) (Corada et al., 2013; Lizama et al.,
2015; Wu et al., 2005). We therefore conducted a detailed in silico
analysis of the NOTCH1 locus with the aim of identifying novel,
arterial-specific enhancers. This analysis focused on humanNOTCH1
in order to take advantage of the wealth of publicly available
information describing chromatin modifications in human endothelial
cell lines. Using this information, we were able to pinpoint four
regions of DNA rich in endothelial cell-specific H3K4me1 and
H3K27ac histone modifications and DNaseI digital genomic
footprints, all marks closely associated with enhancer activity
(Heintzman and Ren, 2009; Sabo et al., 2004) (Fig. 1A, Fig. S1).
Fig. 1. The humanNOTCH1 locus containsmultiple putative endothelial enhancers. (A) The humanNOTCH1 locus fromUCSCENCODEGenomeBrowser
(http://genome.ucsc.edu). Human umbilical vein endothelial cell (HUVEC)-specific H3me1 and H3K27ac (enhancer associated) and H3K4me3 (promoter
associated) peaks are indicated in light blue [both in the separate HUVEC and combined tracks (denoted as ‘all’)]; other colours indicate H3K4me1, H3K4me3 and
H3K4ac peaks specific to non-endothelial cell lines: GM12878 cells (red), H1-hESC cells (yellow), HSMM cells (green), K562 cells (purple) NHEK cells (lilac) and
NHLF cells (pink). INPP5E and SEC16A are shown (blue text) in addition to NOTCH1 (black text). DNase I digital hypersensitive hotspots are indicated by black
vertical lines on grey (HUVEC, HMVEC-dBl-Ad, HMVEC-dBl-Neo and HMVEC-LBl, which are all different endothelial cell types). The four NOTCH1 putative
enhancer regions (black bars) were identified by high levels of HUVEC-specific H3K4me1 and H3K27ac associated with endothelial cell-specific DNaseI
hypersensitivity hotspots. P, putative promoters identified by H3K4me3. (B) The human NOTCH1 gene (top, in 5′ to 3′ orientation with putative enhancers
indicated) and the NOTCH1+16hsp transgene (bottom).
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The putative enhancer regions were named NOTCH1+33,
NOTCH1+16, NOTCH1+3/5 and NOTCH1−68 to reflect their
distance from the transcription start site (TSS) in kb. Each enhancer
region was cloned upstream of the silent hsp68 minimal promoter
and the lacZ reporter gene (Fig. 1B) and tested for its ability to drive
reporter gene expression specifically in arterial endothelial cells of
transient transgenic mice at embryonic day (E) 12-13. Although
each of the four putative enhancer regions was able to drive
detectable levels of lacZ in transgenic mice, this expression was
primarily neural, an expression pattern commonly seen when using
the hsp68 minimal promoter (e.g. Becker et al., 2016; Sacilotto
et al., 2013) (Table 1, Fig. S2). Only the NOTCH1+33 and
NOTCH1+16 enhancers were able to direct expression in
endothelial cells (Table 1, Fig. S2). In the case of NOTCH1+33,
vascular expression was detected in only one of the five transgenic
mice analysed. This expression was not restricted to the arterial
endothelium but was pan-endothelial (Table 1, Fig. S2). This agrees
with previous reports indicating that the mouse orthologue of this
region, termed Notch1_enh1, also directs occasional vascular
enhancer activity but did not show arterial-specific expression
(Zhou et al., 2017). Conversely, the 274 bp NOTCH1+16 enhancer
was able to robustly direct expression specifically to arterial
endothelial cells within the vasculature at E12 in multiple
independent transgenic embryos (Table 1, Fig. 2 and Fig. S2).
This indicates that the NOTCH1+16 enhancer represents a novel,
arterially restricted enhancer within the NOTCH1 locus. Analysis of
a stable mouse line expressing the NOTCH1+16:lacZ transgene
clearly demonstrated that this enhancer is strongly active from
the very early stages of vascular development, mimicking the
expression of endogenous Notch by becoming restricted to the
arteries by late E9.5 and then maintaining an arterial endothelial
cell-restricted expression pattern throughout embryonic
development (Chong et al., 2011; Jahnsen et al., 2015) (Fig. 2).
The NOTCH1+16 enhancer is bound and regulated
by SoxF factors
To identify the transcription factors that potentially regulate the
NOTCH1+16 enhancer, we performed a ClustalW analysis of
orthologous mammalian sequences (Fig. 3A). This analysis clearly
identified nine conserved core consensus ETS binding motifs [GGAW
(Hollenhorst et al., 2011)] and two consensus SOX binding motifs
[WWCAAW (Mertin et al., 1999)] (Fig. 3A) within the 274 bp
NOTCH1+16 enhancer. Because not all in silico consensus binding
motifs are able to functionally bind the cognate protein, these motifs
were then tested by electrophoretic mobility shift assay (EMSA). Both
SOX motifs (termed hmSOX-a and hmSOX-b) were able to bind
recombinant SOX7 and SOX18 proteins in EMSA (Fig. 3B), and three
ETS motifs (termed hmETS-a, hmETS-b and hmETS-c) were able to
bind the endothelial Ets protein ETV2 (Fig. 3C).
ETS motifs are common to all endothelial-expressed gene
enhancers (De Val and Black, 2009). Although the Ets factor Erg
has been implicated in arterial specification (Wythe et al., 2013),
previous studies have shown that ETS motifs were unable to
direct expression of the arterial-specific Dll4 and Flk1 enhancers
without additional transcription factor binding motifs (Becker
et al., 2016; Sacilotto et al., 2013; Wythe et al., 2013), suggesting
that Ets factors alone are unlikely to regulate the NOTCH1+16
enhancer.
To test whether the SOX motifs play a role in NOTCH1+16
enhancer activity, we mutated the core nucleotides of these motifs
(see Materials and Methods for sequences) and tested the ability of
the resultant NOTCH1+16mutSOX-a/b enhancer to drive reporter
gene expression. Strikingly, enhancer mutation resulted in a
dramatic reduction in reporter gene expression in endothelial cells
in transgenic mice, although transgene expression was detected
outside of the vascular system (Fig. 4, Table 1). This result differs
notably from that reported for the Dll4 enhancers, where mutations
in SOX motifs, or loss of SoxF factors, resulted in no detectable
decrease in Dll4 expression unless accompanied by ablation of
Notch signalling (Sacilotto et al., 2013).
Table 1. Reporter gene expression patterns in E12 mice transgenic for
each putative NOTCH1 enhancer region and the effects of SOX motif
mutation on NOTCH1+16 enhancer activity
Transgene n
Any lacZ
expression
lacZ in
AECs
lacZ in
VECs
NOTCH1−68 5 3 0 0
NOTCH1+3/5 4 4 0 0
NOTCH1+16 10 9 6 0
NOTCH1+33 5 5 1 1
NOTCH1+16 WT 8 7 4 0
NOTCH1+16mutSOX-a/b 9 6 0* 0*
*Faint vascular expression was detected in section analysis but was not visible
in whole-mount analysis. n, number of transgenic mice analysed. AECs,
arterial endothelial cells; VECs, venous endothelial cells.
Fig. 2. The NOTCH1+16 transgene directs arterial endothelial cell-
restricted expression in transgenic mice. (A-N) Representative transgenic
whole-mount embryos (A-H) and transverse sections (I-N) showing lacZ
reporter gene expression (β-galactosidase detected by blue X-gal staining) in
arterial endothelial cells throughout embryonic development. The boxed region
in J is magnified in K. (O,P) E12 transverse section showing that expression of
the venous marker endomucin (Emcn) does not overlap with lacZ reporter
gene expression on the same section. cv, cardinal vein; da, dorsal aorta;
Emcn, endomucin; en, endocardium; mda, midline dorsal aorta; uv,umbilical
vein; v, vein.
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Zebrafish notch1b is directly transcriptionally regulated by
SoxF factors via an evolutionarily non-conserved enhancer
The SoxF-dependent NOTCH1+16 enhancer robustly directed
arterial-restricted expression in transgenic mouse models. However,
this enhancer did not exhibit sequence conservation beyond
mammals (Fig. S1B), leaving it unclear how relevant these
observations are to Notch signalling during arteriovenous
specification in zebrafish, an extremely well-studied model system
(Gore et al., 2012). We therefore investigated whether SoxF factors
were able to transcriptionally regulate the zebrafish orthologue of
NOTCH1, notch1b, by examining the binding patterns of the
zebrafish SoxF transcription factors around the notch1b locus.
Zebrafish SoxF are expressed in early endothelial cells and
implicated in arteriovenous differentiation (Cermenati et al., 2008;
Hermkens et al., 2015; Herpers et al., 2008; Pendeville et al., 2008).
To probe for SoxF (Sox7, Sox17 and Sox18) genome-wide
binding locations we used an endothelial-specific SOX18Ragged
overexpression line. The SOX18Ragged dominant-negative protein
has been shown to interfere with the endogenous function of all
three SoxF transcription factors (James et al., 2003; Pennisi et al.,
2000b). Using 26-28 hours post fertilisation (hpf ) embryos from the
tg(fli1a:Gal4FF;10×UAS:Sox18Ragged-mCherry) zebrafish line,
in which a tagged SOX18Ragged is expressed specifically in
endothelial cells (Fig. S3A), ChIP-seq analysis identified a SoxF
binding event 15 kb upstream of the notch1b first exon (Fig. 5A).
This binding peak was enriched in the enhancer-associated histone
modifications H3K4me1 and H3K27ac at 24 hpf (Bogdanovic ́
et al., 2012; Kent et al., 2002) (Fig. 5A), suggesting that it might
represent a novel enhancer of notch1b. A 1219 bp zebrafish DNA
fragment corresponding to the SOX18-bound region, termed the
notch1b-15 enhancer, was cloned upstream of a silent gata2a
promoter and GFP reporter gene within the zebrafish enhancer
detection (ZED) vector (Bessa et al., 2009) (Fig. 5B) and used to
generate the stable tg(notch1b-15:GFP) fish line (Fig. 5C). The
GFP transcript was detected in the vascular cord around the midline
from 19 hpf, and persisted in the vascular rod as it formed the dorsal
aorta at 22 hpf (Fig. 5C). GFP expression continued to be restricted
to the dorsal aorta and the segmental arteries in larvae from 24 hpf
until 48 hpf. This arterial-restricted pattern of expression within the
vasculature was similar to that of endogenous notch1b (Fig. S3B),
indicating that the SOX18-bound notch1b-15 element is a bona fide
notch1b enhancer and suggesting that SoxF factors directly
transactivate Notch receptor transcription in arterial endothelial
cells in zebrafish.
ClustalW analysis comparing the orthologous enhancer
sequences from fugu, stickleback and medaka revealed a
remarkably similar pattern of conserved transcription factor motifs
when compared with the NOTCH1+16 enhancer (Fig. 6A), with
multiple ETS and two SOX binding motifs, termed zfSOX-a and
zfSOX-b, confirmed by EMSA analysis (Fig. 6B,C). To establish
whether the zfSOX-a and zfSOX-b binding motifs were required for
notch1b-15 arterial enhancer function, we generated transient
transgenic fish lines harbouring mutated SOX binding motifs
(notch1b-15mutSOX-a/b:GFP) and compared the activity of the
transgene with wild-type (WT) notch1b-15:GFP control transient
transgenic animals (Fig. S4A,B). Simultaneous disruption of both
zfSOX-a and zfSOX-b sites led to a reduction of arterial-specific
GFP expression in endothelial cells. Although a minority of mutant
fish still expressed GFP after SOX binding site mutation, the loss of
expression was still much greater than that seen after SOX motif
mutation in a previously published Dll4 enhancer in transgenic
zebrafish, where vascular expression rates were unaffected by
Fig. 3. The NOTCH1+16 enhancer contains SOX and ETS binding motifs.
(A) Multispecies alignment of the orthologous region of the NOTCH1+16
enhancer from human, mouse and opossum (oposs) using ClustalW. Coloured
sequences are confirmed by EMSA; grey sequences are motifs identified
in silico that did not bind in EMSA. (B) Radiolabelled oligonucleotide probes
encompassing NOTCH1+16 hmSOX-a (lanes 1-8) and hmSOX-b (lanes 9-16)
were bound to recombinant SOX7 (lanes 2-4 and 10-12) and SOX18 (lanes 6-8
and 14-16). Both proteins, which efficiently bound labelled probes (lanes 2,
6, 10 and 14), were competed by excess unlabelled self-probe (WT, lanes 3, 7,
11 and 15) but not by mutant self-probe (MT, lanes 4, 8, 12 and 16).
(C) Radiolabelled oligonucleotide probes encompassing NOTCH1+16 hmETS-
a (lanes 17-20), hmETS-b (lanes 21-24) and hmETS-c (lanes 25-28) were
bound to recombinant ETV2 protein. ETV2, which efficiently bound to
labelled probes (lanes 18, 22 and 26), was competed by excess unlabelled self-
probe (WT, lanes 19, 23 and 27) but not by mutant self-probe (MT, lanes
20, 24 and 28).
Fig. 4. SoxF factors are required for NOTCH1+16 activity. (A) Four
representative whole-mount E12 X-gal-stained embryos transgenic for the
NOTCH1+16mutSOX-a/b construct. Numbers at the bottom left indicate the
unique embryo identifier. (B) Transverse sections taken from two NOTCH1
+16mutSOX-a/b embryos demonstrate the very limited endothelial expression
detected in these embryos (asterisks). In each case, the section to the left
is through the head region, the section to the right is through the upper
torso region.
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mutations of SoxF binding motifs (Sacilotto et al., 2013),
supporting a key role for SoxF factors in notch1b activation. To
further confirm our observation, we established stable transgenic
notch1b-15mutSOX-a/b:GFP fish lines and compared them with
the established WT notch1b-15:GFP lines. Analysis of the stably
transgenic embryos (Fig. 7A) confirmed aGFP expression pattern in
the dorsal aorta and segmental arteries for the WT transgene. By
contrast, the tg(notch1b-15mutSOX-a/b:GFP) lines showed ectopic
GFP expression in neurons and a significant decrease of GFP
expression in the arterial endothelium (Fig. 7A). Quantitative
analysis of GFP intensity in both dorsal aorta and segmental arteries
showed lower expression in most tg(notch1b-15mutSOX-a/b:GFP)
than in WT tg(notch1b-15:GFP) embryos (Fig. 7B,C, Fig. S4C).
Taken together, these data clearly demonstrate that the zfSOX-a/b
binding sites are required to guide notch1b-15-specific enhancer
activity in vivo during arterial development.
We next investigated the consequences of morpholino (MO)-based
knockdown of SoxF on tg(notch1b-15:GFP) fish. sox7/sox18 double
morphants exhibit a severe vascular phenotype (Fig. S5), including
fusions and shunts between the dorsal aorta and cardinal vein
(Cermenati et al., 2008; Herpers et al., 2008; Pendeville et al., 2008),
phenotypes that are shared with sox7;sox18 double-mutant fish
(Hermkens et al., 2015). MO-induced transcript depletion of sox7 or
sox18 resulted in downregulation of notch1b-15:GFP expression, while
sox7/sox18 double-morphant tg(notch1b-15:GFP) fish demonstrated a
near-complete loss of reporter gene expression (Fig. 7D,E).
Taken together, these results indicate that SoxF proteins directly
modulate the activity of arterial-specific enhancers for both
the mammalian NOTCH1 and zebrafish Notch1b receptors,
positioning SoxF transcription factors directly upstream of
Notch signalling during early arterial differentiation in both
mammals and zebrafish.
Loss of endogenous notch1b-15 enhancer activity perturbs
notch1b transcription and causes arteriovenous defects
To assess whether the endogenous notch1b-15 regulatory element is
functionally relevant during arteriovenous differentiation in vivo, we
deleted the endogenous notch1b-15 enhancer in zebrafish. The
resultant notch1b-15uq1mf allelewas generated using two guide RNAs
to drive rapid genome editing using the CRISPR/Cas9 system
(Fig. 8A), resulting in excision of a 203 bp fragment overlapping the
Fig. 5. A SOX18-bound regionwithin the notch1b locus represents a bona
fide arterial-specific enhancer. (A) Part of the zebrafish notch1b locus from
the UCSC ENCODE Genome Browser. The notch1b gene is in 3′ to 5′
orientation, H3K27ac peaks at 24 hpf are in purple, H3K4me1 peaks at 24 hpf
are blue, SOX18Ragged ChIP-seq peaks are red, and the region
encompassing the notch1b-15 enhancer is indicated by the purple horizontal
bar. (B) The ZED notch1b-15:GFP transgene. Ins, insulator sequences;
GATA2 prom, the silent GATA2 promoter; ZED control:RFP, the active cardiac
actin enhancer/promoter construct fused to the RFP gene used as a positive
control in the ZED vector. (C) The notch1b-15:GFP transgene directs arterial
endothelial cell-specific expression in the zebrafish line tg(notch1b-15:GFP).
Representative transgenic whole-mount embryos and transverse sections
show reporter gene expression, as detected by in situ hybridisation (top row,
blue) or GFP fluorescence (bottom rows, green) in arterial endothelial cells
throughout embryonic development. nt, neural tube; nc, notochord; DA, dorsal
aorta; PCV, posterior cardinal vein; aISV (arrows), arterial intersomitic vessel;
DLAV, dorsal longitudinal anastomotic vessel.
Fig. 6. The notch1b-15 enhancer contains essential SoxF binding motifs.
(A) Multispecies alignment of the orthologous regions of the notch1b-15
enhancer from zebrafish (zfish), fugu, stickleback (stickle) and medaka using
ClustalW. Coloured sequences are confirmed by EMSA; grey sequences are
motifs identified in silico that did not bind robustly in EMSA. (B) Radiolabelled
oligonucleotide probes encompassing notch1b-15 zfSOX-a (lanes 1-8) and
zfSOX-b (lanes 9-16) were bound by recombinant SOX7 (lanes 2-4 and 10-12)
and SOX18 (lanes 6-8 and 14-16). Both proteins, which efficiently bound
labelled probes (lanes 2, 6, 10 and 14), were competed by excess unlabelled
self-probe (WT, lanes 3, 7, 11 and 15) but not bymutant self-probe (MT, lanes 4,
8, 12 and 16). (C) Radiolabelled oligonucleotide probes encompassingnotch1b-
15 zfETS-a (lanes 17-20) and zfETS-b (lanes 21-24) (see A) were bound by
recombinant ETV2 proteins. ETV2, which efficiently bound to labelled probes
(lanes 18 and 22), was competed byexcess unlabelled self-probe (WT, lanes 19
and 23) but not by mutant self-probe (MT, lanes 20 and 24).
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notch1b-15 enhancer. Analysis of endogenous notch1b expression in
the F2 generation demonstrated lower notch1b expression levels in
both dorsal aorta and arterial intersomitic vessel (aISV) of the
notch1b-15uq1mf/uq1mf homozygous embryos as compared with their
sibling controls, whereas no change was observed in the neural tube
(Fig. 8B). Next, we assessed the notch1b transcript levels in purified
flt1-positive arterial endothelial cell populations from the F3
generation of homozygous fish (F2 notch1b-15uq1mf homozygous
in-cross) compared with WT control larvae (F2 notch1b-15+/+ × flt1:
YFP;lyve1:dsRed) at 24-28 hpf (Fig. 8C). As expected, notch1b
transcripts were significantly downregulated in the homozygous
animals, strongly supporting a role for the notch1b-15 enhancer in the
transcription of endogenous notch1b in arterial endothelial cells.
To assess the phenotypic outcome of notch1b-15 loss of function,
we took advantage of the tg(notch1b-15uq1mf/+;flt1:YFP;lyve1:
dsRed) line to analyse the developing vasculature after notch1b-15
enhancer deletion in both the F2 and F3 generations. Surprisingly,
given the reduced levels of notch1b (Fig. 8B), no overt vascular
Fig. 7. SoxF factors are required for notch1b-15 activity. (A) Confocal
projection of stably transgenic WT tg(notch1b-15:GFP) (left) and tg(notch1b-
15mutSOX-a/b:GFP) (right), where both zfSOX-a and zfSOX-b sites have
been simultaneously mutated. Representative larvae from four independent
founders are shown. Asterisks indicate the reduced GFP expression in the
dorsal aorta. Arrowheads show the ectopic neuronal expression observed in
tg(notch1b-15mutSOX-a/b:GFP). All panels show composite images from
tile scan acquisition. (B,C) The intensity of GFP expression in the dorsal aorta
and arterial intersomitic vessels of the stably transgenic tg(notch1b-15:GFP)
and tg(notch1b-15mutSOX-a/b:GFP) at 2 dpf. Expression is normalised to
GFP genomic copy number. Fish were pooled from three or four separate
founders. Mean±s.e.m. tg(notch1b-15), n=41; tg(notch1b-15mutSOX-a/b:
GFP), n=29. ****P<0.0001 (Mann–Whitney U-test). (D) Levels of GFP
expression in tg(notch1b-15:GFP) zebrafish embryos after MO injection.
Number of fish for each condition is indicated. (E) Representative examples of
sox7/18 double-morphant tg(notch1b-15:GFP) zebrafish at 24 hpf as
compared with uninjected controls. Double morphants (dMO) demonstrated
reduced EGFP expression in the dorsal aorta and intersomitic vessels. DA,
dorsal aorta; PCV, posterior cardinal vein; aISV, arterial intersomitic vessel.
Fig. 8. Loss of endogenous notch1b-15 compromises artery formation
and reduces the endogenous notch1b transcript level. (A) The deleted
region (dashed line) of notch1b-15 mutant allele uq1mf, which includes both
the zfSOX-a and zfSOX-b sites (yellow). (B) F2 notch1b-15uq1mf/uq1mf has
reduced notch1b expression in dorsal aorta and intersomitic vessels (white
arrows) as compared with sibling WT and heterozygotes (black arrows) at 26-
28 hpf. The number of embryos showing the illustrated phenotype among the
total examined is indicated. (C) Quantitative PCR on FACS-sorted endothelial
populations at 24-28 hpf, showing that F3 notch1b-15uq1mf/uq1mf fish have lower
notch1b expression thanWT fish. Expression is relative to kdrl and flt1. Mean±
s.e.m. n=6 (uq1mf/uq1mf ) and n=8 (WT) independent sorts, where each sort
was pooled from 60-100 larvae;. *P<0.05, ***P<0.001 (t-test). (D) The
treatment regime conducted to characterise the vascular phenotype of the
uq1mf/+ cross. In treatment 1 (T1, red), notch1bMOwas injected at the 1-2 cell
stage. The developing vasculature of each embryo was then analysed blindly at
3 dpf. After scoring, genotypes were assigned to each larva. In treatment 2 (T2,
blue), larvae from the uq1mf/+ cross were treated with or without DAPT (5 µM)
from 15-16 hpf until 3 dpf. Vessels of these treated larvae were blindly scored
prior to genotyping, as reported for T1. (E) At 3 dpf, notch1b-15uq1mf/uq1mf
notch1b morphants frequently showed ectopic sprouting in between the
intersomitic vessels (asterisks) as compared with sibling WT notch1b
morphants. Mutants also show loss of arterial connections (red arrowheads)
between the dorsal longitudinal anastomotic vessel (DLAV) and dorsal
aorta (DA), as indicated by the loss of YFP expression in the tg(flt1:YFP)
background. (F) (Top) Quantification of hypersprouting ISV number in individual
notch1b morphants labelled by tg(flt1:YFP) at 3 dpf. Mean±s.e.m. Sibling WT
(+/+), n=20; heterozygote (uq1mf/+), n=32; homozygous mutant (uq1mf/
uq1mf ), n=21. (Bottom) Quantification of YFP-positive intersomitic vessels that
connect between DLAV and DA in individual notch1b morphants labelled by
tg(flt1:YFP) at 3 dpf. Mean±s.e.m. Sibling WT, n=20; heterozygote, n=32;
homozygous mutant, n=21. **P<0.005 (Mann–Whitney U-test). (G)
Quantification of YFP-positive intersomitic vessels that connect between DLAV
and DA in individual embryos treated with 5 μM DAPT at 3 dpf. Vessels are
labelled by tg(flt1:YFP). Mean±s.e.m. Sibling WT, n=9; heterozygote, n=25;
homozygous mutant, n=14. *P<0.05 (Mann–Whitney U-test).
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phenotype was detected in F2 notch1b-15uq1mf/uq1mf homozygous
zebrafish (F1 heterozygous notch1b-15uq1mf/+ in-cross) (Fig. S6A),
suggesting partial enhancer redundancy. Such redundancy, which is
potentially explained by the pervasiveness of redundant, or
ʻshadow’, enhancers around developmental genes (Cannavò
et al., 2016), has previously been well documented in key
endothelial genes, with examples including the Dll4, Flk1 and
Tal1 loci (Cannavò et al., 2016). By contrast, we detected a
subpopulation (20-30%) of larvae from the F3 generation
(F2 homozygous notch1b-15uq1mf/uq1mf in-cross) that displayed a
phenocopy of the notch1b loss-of-function phenotype (Fig. S6B).
This increase in the phenotypic severity in the F3 generation
suggests that, in the context of the notch1b-15uq1mf/+ cross,
maternal mRNA deposition is likely to help compensate for
the disruption of notch1b transcription caused by deletion of the
notch1b enhancer, a compensation that is reduced in a purer
notch1b-15uq1mf /uq1mf genetic background (Harvey et al., 2013).
To bypass potential rescue effects of shadow enhancers
or maternally deposited transcripts, we also investigated
arteriovenous differentiation and sprouting angiogenesis in F2
notch1b-15uq1mf/uq1mf zebrafish after low-level depletion of notch1b
mRNA. A splice notch1b MO was injected into eggs from a
notch1b-15uq1mf/+ in-cross in the tg(flt1:YFP;lyve1:dsRed)
background. The notch1b MO was used at suboptimal
concentration (5 ng/embryo), which is known to result in minimal
phenotypes (Sacilotto et al., 2013). The developing vasculature of
each resulting embryo was analysed blindly at 3 dpf, and genotypes
were assigned to embryos after image acquisition (Fig. 8D, red).
Whereas most WT siblings had normal ISV development, we
observed an increased number of hypersprouting ISVs across the
notch1b-15uq1mf/+ and notch1b-15uq1mf/uq1mf population (Fig. 8E,
asterisks; Fig. 8F, top) in a gene dosage-dependent manner, similar
to the phenotype described previously in high MO concentration
notch1b morphants and Notch signalling-deficient embryos
(Geudens et al., 2010; Siekmann and Lawson, 2007). Further,
mutant embryos also demonstrated loss of arterial connections
between the dorsal aorta and dorsal longitudinal anastomotic vessel,
similar to those described in Notch signalling-deficient zebrafish
(Geudens et al., 2010; Quillien et al., 2014), while the notch1b-
depleted notch1b-15+/+ and notch1b-15uq1mf/+ morphant embryos
demonstrated an equal proportion of arterial and venous ISVs as
previously reported (Bussmann et al., 2010) (Fig. 8E,F bottom).
To further confirm that interfering with notch1b-15 enhancer
activity is additive to notch1b transcript depletion, we chemically
treated the notch1b-15uq1mf/+ cross with DAPT, a well characterised
Notch signalling inhibitor, over the course of endothelial
differentiation (15- to 16-somite stage through to 3 dpf) (Fig. 8D,
blue). All embryos treated with a suboptimal concentration of
DAPT (5 µM) showed a straight body axis, indicating that
somitogenesis (and therefore Notch activity) was not significantly
compromised (Fig. S7A). Interestingly, despite this lack of
morphological defects, F2 fish homozygous for the notch1b-
15uq1mf allele displayed a lower arterial-to-total ISV ratio (Fig. 8G,
Fig. S7A). By contrast, fish homozygous for the notch1b-15uq1mf
allele treated with DMSO vehicle alone had a comparable aISV ratio
to both notch1b-15+/+ and notch1b-15uq1mf/+ siblings (Fig. S7B),
similar to the untreated control. This suggests that the observed loss
of aISV is specific to an additive effect of DAPT treatment and
notch1b-15 enhancer activity disruption. Overall, these data suggest
a functional role of the notch1-15 enhancer in the endothelial-
specific initiation of notch1b transcription to promote the
acquisition of arterial cell identity.
SoxF factors are required for endogenous Notch1/notch1b
expression
Our results have clearly implicated SoxF factors as direct upstream
regulators of arterial Notch enhancers, and therefore suggest a
considerably greater role for SoxF in the regulation of the Notch
receptors than of the Notch ligands. However, since the notch1b-15
enhancer is partially redundant with other notch1b shadow
enhancers, we wished to establish whether SoxF regulation is
required for endogenous notch1b expression itself, not just enhancer
activity. Further, our results so far do not entirely rule out the
possibility of SoxF/Rbpj combinatorial regulation of notch1b, as
was previously shown for Dll4 enhancers (Sacilotto et al., 2013).
Although neither the human NOTCH1+16 nor the zebrafish
notch1b-15 enhancer contains conserved consensus Rbpj/Notch
bindingmotifs, transcription factors can bind non-consensus motifs,
and not all transcription factors necessarily bind conserved motifs
(Wong et al., 2015). The nature of the SoxF/Notch combinatorial
regulation of Dll4, where the SOX or RBPJ binding motifs play
functionally interchangeable roles, indicates potential direct
interactions between these two proteins, such that only a single
SOX binding motif might be necessary for SoxF/Rbpj synergy. We
therefore investigated the consequences of SoxF depletion on
endogenous Notch1/notch1b expression in vivo.
Although Sox17 is robustly expressed in arterial endothelial cells
(Corada et al., 2013; Hosking et al., 2009), compound Sox7;Sox18
deletion in mice resulted in a reduction of Notch1 mRNA levels in
the trunk dorsal aorta and primitive heart cavities of E8.5 embryos
(Fig. 9A, Fig. S8A). These results concur with observations in the
mouse retina, where the vascular phenotype after Sox7;Sox17;
Sox18 endothelial-specific triple deletion closely resembled defects
caused by loss of Notch signalling (Zhou et al., 2015). Strikingly,
both MO-induced gene knockdown and compound mutation of
sox7 and sox18 in zebrafish embryos also led to a near-complete
loss of notch1b transcript expression specifically in endothelial
cells, as shown by in situ hybridisation analysis (Fig. 9B,C,
Fig. S8B). These results further establish an essential role for SoxF
transcription factors in the induction of Notch1/notch1b gene
expression, and position SoxF proteins at the top of the
transcriptional hierarchy regulating arterial specification.
DISCUSSION
Recent work has implicated SoxF, Ets and Rbpj, the Notch
transcriptional effector, in the regulation of the Notch ligand Dll4
and many other key arterial genes (Corada et al., 2013; Lizama et al.,
2015; Sacilotto et al., 2013; Wythe et al., 2013), but has not
established the hierarchical arrangement of these diverse factors
in arterial specification and differentiation. In this study, we
demonstrate that arterial expression of the Notch receptor Notch1/
notch1b, a key player in arterial specification, is directly
downstream of SoxF regulation in both fish and mouse. Unlike
other key arterial specification markers, including Dll4, Efnb2a and
Dlc (Sacilotto et al., 2013), ablation of Notch1/Notch1b expression
after depletion of SoxF factors occurred without concurrent
inhibition of Notch signalling. Therefore, this work positions
SoxF factors directly above Notch signalling in the transcriptional
hierarchy initiating arterial development, and suggests that SoxF
factors might initiate a feed-forward loop directing arterial identity.
In this model, SoxF factors would first activate Notch signalling via
the transcriptional activation of Notch receptors in combination
with weak activation of Notch ligands (Sacilotto et al., 2013). This
early SoxF-mediated activity would then be boosted by the
initiation of Notch signalling, resulting in the sustained activation
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of other downstream genes, eventually activating the full cohort of
genes necessary to acquire and maintain arterial endothelial
cell identity.
Understanding the function of SoxF factors through mutational
analysis has presented significant challenges. Strain-specific
variations in mice after depletion of individual SoxF genes and
varying levels of compensation from other SoxF factors have
resulted in some contradictory reports (Corada et al., 2013; Lee
et al., 2014), as is also the case for zebrafish morphant analysis
(Cermenati et al., 2008; Herpers et al., 2008; Pendeville et al.,
2008). Nonetheless, the results described here agree with an
increasingly convincing body of work suggesting that SoxF factors
influence Notch signalling yet are unaffected by Notch ablation. For
example, overexpression of Sox17 upregulates components of the
Notch pathway (Corada et al., 2013; Lizama et al., 2015), loss of
functional SoxF factors results in defects similar to those observed
after Notch inhibition in mice and fish (Corada et al., 2013;
Sakamoto et al., 2007; Zhou et al., 2015), while Notch ablation
results in little alteration to the endothelial expression of SoxF
factors in mice and fish (Abdelilah et al., 1996; Corada et al., 2013).
Data reported here combine with these reports to strongly support a
role for SoxF factors as part of the initial transcriptional machinery
that instructs arterial specification events.
However, some questions remain. In particular, it is notable that
sox7;sox18 double-mutant fish, although exhibiting severe
arteriovenous defects very similar to those seen in Notch-
deficient fish (Lawson et al., 2001), do not fully recapitulate the
effects of Vegfa depletion on arterial specification (Lawson et al.,
2002). While this difference may in part be attributed to weak
expression of zebrafish sox17, which is expressed in some arterial
endothelial cells (Hermkens et al., 2015), it is also expected that
the Vegfa pathway has a wider effect on arterial endothelial cells
more generally, away from SoxF-mediated activation of Notch
signalling. SoxF factors are also influenced by signalling
pathways beyond Vegfa. The diverse nature of Vegfa roles in
the vasculature, including the regulation of both sprouting
angiogenesis and arteriogenesis, processes that inevitably
involve different cohorts of downstream targets, make it
necessary that multiple regulatory pathways interact with Vegfa
during vascular development. While recent work has shown that
Vegfa signalling increases the nuclear translocation of SoxF
(Duong et al., 2014), and inhibition of Vegfa results in the loss of
vascular sox7 in fish, sox18 is still expressed in the absence of
intact Vegfa signalling (Pendeville et al., 2008). Additionally, loss
of the Vegf co-receptor Nrp1 has little effect on SoxF expression in
mouse retinal vasculature (Zhou et al., 2015), pointing to other
upstream influences on SoxF function in endothelial cells. Other
upstream effectors of SoxF function are likely to include canonical
Wnt signalling and Vegfd, both of which have been shown to
influence SoxF nuclear localisation (Corada et al., 2013; Duong
et al., 2014; Zhou et al., 2015).
Recent evidence has also implicated a role for a coordinated
Vegf-Mapk-Ets pathway in the induction of Notch signalling
components and early arterial differentiation (Wythe et al., 2013).
Notably, in addition to SoxF motifs, both the Notch1 and Dll4
enhancers share a number of highly conserved consensus motifs
for the Ets family of transcription factors. While ETS motifs are
common to all vascular enhancer elements, including many that
are not preferentially expressed in the arterial vasculature (De Val
and Black, 2009), the Ets factor Erg has been specifically
implicated in arterial-specific regulation of Dll4 (Wythe et al.,
2013). It is therefore likely that Vegfa-mediated activation of
Ets factors may contribute to the transcriptional activity of
Notch downstream effectors, and thus may influence arterial
establishment independently of SoxF factors. However, it is
notable that Vegfa-mediated activation of Ets transcription factors
alone does not appear to be sufficient for arterial gene expression.
Dll4 enhancers lacking SOX and RBPJ motifs but retaining all
ETS motifs were unable to drive any transgene expression
(Sacilotto et al., 2013), nor were Notch enhancers lacking SOX
motifs (Figs 2-4). Similar results were found in other delineated
arterial enhancers, including the Ece1 upstream enhancer
(Robinson et al., 2014) and the Flk1 intron 10 enhancer, where
loss of Rbpj-mediated repression resulted in expansion of
enhancer activity into venous cells without alterations to ETS
motif binding (Becker et al., 2016). Combined with recent
observations demonstrating that Erg also plays a crucial role in
venous specification through activation ofAplnr (Lathen et al., 2014),
Fig. 9. Mouse and zebrafish arterial Notch1 expression is dependent on
SOX7/18 activity. (A) Transverse sections of whole-mount in situ hybridisation
for Notch1 transcript on E8.5 mouse embryos shows a reduction of Notch1
expression (asterisks) in the bulbus cordis (bc) region of the primitive heart and
vitelline artery (va) of Sox7/Sox18 double knockouts. (B) At 24 hpf notch1b
expression is significantly downregulated in the dorsal aorta (asterisks) of
sox7/sox18 double-morphant zebrafish, whereas its signal is unaffected in the
neural tube. flt1 expression is comparable between controls and sox7/sox18
double morphants, indicating that the dorsal aorta is correctly formed.
(C) notch1b was barely detectable in the dorsal aorta and ISVs of sox7/18
double-knockout zebrafish (asterisks), as compared with the WT, sox7 or
sox18 heterozygotes (arrows). The number of embryos showing the illustrated
phenotype among the total examined is indicated. DA, dorsal aorta; PCV,
posterior cardinal vein.
2636
RESEARCH ARTICLE Development (2017) 144, 2629-2639 doi:10.1242/dev.146241
D
E
V
E
LO
P
M
E
N
T
it is therefore likely that the role of Erg, and of other Ets factors,
downstream of Vegfa in arterial-restricted gene expression occurs
in co-operation with additional essential, arterial-specifying
transcription factors. The data presented in this work, combined
with the analysis of further arterial enhancers, including those ofDll4
and Ece1 (Robinson et al., 2014; Sacilotto et al., 2013; Wythe et al.,
2013), increasingly suggest that SoxF may fulfil this role.
MATERIALS AND METHODS
Cloning
The 10×UAS:Sox18Ragged-mCherry plasmid was generated using the full-
length mouse Sox18Ragged cDNA sequence, tagged with 10×UAS and
mCherry and cloned into pDestTol2CG2 (Kwan et al., 2007). notch1b-15:
GFPWTwas generated by cloning a 1219 bp PCR fragment from zebrafish
genomic DNA together with gata2a promoter and GFP reporter gene into
the zebrafish enhancer detection (ZED) vector (Bessa et al., 2009). notch1b-
15mutSOX-a/b was generated by site-directed PCR mutagenesis of the WT
construct. The NOTCH1−68, NOTCH1+3/5 and NOTCH1+33 enhancers
were generated by PCR from human genomic DNA, NOTCH1+16WT and
NOTCH1+16mutSOX-a/b enhancers were generated as custom-made,
double-stranded linear DNA fragments (GeneArt Strings, Life
Technologies). All mammalian fragments were cloned into the hsp68-
lacZ Gateway vector (provided by N. Ahituv) (De Val et al., 2004). Primers
and sequences for DNA fragments are listed in the supplementary Materials
and Methods.
Transgenic animals and genome editing
Animal procedures were approved by local ethical review and licensed by
the UK Home Office or conformed to institutional guidelines of the
University of Queensland Animal Ethics Committee. Transgenic mice were
generated by oocyte microinjection and analysed as detailed in the
supplementary Materials and Methods (De Val et al., 2004). Compound
Sox7−/−;Sox18−/− (C57BL/6) mouse embryos were generated on the
C57BL/6 background through crossing heterozygous Sox7:tm1 to Sox18:
tm1 generating Sox7+/−;Sox18+/− mice, which were subsequently
in-crossed (Pennisi et al., 2000a).
Transgenic zebrafish embryos were generated using the Tol2 system in
conjunction with the ZED vector (Bessa et al., 2009). The sox7hu5626;
sox18hu10320 double-homozygous mutant zebrafish have been described
previously (Hermkens et al., 2015). The tg(fli1a:Gal4FF,10×UAS:
Sox18Ragged-mCherry) zebrafish line was generated by crossing
10×UAS:Sox18Ragged-mCherry with fli1a:Gal4FF, 4×UAS Utrophin
GFP. MO-mediated knockdown was performed as previously described
(Herpers et al., 2008). CRISPR genome editing for notch1b-15 was
performed as described by Gagnon et al. (2014) using the primers listed
in the supplementary Materials and Methods to generate notch1b-15uq1mf
(203 bp deletion) allele.
The F2 notch1b-15uq1mf/uq1mf was generated by in-crossing notch1b-
15uq1mf/+, while F3 notch1b-15uq1mf/uq1mfwas generated from the F2 notch1b-
15uq1mf/uq1mf in-cross, both in the tg(flt1:YFP;lyve1:dsRed) background.
Chromatin immunoprecipitation (ChIP)
Positive tg(fli1a:Gal4FF;10×UAS:Sox18Ragged-mCherry) fish larvae were
collected at 26-28 hpf and processed as described in supplementary Materials
and Methods (Mohammed et al., 2013). DNA amplification was performed
using the TruSeq ChIP-seq Kit (Illumina, IP-202-1012) following
immunoprecipitation. The library was quantified using the KAPA library
quantification kit for Illumina sequencing platforms (KAPA Biosystems,
KK4824) and 50 bp single-end reads were sequenced on a HiSeq 2500
(Illumina) following the manufacturer’s protocol. FASTQ files were mapped
toGRCz10/danRer10 genome assembly using bowtie (Langmead, 2010), and
peaks were called using MACS version 2.1.0. using input as a reference. To
avoid false-positive peaks calling due to the mCherry epitope, ChIP-seq with
the mCherry epitope only was performed in parallel to SOX18Ragged-
mCherry ChIP-seq and peaks called in these experimental conditions were
subtracted from the peaks called in the SOX18Ragged-mCherry conditions.
For details, see the supplementary Materials and Methods.
Motif identification and EMSA
Sequences were analysed for consensus sequence motifs by eye and using
TRANSFAC (BIOBASE; http://genexplain.com/transfac/) (Matys et al.,
2006). EMSAs were performed as previously described (De Val et al.,
2004), as outlined in the supplementary Materials and Methods.
Morpholinos and drug treatment
MO-mediated knockdown was performed as previously described (Duong
et al., 2014; Cermenati et al., 2008). ATGMOs against sox7 and sox18were
injected into the tg(notch1b-15:GFP) stable line at the 1-2 cell stage at 5 ng/
embryo (Herpers et al., 2008). To assess the effect of sox7/18 knockdown on
endogenous notch1b transcripts, sox7 and sox18 MOs were injected into
WT zebrafish larvae at 1 ng/embryo in parallel with a standard control MO
(std-MO) injected at 2 ng/embryo (Cermenati et al., 2008). To characterise
notch1b-15uq1mf, notch1bMOwas injected into the notch1b-15uq1mf/+ cross
at 5 ng/embryo. For MO sequences, see the supplementary Materials
and Methods.
N-[(3,5-difluorophenyl)acetyl]-L-alanyl-2-phenyl]glycine-1,1-dimethylethyl
ester (DAPT; Sigma-Aldrich) was used at 5 μM dissolved in 1% DMSO. Fish
were treated from the 15- to 16-somite stage to 3 dpf and themedium containing
DAPT was refreshed daily.
In situ hybridisation and immunofluorescence staining
Whole-mount in situ hybridisation in zebrafish larvae was performed as
described (Coxam et al., 2015; Duong et al., 2014). Section and whole-mount
in situ hybridisation in mouse was performed as described (Metzis et al.,
2013; Fowles et al., 2003). The Notch1 probe was generated by PCR from
mouse embryo cDNA pool at E14.5, and reverse transcribed with T7
polymerase. Whole-mount immunohistochemistry for anti-GFP was
performed as described (Koltowska et al., 2015). For details, see the
supplementary Materials and Methods.
Quantification and data analysis
To characterise the vasculature in Fig. 8E-G and Figs S6, S7, intersomitic
vessels (20-22 ISVs) expressing tg(flt1:YFP) were analysed across 10-11
somites through a z-stack using ImageJ (NIH) after image acquisition
by confocal microscopy. Intersomitic vessels connecting the dorsal
longitudinal anastomotic vessel to the dorsal aorta expressing YFP were
assigned as arterial ISVs. Vessels were also scored for ectopic sprouting.
The proportion of aISVs or hypersprouts among the total number of ISVs
was analysed by two-tailed Mann–Whitney U-test. To quantify the GFP
intensity of tg(notch1b-15:GFP) and tg(notch1b-15mutSOX-a/b:GFP)
(Fig. 7A), two to three ISVs across five to six somites in the trunk
region were analysed using ImageJ. A region of interest (ROI) covering a
single ISV was selected and mean pixel intensity for each ISV was
quantified from each individual stack across three z-sections. This value
was further corrected by subtracting the background value. Average ISV
GFP intensity (quantified from two to three ISVs) for each fish larva was
subsequently corrected for its genomic GFP copy number. A similar
method was used to quantify GFP intensity in the endothelial lining along
the dorsal aorta.
Fluorescence-activated cell sorting (FACS) and expression
analysis
Flt1:YFP-positive endothelial cells were isolated from WT and F3 notch1b-
15uq1mf/uq1mf at 24-28 hpf. RNA was extracted, amplified and cDNA was
synthesized as previously described (Coxam et al., 2014; Picelli et al.,
2014). Primer sequences and details of the quantitative PCR analysis are
provided in the supplementary Materials and Methods.
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